"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CU,A1,CU 22918 A1,087-828-498-235-778,2005-05-20,2005,CU 20000231 A,2000-10-27,CU 20000231 A,2000-10-27,PROCEDIMIENTO DE OBTENCION DE UN AGLOMERANTE HODROFOBO DE BASE CEMENTOSA Y AGLOMERANTE HIDROFOBO ASI OBTENIDO,,INSTITUTO SUPERIOR POLITECNICO JOSE ANTONIO ECHEVERRIA,ACEVEDO CATA JORGE BERNARDO,,https://lens.org/087-828-498-235-778,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
2,DE,D1,DE 69920747 D1,031-827-221-443-543,2004-11-04,2004,DE 69920747 T,1999-11-30,US 20497998 A;;US 9928255 W,1998-12-03,METHODE ZUR HERSTELLUNG VON REKOMBINANTEN ZELLEN,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE R,,https://lens.org/031-827-221-443-543,Granted Patent,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
3,DE,T2,DE 69920747 T2,014-605-348-382-653,2005-10-06,2005,DE 69920747 T,1999-11-30,US 20497998 A;;US 9928255 W,1998-12-03,METHODE ZUR HERSTELLUNG VON REKOMBINANTEN ZELLEN,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE R,,https://lens.org/014-605-348-382-653,Granted Patent,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
4,DK,T3,DK 1137808 T3,019-160-486-663-384,2005-01-31,2005,DK 99961864 T,1999-11-30,EP 99961864 A;;US 20497998 A,1998-12-03,Fremgangsmåde til fremstilling af rekombinante celler,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,RHODE PETER R;;ACEVEDO JORGE L,,https://lens.org/019-160-486-663-384,Granted Patent,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
5,AU,A,AU 2000/018356 A,121-137-805-911-122,2000-06-19,2000,AU 2000/018356 A,1999-11-30,US 20497998 A;;US 9928255 W,1998-12-03,Methods for making recombinant cells,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/121-137-805-911-122,Patent Application,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
6,WO,A1,WO 2000/032821 A1,135-627-212-621-832,2000-06-08,2000,US 9928255 W,1999-11-30,US 20497998 A,1998-12-03,METHODS FOR MAKING RECOMBINANT CELLS,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/135-627-212-621-832,Patent Application,yes,2,2,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C07K16/28;;C12N15/09;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,PATENTED
7,CN,C,CN 1202261 C,116-751-491-234-876,2005-05-18,2005,CN 99813873 A,1999-11-30,US 20497998 A,1998-12-03,Methods for making recombinant cells,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/116-751-491-234-876,Granted Patent,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
8,CA,A1,CA 2353575 A1,141-962-927-665-607,2000-06-08,2000,CA 2353575 A,1999-11-30,US 20497998 A;;US 9928255 W,1998-12-03,METHODS FOR MAKING RECOMBINANT CELLS,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptide s.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/141-962-927-665-607,Patent Application,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,DISCONTINUED
9,EP,A4,EP 1137808 A4,100-126-429-319-778,2002-10-02,2002,EP 99961864 A,1999-11-30,US 9928255 W;;US 20497998 A,1998-12-03,METHODS FOR MAKING RECOMBINANT CELLS,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/100-126-429-319-778,Search Report,no,3,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,1,0,,,"PAWLIUK R ET AL: ""SELECTION OF RETROVIRALLY TRANSDUCED HEMATOPOIETIC CELLS USING CD24 AS A MARKER OF GENE TRANSFER"", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 9, no. 84, 1 November 1994 (1994-11-01), pages 2868 - 2877, XP008002532, ISSN: 0006-4971",EXPIRED
10,TW,B,TW I221483 B,137-260-780-246-844,2004-10-01,2004,TW 88120940 A,1999-12-01,US 20497998 A,1998-12-03,Method for producing recombinant cell line featuring increased expression of amino acid sequence,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/137-260-780-246-844,Granted Patent,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C07K16/28;;C12N15/09;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
11,AU,B2,AU 770119 B2,188-069-465-755-846,2004-02-12,2004,AU 2000/018356 A,1999-11-30,US 20497998 A;;US 9928255 W,1998-12-03,Methods for making recombinant cells,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/188-069-465-755-846,Granted Patent,no,2,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
12,EP,B1,EP 1137808 B1,130-558-251-306-028,2004-09-29,2004,EP 99961864 A,1999-11-30,US 9928255 W;;US 20497998 A,1998-12-03,METHODS FOR MAKING RECOMBINANT CELLS,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/130-558-251-306-028,Granted Patent,yes,1,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
13,US,A,US 6156514 A,000-742-596-748-856,2000-12-05,2000,US 20497998 A,1998-12-03,US 20497998 A,1998-12-03,Methods for making recombinant cells,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,SUNOL MOLECULAR CORPORATION (1999-02-17),https://lens.org/000-742-596-748-856,Granted Patent,yes,12,35,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C07K16/28;;C12N15/09;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,435/6;;435/440;;435/325,4,2,047-856-512-210-903;;025-227-073-292-168,8659926;;10.1111/j.1749-6632.1996.tb40548.x;;2112395;;10.1089/dna.1990.9.293,"Mitchell Roff, Homologous Recombination In CHO Cells , Biopharm. (1988), V. 11, No. 7: pp. 34 35.;;Florian M. Wurm, et al. Gene Transfer and Amplification In CHO Cells , Annals New York Academy Of Sciences , pp. 70 78.;;Martin Montoya Zavala, et al. Increased TPA Expression In C127 Cells Have Been Sequentially Tranfected With Two Different BPV Based Expression Vectors , J. Cell Biochem. Suppl. 13 Part C (1989), p. 210.;;J. Barsoum, Introduction Of Stable High Copy Number DNA Into Chinese Hamster Ovary Cells By Electroporation , DNA And Cell Biol. , vol. 9, No. 4, 1990, Mary Ann Liebert, Inc., Publishers, pp. 293 300.",EXPIRED
14,ES,T3,ES 2230908 T3,195-243-890-048-493,2005-05-01,2005,ES 99961864 T,1999-11-30,US 20497998 A,1998-12-03,PROCEDIMIENTO PARA LA PREPARACION DE CELULAS RECOMBINANTES.,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/195-243-890-048-493,Granted Patent,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
15,US,B1,US 6306605 B1,044-054-239-078-521,2001-10-23,2001,US 49631100 A,2000-02-01,US 49631100 A;;US 20497998 A,1998-12-03,Methods for making recombinant cells,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/044-054-239-078-521,Granted Patent,yes,13,20,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C07K16/28;;C12N15/09;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,435/6;;435/69.1;;435/458;;435/358,5,2,047-856-512-210-903;;025-227-073-292-168,8659926;;10.1111/j.1749-6632.1996.tb40548.x;;2112395;;10.1089/dna.1990.9.293,"Mitchell Roff, ""Homologous Recombination In CHO Cells"", Biopharm. (1988), V. 11, No. 7: pp. 34-35.;;Florian M. Wurm, et al. ""Gene Transfer And Amplification In CHO Cells"", Annals New York Academy Of Sciences, pp. 70-78.;;Martin Montoya-Zavala, et al. ""Increased TPA Expression In C127 Cells Have Been Sequentially Transfected With Two Different BPV Based Expression Vectors"", J. Cell Biochem. Suppl. #13 Part C (1989), p. 210.;;J. Barsoum, ""Introduction Of Stable High-Copy-Number DNA Into Chinese Hamster Ovary Cells By Electroporation"", DNA And Cell Biol., vol. 9, No. 4, 1990, Mary Ann Liebert, Inc., Publishers, pp. 293-300.;;Copy of Int'l Search Report dated Mar. 20, 2000 re corresponding Int'l Application No. PCT/US99/28255 (three pages).",EXPIRED
16,CN,A,CN 1328605 A,004-421-625-037-649,2001-12-26,2001,CN 99813873 A,1999-11-30,US 20497998 A,1998-12-03,Methods for making recombinant cells,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/004-421-625-037-649,Patent Application,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
17,EP,A1,EP 1137808 A1,097-283-505-541-921,2001-10-04,2001,EP 99961864 A,1999-11-30,US 9928255 W;;US 20497998 A,1998-12-03,METHODS FOR MAKING RECOMBINANT CELLS,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/097-283-505-541-921,Patent Application,yes,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,EXPIRED
18,AT,T1,AT E278024 T1,045-533-256-967-94X,2004-10-15,2004,AT 99961864 T,1999-11-30,US 20497998 A;;US 9928255 W,1998-12-03,METHODE ZUR HERSTELLUNG VON REKOMBINANTEN ZELLEN,Disclosed are methods for producing recombinant cells and especially recombinant mammalian cell lines with enhanced expression of an amino acid sequence. Also disclosed are recombinant mammalian cell lines producing high levels of the amino acid sequence. The methods and recombinant cell lines of the invention have a number of useful applications including use in the efficient and large-scale production of recombinant proteins and polypeptides.,SUNOL MOLECULAR CORP,ACEVEDO JORGE L;;RHODE PETER R,,https://lens.org/045-533-256-967-94X,Granted Patent,no,0,0,18,18,0,C07K16/2896;;C07K2317/24;;C07K2319/00;;C12N15/65;;C12N15/67;;C12N15/67;;C07K16/2896;;C07K2317/24;;C12N15/65;;C07K2319/00,C12N15/09;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/65;;C12N15/67;;C12P21/02;;C12Q1/68,,0,0,,,,PENDING
19,WO,A1,WO 2012/162768 A1,122-535-982-846-296,2012-12-06,2012,BR 2011000240 W,2011-07-20,BR MU9101291 U,2011-06-01,TECHNICAL ARRANGEMENT FOR FULL CLOSURE SAFETY VALVE,"The claimed arrangement comprises a body that can be coupled to the container and has at least one through passage extending from the inside to the outside of the container, and an axially displaceable spindle located inside this passage and having an inner end that faces a first seat that defines a gate valve. At the ""upstream"" end thereof, relative to the first seat, the passage has a second shut-off element, in front of which is arranged an ""upstream"" shut-off body with a matching geometry and permanently biased away from the shut-off element by calibrated elastic means, the base of the shut-off body being in communication with the inlet into the gate valve body. The matching portions of the shut-off body and seat thereof in the spaced apart position forms a fluid passage that creates a Venturi effect that defines a negative pressure capable of overcoming the opposite bias of the elastic means, forming an absolute closure safety valve under excess flow rate inside the container. The spindle has a truncated cone section ""downstream"" of the first seat, with a matching seat that forms an end-of-travel stop and defines a hermetic seal seat between the spindle and the body of the gate valve in the ""downstream"" movement thereof. The spindle extends axially over such a distance that, when it is in the shut-off position on the first seat, it applies a pushing pressure on a shut-off means that causes the pressure inside the container to equal the pressure inside the first passage ""upstream"" of the first seat.",ACEVEDO IBANEZ RODRIGO IGNACIO;;MUSTAFA JORGE IAMAEL,ACEVEDO IBANEZ RODRIGO IGNACIO;;MUSTAFA JORGE IAMAEL,,https://lens.org/122-535-982-846-296,Patent Application,yes,2,0,2,2,0,F17C13/04;;F16K1/305;;F16K1/307;;F16K17/30;;F17C2205/0329;;F17C2205/0332;;F17C2205/0385;;F17C2205/0394;;F17C2221/014;;F17C2221/018;;F17C2221/033;;F17C2223/0123;;F17C2223/0161,F17C13/04,,0,0,,,,PENDING
20,US,S,US D0840486 S,119-792-483-500-839,2019-02-12,2019,US 201729630519 F,2017-12-21,US 201729630519 F,2017-12-21,Rescue buoy with instructions,,ACEVEDO KYLE;;BHUYIAN RAAD;;GALLION STEVE;;FERNANDEZ JORGE,ACEVEDO KYLE;;BHUYIAN RAAD;;GALLION STEVE;;FERNANDEZ JORGE,GALLION STEVE (2018-10-22),https://lens.org/119-792-483-500-839,Design Right,no,13,1,1,1,0,,,2102;;D21/803;;D29/124,1,0,,,"50 Lifeguard Rescue Tube w/ 8 foot strap—Free Guard Logo-: Published Apr. 25, 2014 [online], site visited Aug. 21, 2018. Available from Internet URL:https://web.archive.org/web/20140425234509/http://www.americanlifeguard.net/50-Lifeguard-Rescue-Tube-w_-8-foot-strap-FREE-Guard-Logo-4295/productinfo/11-004GW/.",ACTIVE
21,US,A1,US 2021/0015498 A1,033-926-711-921-604,2021-01-21,2021,US 202017060195 A,2020-10-01,US 202017060195 A;;US 201715795109 A,2017-10-26,SURGICAL DRILL GUIDE,Drill guides are disclosed herein that include a tapered projection that hooks under a bone to position the drill guide relative to the bone. The drill guide is used to drill a hole that receives a suture anchor.,ARTHREX INC,ACEVEDO JORGE;;MANGONE PETER;;DAY ZACHARY;;MCWILLIAM JAMES,,https://lens.org/033-926-711-921-604,Patent Application,yes,2,0,3,3,0,A61B17/1682;;A61B2017/00429;;A61B2090/033;;A61B17/1775;;A61B17/1697;;A61B17/17;;A61B17/1796;;A61B2017/00429;;A61B17/1775;;A61B17/1682;;A61B2090/033;;A61B17/3421;;A61B2017/320052;;A61B17/1615;;A61B17/320016,A61B17/16;;A61B17/17,,0,0,,,,PENDING
22,US,B2,US 10792052 B2,016-577-161-370-633,2020-10-06,2020,US 201715795109 A,2017-10-26,US 201715795109 A,2017-10-26,Surgical drill guide,Drill guides are disclosed herein that include a tapered projection that hooks under a bone to position the drill guide relative to the bone. The drill guide is used to drill a hole that receives a suture anchor.,ARTHREX INC,ACEVEDO JORGE;;MANGONE PETER;;DAY ZACHARY;;MCWILLIAM JAMES;;GULVAS JEROME,ARTHREX INC (2017-11-07),https://lens.org/016-577-161-370-633,Granted Patent,yes,23,1,3,3,0,A61B17/1682;;A61B2017/00429;;A61B2090/033;;A61B17/1775;;A61B17/1697;;A61B17/17;;A61B17/1796;;A61B2017/00429;;A61B17/1775;;A61B17/1682;;A61B2090/033;;A61B17/3421;;A61B2017/320052;;A61B17/1615;;A61B17/320016,A61B17/16;;A61B17/00;;A61B17/17;;A61B17/32;;A61B17/34;;A61B90/00,,0,0,,,,ACTIVE
23,US,A1,US 2019/0125367 A1,060-898-395-462-242,2019-05-02,2019,US 201715795109 A,2017-10-26,US 201715795109 A,2017-10-26,SURGICAL DRILL GUIDE,Drill guides are disclosed herein that include a tapered projection that hooks under a bone to position the drill guide relative to the bone. The drill guide is used to drill a hole that receives a suture anchor.,ARTHREX INC,ACEVEDO JORGE;;MANGONE PETER;;DAY ZACHARY;;MCWILLIAM JAMES;;GULVAS JEROME,ARTHREX INC (2017-11-07),https://lens.org/060-898-395-462-242,Patent Application,yes,9,1,3,3,0,A61B17/1682;;A61B2017/00429;;A61B2090/033;;A61B17/1775;;A61B17/1697;;A61B17/17;;A61B17/1796;;A61B2017/00429;;A61B17/1775;;A61B17/1682;;A61B2090/033;;A61B17/3421;;A61B2017/320052;;A61B17/1615;;A61B17/320016,A61B17/16;;A61B17/17,,0,0,,,,ACTIVE
24,PE,A1,PE 20130164 A1,013-785-476-251-687,2013-02-20,2013,PE 2012000332 A,2009-06-05,PE 2012000332 A,2009-06-05,"SECADORA DE ROPA, METALICA, ELECTRICA, PLEGABLE, DE MUY BAJO CONSUMO DE ENERGIA Y TOTALMENTE SILENCIOSA","QUE CONSTA DE: a) UNA CAJA RECTANGULAR CON TAPA Y VENTANA PROTEGIDA CON MALLA; b) UN CIRCUITO ELECTRICO ALOJADO EN EL FONDO DE LA CAJA METALICA, COMPUESTO DE AL MENOS TRES CORREDERAS QUE ASEGURAN AISLADORES CERAMICOS; c) DOS SEMIBASTIDORES DE VARILLA REDONDA EN FORMA DE ""U"" INVERTIDA, SOPORTADOS POR MEDIO DE DOS VASTAGOS HORIZONTALES INTRODUCIDOS A LA CAJA METALICA; d) UN BASTIDOR CON TENDALES PARA UBICAR LA ROPA A SECAR, QUE TIENE UN ORIFICIO PARA ARTICULARSE A UNO DE LOS DOS SEMIBASTIDORES, Y UNA MUESCA DE FIJACION PARA UNIRSE AL OTRO SEMIBASTIDOR; e) UN INTERRUPTOR DIFERENCIAL, MONTADO A UNA PLACA PORTADORA Y ASEGURADO EN UN EXTREMO DE LA CAJA METALICA Y AISLADO A ELLA CON TECNOPOR; f) UNA CUBIERTA VERTICAL PERIMETRICA QUE LLEVA UNA VENTANILLA DE TRANSFERENCIA EN UNO DE LOS LADOS CORTOS, Y A LA TAPA HORIZONTAL DE TELA; g) ESPIGA DE BRONCE Y CERAMICA, ENCARGADA DE RECIBIR LA ENERGIA DEL EXTERIOR PARA TRASLADARLA AL INTERIOR DEL CIRCUITO; h) ENCHUFE DE CERAMICA Y BAKELITA, ENCARGADA DE LA CONEXION DE LA PARTE EXTERIOR DEL CIRCUITO A LA PARTE INTERMEDIA, PERMITIENDO EL MONTAJE EN DOS ETAPAS; i) ELEMENTOS DE ESTABILIDAD ESTRUCTURAL QUE JUNTO CON LA MUESCA DE ATRAQUE PERMITEN QUE LA SECADORA SE MANTENGA VERTICAL PARA SER ABASTECIDA; j) REGATONES DE JEBE, UBICADOS EN LOS EXTREMOS INFERIORES DE LOS SEMIBASTIDORES",VALDERRAMA ACEVEDO JORGE MIGUEL;;FARRONAY GIURIA LUIS RODOLFO;;MEDINA GIURIA MARIANA,VALDERRAMA ACEVEDO JORGE MIGUEL;;FARRONAY GIURIA LUIS RODOLFO;;MEDINA GIURIA MARIANA,,https://lens.org/013-785-476-251-687,Patent Application,no,0,0,1,1,0,,D06F58/16,,0,0,,,,ACTIVE
25,PE,A1,PE 20110013 A1,023-222-290-890-265,2011-02-18,2011,PE 2009000785 A,2009-06-05,PE 2009000785 A,2009-06-05,"SECADORA DE ROPA METALICA, ELECTRICA, PLEGABLE, DE MUY BAJO CONSUMO DE ENERGIA Y TOTALMENTE SILENCIOSA","QUE CONSTA DE: a) UNA CAJA METALICA CON TAPA Y VENTANA PROTEGIDA CON MALLA; b) UN CIRCUITO ELECTRICO ALOJADO EN EL FONDO DE DICHA CAJA METALICA, COMPUESTO DE AL MENOS TRES CORREDERAS QUE ASEGURAN AISLADORES CERAMICOS QUE SOSTIENEN UN ALAMBRADO DE NICROM; c) DOS SEMIBASTIDORES DE VARILLA REDONDA EN FORMA DE ""U"" INVERTIDA, SOPORTADOS POR MEDIO DE DOS VASTAGOS HORIZONTALES INTRODUCIDOS A LA CAJA METALICA; d) UN BASTIDOR CON TENDALES PARA UBICAR LA ROPA A SECAR, QUE TIENE UN ORIFICIO DE ARTICULACION PARA UNIRSE A UNO DE LOS DOS SEMIBASTIDORES, Y UNA MUESCA DE FIJACION PARA UNIRSE AL OTRO SEMIBASTIDOR; e) UN INTERRUPTOR DIFERENCIAL, INSTALADO EN UNA PLACA PORTADORA Y ASEGURADO EN UN EXTREMO DE LA CAJA METALICA; f) UNA CUBIERTA QUE COMPRENDE UNA ENVOLTURA VERTICAL PERIMETRICA CON UNA VENTANILLA EN UN LADO, Y UNA TAPA DE TELA, ASEGURADA A LA CAJA METALICA POR MEDIO DE TORNILLOS AUTORROSCANTES, Y A CADA SEMIBASTIDOR, POR MEDIO DE ANILLOS DE TELA CAUTIVOS Y POR CORREAS DE TELA EN TODO EL PERIMETRO SUPERIOR DE LA SECADORA; Y g) REGATONES DE JEBE, UBICADOS EN LOS EXTREMOS INFERIORES DE LOS SEMIBASTIDORES",VALDERRAMA ACEVEDO JORGE MIGUEL;;FARRONAY GUIRIA LUIS RODOLFO;;MEDINA GIURIA MARIANA,VALDERRAMA ACEVEDO JORGE MIGUEL;;FARRONAY GUIRIA LUIS R;;MEDINA GIURIA MARIANA,,https://lens.org/023-222-290-890-265,Patent Application,no,0,0,1,1,0,,D06F58/16,,0,0,,,,DISCONTINUED
26,CO,A1,CO 2022004782 A1,021-809-139-093-749,2022-04-29,2022,CO 2022004782 A,2022-04-13,CO 2022004782 A,2022-04-13,Dispositivo de moldeo y templado de chocolate,"Se describe un dispositivo de moldeo y templado de chocolate que tiene un recipiente para recibir el chocolate y que está acoplado a un contenedor. El contenedor tiene un diámetro mayor al diámetro del recipiente permitiendo un alojamiento formado entre las paredes cilíndricas del recipiente y el contenedor. De igual manera, el dispositivo de moldeo y templado de chocolate tiene un agitador acoplado de manera giratoria al centro del recipiente para la mezcla y la agitación del chocolate y un sistema térmico alojado en el alojamiento. El sistema térmico incluye un evaporador de un sistema de enfriamiento en contacto directo con el recipiente que extrae calor del chocolate en un menor tiempo y un sistema de calentamiento en contacto directo con el recipiente que transfiere calor al chocolate en un menor tiempo. Por último, el dispositivo de moldeo y templado de chocolate tiene un sistema de moldeo que moldea el chocolate por medio de al menos dos elementos de moldeo y un evaporador de un subsistema de enfriamiento en contacto directo con el sistema de moldeo que extrae calor del chocolate en un menor tiempo. La transferencia y extracción de calor del sistema térmico se mantiene uniforme en todo el recipiente al ingresar un fluido térmico al alojamiento.",UNIV AUTONOMA DE BUCARAMANGA,HERNÁNDEZ OVIEDO JORGE ARMANDO;;RODRÍGUEZ MILLAN DUVÁN FELIPE;;GONZÁLEZ ACEVEDO HERNANDO,,https://lens.org/021-809-139-093-749,Patent Application,no,0,0,1,1,0,,A23G1/00;;A23G1/04;;A23G1/10;;A23G1/16;;A23G1/18;;A23G3/00;;A23G3/22;;A23G9/24,,0,0,,,,PENDING
27,WO,A1,WO 2020/036865 A1,148-522-696-214-440,2020-02-20,2020,US 2019/0046147 W,2019-08-12,US 201862718656 P,2018-08-14,INTRAMEDULLARY IMPLANT SYSTEMS AND METHODS,"This disclosure describes exemplary intramedullary implant systems. The intramedullary implant systems may be used for performing bone fracture, bone fusion, or osteotomy procedures within joints.",ARTHREX INC,KNIGHT MICHAEL;;GUEDERIAN GREG;;ACEVEDO JORGE;;MCWILLIAM JAMES;;SIDDIQUI NORMAN;;DAY ZACK,,https://lens.org/148-522-696-214-440,Patent Application,yes,9,0,4,4,0,A61B17/7291;;A61B17/8695;;A61B17/7233;;A61B2017/565;;A61B17/7233;;A61B17/725;;A61B17/7291;;A61B17/8057;;A61B2017/565,A61B17/80;;A61B17/72,,0,0,,,,PENDING
28,WO,A1,WO 2022/094737 A1,068-876-338-240-196,2022-05-12,2022,CL 2021050106 W,2021-10-29,CL 2020002901 A,2020-11-09,METHOD FOR THE TREATMENT OF A MINERAL,"A method for increasing the density of cracks and pores in a treated mineral, thereby improving the geomechanical conditions of the rock, so as to facilitate its comminution, and also improving penetration of leaching agents, for the enhanced extraction of valuable metals and the weakening of a mineral to be treated, so as to facilitate its fragmentation, with the application of high-frequency electrical power discharges to the mineral material to be treated.",NGEN POWER SPA,SANHUEZA LOYOLA CARLOS;;ACEVEDO ESCOBAR MANUEL;;FERNANDEZ DIAZ FERNANDO;;MUÑOZ FREIRE JORGE,,https://lens.org/068-876-338-240-196,Patent Application,yes,4,0,2,2,0,E21B43/20;;B02C19/18,B02C19/18,,0,0,,,,PENDING
29,EP,A1,EP 3820391 A1,147-074-846-537-18X,2021-05-19,2021,EP 19762000 A,2019-08-12,US 201862718656 P;;US 2019/0046147 W,2018-08-14,INTRAMEDULLARY IMPLANT SYSTEMS AND METHODS,,ARTHREX INC,KNIGHT MICHAEL;;GUEDERIAN GREGORY;;ACEVEDO JORGE;;MCWILLIAM JAMES;;SIDDIQUI NORMAN;;DAY ZACK,,https://lens.org/147-074-846-537-18X,Patent Application,yes,0,0,4,4,0,A61B17/7291;;A61B17/8695;;A61B17/7233;;A61B2017/565;;A61B17/7233;;A61B17/725;;A61B17/7291;;A61B17/8057;;A61B2017/565,A61B17/72;;A61B17/80,,0,0,,,,PENDING
30,US,A1,US 2023/0000505 A1,086-844-112-290-170,2023-01-05,2023,US 202217885803 A,2022-08-11,US 202217885803 A;;EP 18178849 A;;US 202017252865 A;;US 2019/0038116 W,2018-06-20,PERCUTANEOUS TARGETING DEVICE,"A percutaneous targeting device comprises a body holding an extension. The body has a target guide holding a target pin which may be a K-wire. The extension has two guide sleeves, holding a guide wire. All wires are held in a common plane. The guide wires serve as a guide for cannulated fixation screws. The extension is movable against the body to adjust the angle between the target pin and the guide wires.",ARTHREX INC,SCHAUMANN MICHAEL;;WESCHENFELDER REBECCA;;MIETZNER JÖRG;;DUBOIS-FERRIÈRE VICTOR;;DAY ZACK;;ACEVEDO JORGE,,https://lens.org/086-844-112-290-170,Patent Application,yes,0,0,9,9,0,A61B17/1775;;A61B2017/565;;A61B17/1775;;A61B17/848;;A61B17/8897;;A61B2017/565;;A61B90/11,A61B17/17;;A61B17/84;;A61B17/88,,0,0,,,,PENDING
31,CA,A1,CA 2307178 A1,062-830-578-653-422,1999-05-06,1999,CA 2307178 A,1998-10-13,US 96019097 A;;US 9821520 W,1997-10-29,SOLUBLE MHC COMPLEXES AND METHODS OF USE THEREOF,"The present invention relates to novel complexes of major histocompatibility complexe (MHC) molecules and uses of such complexes. In one aspect, the invention relates to single chain MHC class II complexes that include a class II .beta.2 chain modification, e.g., deletion of essentially the entire class II .beta.2 chain. In another aspect, the invention features single chain MHC class II which comprise an immunoglobin constant chain or fragment. Further provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.",SUNOL MOLECULAR CORP,RHODE PETER R;;WONG HING C;;JIAO JIN-AN;;ACEVEDO JORGE;;BURKHARDT MARTIN,,https://lens.org/062-830-578-653-422,Patent Application,no,0,0,15,15,38,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C12N15/09;;A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C07K19/00;;C12P21/08,,0,0,,,,DISCONTINUED
32,US,B1,US 6232445 B1,102-160-564-129-91X,2001-05-15,2001,US 96019097 A,1997-10-29,US 96019097 A,1997-10-29,Soluble MHC complexes and methods of use thereof,"The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to single chain MHC class II complexes that include a class II .beta.2 chain modification, e.g., deletion of essentially the entire class II .beta.2 chain. In another aspect, the invention features single chain MHC class II which comprise an immunoglobin constant chain or fragment. Further provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.",SUNOL MOLECULAR CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,ALTOR BIOSCIENCE CORPORATION (2003-02-06);;SUNOL MOLECULAR CORPORATION (1998-01-26),https://lens.org/102-160-564-129-91X,Granted Patent,yes,21,102,15,15,37,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C12N15/09;;C07K19/00;;C12P21/08,530/387.3;;530/350;;530/395;;435/69.3;;424/185.1;;424/193.1;;424/192.1;;424/133.1,25,24,047-502-746-319-567;;035-169-075-548-745;;110-119-248-558-099;;002-977-470-822-87X;;010-175-224-382-210;;003-169-562-620-897;;067-414-734-509-350;;053-896-041-421-90X;;056-178-403-528-775;;004-486-735-222-762;;110-983-633-899-692;;007-992-761-284-968;;070-570-207-285-642;;073-769-603-441-536;;019-844-160-509-253;;028-076-553-910-600;;033-612-583-763-645;;065-657-142-779-553;;017-481-135-511-180;;110-449-849-034-938;;024-947-545-870-093;;119-721-080-776-226;;096-808-659-810-496;;001-935-495-782-059,8177320;;10.1038/369151a0;;8234294;;pmc47768;;10.1073/pnas.90.21.10330;;10.1038/368215a0;;8145819;;10.2210/pdb1dlh/pdb;;10.1073/pnas.88.24.11465;;pmc53156;;1722335;;8110375;;7512979;;10.1172/jci117112;;pmc294148;;7512724;;10.1073/pnas.91.8.3137;;pmc43530;;8305133;;10.1016/0167-5699(93)90200-5;;7515244;;10.1016/0167-5699(94)90311-5;;pmc42963;;8290544;;10.1073/pnas.91.2.437;;10.1126/science.8456293;;8456293;;10.1126/science.8456302;;8456302;;10.1038/364016d0;;8316292;;8316295;;10.1038/364033a0;;1717570;;1402647;;pmc2119397;;10.1084/jem.176.4.1007;;1371238;;10.1016/0092-8674(92)90184-e;;10.1016/0161-5890(94)00150-y;;7723770;;7913461;;10.1016/s0021-9258(17)32310-4;;2389143;;10.1126/science.2389143;;1447172;;10.1016/s0021-9258(18)35753-3;;1379437;;10.1007/bf02918107;;3114395;;7679510;;pmc45923;;10.1073/pnas.90.4.1604,"H. Konozo et al., Nature, 369:151-154 (1994).;;J. Altman, et al., Proc. Natl. Acad. Sci, USA, 90:10330-10334 (1993).;;L. Stern, et al., Nature, 368:215-221 (1994).;;S. Sharma, et al., Proc. Natl. Acad. Sci. USA, 88:11465-11469 (1991).;;J. Guery, et al., Critical Reviews in Immunology, 13(3/4):195-206 (1993).;;M. Nicolle, et al., J. Clin. Invest., 93:1361-1369 (1994).;;D. Harlan, et al., Proc. Natl. Acad. Sci. USA, 91:3137-3141 (1994).;;E. Evahold, et al., Immunology Today, 14(12):602-609 (1993).;;R. Chicz, et al., Immunology Today, 15(4):155-160 (1994).;;R. Tisch, et al., Proc. Natl. Acad. Sci. USA, 91:437-438 (1994).;;Science, 259:1691-1692 (1993).;;J. Ulmer, et al., Science, 259:1745-1749 (1993).;;H. Ploegh, et al., Nature, 364:16-17 (1993).;;J. Brown, et al., Nature, 364:33-39 (1993).;;D. O'Sullivan, et al., Journal of Immunology, 147:2663-2669 (1991).;;J. Hammer, et al., J. Exp. Med., 176:1007-1013 (1992).;;L. Stern, et al., Cell, 68:465-477 (1992).;;K. Webber, et al., Molecular Immunology, 32:249-258 (1995).;;Y. Reiter, et al., The Journal of Biological Chemistry, 269:18327-18331 (1994).;;K. O'Neil, et al., Science, 249:774-778. (1990).;;K. O'Neil, et al., Science, 249:774-778, (1990).;;Godeau, et al., Journal of Biological Chemistry: ""Purification and Ligand Binding of a Soluble Class 1 Major Histocompatibility Complex Module Consisting of the First Three Domains of H-2Kd Fused"" 267: 24223 (1992).;;J. C. Gorga, Ph.D., ""Structural Analysis of Class II Major Histocompatibility Complex Proteins"", Critical Review in Immunology, 11(5): pp. 305-335 (1992).;;D. H. Margulies, et al., ""Engineering Soluble Major Histocompatibility Molecules: Why and How"", Immunol. Res., 6: pp. 101-116 (1987).;;B. Nag, et al., ""Stimulation of T cells by Antigenic Peptide Complexed With Isolated Chains of Major Histocompatibility Complex Class II Molecules"", Proc. Natl. Acad. Sci. USA, 90: pp. 1604-1608 (1993).",EXPIRED
33,US,A1,US 2002/0091079 A1,068-161-703-270-90X,2002-07-11,2002,US 76637801 A,2001-01-19,US 76637801 A;;US 96019097 A,1997-10-29,Soluble MHC complexes and methods of use thereof,"
   The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to single chain MHC class II complexes that include a class II 2 chain modification, e.g., deletion of essentially the entire class II 2 chain. In another aspect, the invention features single chain MHC class II which comprise an immunoglobin constant chain or fragment. Further provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal. 
",SUNOL MOLECULAR CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,,https://lens.org/068-161-703-270-90X,Patent Application,yes,0,33,15,15,38,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C12N15/09;;C07K19/00;;C12P21/08,514/12;;424/130.1;;530/387.1;;536/23.1,0,0,,,,EXPIRED
34,EP,A1,EP 1027066 A1,002-481-043-111-169,2000-08-16,2000,EP 98952256 A,1998-10-13,US 9821520 W;;US 96019097 A,1997-10-29,SOLUBLE MHC COMPLEXES AND METHODS OF USE THEREOF,,SUNOL MOLECULAR CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,ALTOR BIOSCIENCE CORPORATION (2004-05-19),https://lens.org/002-481-043-111-169,Patent Application,yes,0,0,15,15,38,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C12N15/09;;A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C07K19/00;;C12P21/08,,0,0,,,,DISCONTINUED
35,EP,A4,EP 1027066 A4,038-899-883-396-579,2002-10-23,2002,EP 98952256 A,1998-10-13,US 9821520 W;;US 96019097 A,1997-10-29,SOLUBLE MHC COMPLEXES AND METHODS OF USE THEREOF,,SUNOL MOLECULAR CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,ALTOR BIOSCIENCE CORPORATION (2004-05-19),https://lens.org/038-899-883-396-579,Search Report,no,7,0,15,15,0,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C12N15/09;;A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C07K19/00;;C12P21/08,,2,1,082-742-258-395-837,9075851;;10.1097/00007890-199703150-00025,"LEPLEY DENISE M ET AL: ""Biochemical and functional characterization of soluble multivalent MHC L-d/Fc-gamma-1 and L-d/Fc-mu chimeric proteins loaded with specific peptides."", TRANSPLANTATION, vol. 63, no. 5, 1997, pages 765 - 774, XP001097875, ISSN: 0041-1337;;See also references of WO 9921572A1",DISCONTINUED
36,EP,A1,EP 3809986 A1,086-271-019-612-512,2021-04-28,2021,EP 19733919 A,2019-06-20,EP 18178849 A;;US 2019/0038116 W,2018-06-20,PERCUTANEOUS TARGETING DEVICE,,ARTHREX INC,SCHAUMANN MICHAEL;;MAYER REBECCA;;MIETZNER JÖRG;;DUBOIS-FERRIÈRE VICTOR;;DAY ZACK;;ACEVEDO JORGE,,https://lens.org/086-271-019-612-512,Patent Application,yes,0,0,9,9,0,A61B17/1775;;A61B2017/565;;A61B17/1775;;A61B17/848;;A61B17/8897;;A61B2017/565;;A61B90/11,A61B17/17,,0,0,,,,DISCONTINUED
37,US,A1,US 2023/0000506 A1,015-850-212-666-871,2023-01-05,2023,US 202217890350 A,2022-08-18,US 202217890350 A;;EP 18178849 A;;US 202217885803 A;;US 202017252865 A;;US 2019/0038116 W,2018-06-20,PERCUTANEOUS TARGETING DEVICE,"A percutaneous targeting device comprises a body holding an extension. The body has a target guide holding a target pin which may be a K-wire. The extension has two guide sleeves, holding a guide wire. All wires are held in a common plane. The guide wires serve as a guide for cannulated fixation screws. The extension is movable against the body to adjust the angle between the target pin and the guide wires.",ARTHREX INC,SCHAUMANN MICHAEL;;WESCHENFELDER REBECCA;;MIETZNER JÖRG;;DUBOIS-FERRIÈRE VICTOR;;DAY ZACK;;ACEVEDO JORGE,,https://lens.org/015-850-212-666-871,Patent Application,yes,0,0,9,9,0,A61B17/1775;;A61B2017/565;;A61B17/1775;;A61B17/848;;A61B17/8897;;A61B2017/565;;A61B90/11,A61B17/17;;A61B90/11,,0,0,,,,PENDING
38,JP,A,JP 2009213484 A,126-655-935-474-778,2009-09-24,2009,JP 2009114590 A,2009-05-11,US 96019097 A,1997-10-29,SOLUBLE MHC COMPLEX AND METHOD OF USE THEREOF,"<P>PROBLEM TO BE SOLVED: To provide new complexes of major histocompatibility antigen complex (MHC) molecules, and to provide uses of such complexes. <P>SOLUTION: Provided are single chain MHC class II complexes that include deletion of essentially the entire class II β2 chain. Provided is single chain MHC class II which includes an immunoglobin constant chain or fragment. Further provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. Provided are MHC complexes useful for a variety of applications including: (1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and (2) methods for suppressing or inducing an immune response in a mammal. <P>COPYRIGHT: (C)2009,JPO&INPIT",ALTOR BIOSCIENCE CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,,https://lens.org/126-655-935-474-778,Patent Application,no,0,0,15,15,36,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C12N15/09;;A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C07K16/00;;C07K19/00;;C12P21/02;;C12P21/08,,0,0,,,,PENDING
39,WO,A1,WO 2019/246332 A1,181-031-570-547-83X,2019-12-26,2019,US 2019/0038116 W,2019-06-20,EP 18178849 A,2018-06-20,PERCUTANEOUS TARGETING DEVICE,"A percutaneous targeting device comprises a body holding an extension. The body has a target guide holding a target pin which may be a K-wire. The exten-sion has two guide sleeves, holding a guide wire. All wires are held in a common plane. The guide wires serve as a guide for cannulated fixation screws. The ex-tension is movable against the body to adjust the angle between the target pin and the guide wires.",ARTHREX INC,SCHAUMANN MICHAEL;;WESCHENFELDER REBECCA;;MIETZNER JÖRG;;DUBOIS-FERRIÈRE VICTOR;;DAY ZACK;;ACEVEDO JORGE,,https://lens.org/181-031-570-547-83X,Patent Application,yes,4,0,9,9,0,A61B17/1775;;A61B2017/565;;A61B17/1775;;A61B17/848;;A61B17/8897;;A61B2017/565;;A61B90/11,A61B17/17,,0,0,,,,PENDING
40,AU,A1,AU 2019/288398 A1,108-794-511-153-847,2020-12-17,2020,AU 2019/288398 A,2019-06-20,EP 18178849 A;;US 2019/0038116 W,2018-06-20,Percutaneous targeting device,"A percutaneous targeting device comprises a body holding an extension. The body has a target guide holding a target pin which may be a K-wire. The exten-sion has two guide sleeves, holding a guide wire. All wires are held in a common plane. The guide wires serve as a guide for cannulated fixation screws. The ex-tension is movable against the body to adjust the angle between the target pin and the guide wires.",ARTHREX INC,SCHAUMANN MICHAEL;;WESCHENFELDER REBECCA;;MIETZNER JÖRG;;DUBOIS-FERRIÈRE VICTOR;;DAY ZACK;;ACEVEDO JORGE,,https://lens.org/108-794-511-153-847,Patent Application,no,0,0,9,9,0,A61B17/1775;;A61B2017/565;;A61B17/1775;;A61B17/848;;A61B17/8897;;A61B2017/565;;A61B90/11,A61B17/17,,0,0,,,,DISCONTINUED
41,US,B2,US 7074905 B2,019-370-714-596-589,2006-07-11,2006,US 76637801 A,2001-01-19,US 76637801 A;;US 96019097 A,1997-10-29,Soluble MHC complexes and methods of use thereof,"The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to single chain MHC class II complexes that include a class II β2 chain modification, e.g., deletion of essentially the entire class II β2 chain. In another aspect, the invention features single chain MHC class II which comprise an immunoglobin constant chain or fragment. Further provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.",ALTOR BIOSCIENCE CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,,https://lens.org/019-370-714-596-589,Granted Patent,yes,21,9,15,15,38,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C07K16/00;;A61K38/00;;C12N15/09;;A61P37/06;;A61P43/00;;C07K14/74;;C07K19/00;;C12P21/08,530/402;;530/403;;530/391.7,29,24,119-721-080-776-226;;096-808-659-810-496;;001-935-495-782-059;;024-947-545-870-093;;047-502-746-319-567;;035-169-075-548-745;;110-119-248-558-099;;002-977-470-822-87X;;010-175-224-382-210;;003-169-562-620-897;;067-414-734-509-350;;053-896-041-421-90X;;056-178-403-528-775;;004-486-735-222-762;;110-983-633-899-692;;007-992-761-284-968;;070-570-207-285-642;;073-769-603-441-536;;019-844-160-509-253;;028-076-553-910-600;;033-612-583-763-645;;065-657-142-779-553;;017-481-135-511-180;;110-449-849-034-938,1379437;;10.1007/bf02918107;;3114395;;7679510;;pmc45923;;10.1073/pnas.90.4.1604;;1447172;;10.1016/s0021-9258(18)35753-3;;8177320;;10.1038/369151a0;;8234294;;pmc47768;;10.1073/pnas.90.21.10330;;10.1038/368215a0;;8145819;;10.2210/pdb1dlh/pdb;;10.1073/pnas.88.24.11465;;pmc53156;;1722335;;8110375;;7512979;;10.1172/jci117112;;pmc294148;;7512724;;10.1073/pnas.91.8.3137;;pmc43530;;8305133;;10.1016/0167-5699(93)90200-5;;7515244;;10.1016/0167-5699(94)90311-5;;pmc42963;;8290544;;10.1073/pnas.91.2.437;;10.1126/science.8456293;;8456293;;10.1126/science.8456302;;8456302;;10.1038/364016d0;;8316292;;8316295;;10.1038/364033a0;;1717570;;1402647;;pmc2119397;;10.1084/jem.176.4.1007;;1371238;;10.1016/0092-8674(92)90184-e;;10.1016/0161-5890(94)00150-y;;7723770;;7913461;;10.1016/s0021-9258(17)32310-4;;2389143;;10.1126/science.2389143,"J. C. Gorga, Ph.D., ""Structural Analysis of Class II Major Histocompatibility Complex Proteins"", Critical Review in Immunology, 11(5): pp. 305-335 (1992).;;D. H. Margulies, et al., ""Engineering Soluble Major Histocompatibility Molecules: Why and How"", Immunol. Res., 6: pp. 101-116 (1987).;;B. Nag, et al., ""Stimulation of T cells by Antigenic Peptide Complexed With Isolated Chains of Major Histocompatibility Complex Class II Molecules"", Proc. Natl. Acad. Sci. USA, 90: pp. 1604-1608 (1993).;;Copy of Notification & Int'l Search Report dated Feb. 12, 1999 re corresponding Int'l Appln. No. PCT/US98/21520.;;Godeau, et al., Journal of Biological Chemistry: Purification and Ligand Binding of a Soluble Class 1 Major Histocompatibility Complex Module Consisting of the First Three Domains of H-2K<SUP>d </SUP>Fused 267: 24223 (1992).;;H. Konozo, et al., Nature, 369:151-154 (1994).;;J. Altman, et al., Proc. Natl. Acad. Sci, USA, 90:10330-10334 (1993).;;L. Stern, et al., Nature, 368:215-221 (1994).;;S. Sharma, et al., Proc. Natl. Acad. Sci. USA, 88:11465-11469 (1991).;;J. Guery, et al., Critical Reviews in Immunology, 13(3/4):195-206 (1993).;;M. Nicolle, et al., J. Clin. Invest., 93:1361-1369 (1994).;;D. Harlan, et al., Proc. Natl. Acad. Sci. USA, 91:3137-3141 (1994).;;E. Evahold, et al., Immunology Today, 14(12):602-609 (1993).;;R. Chicz, et al., Immunology Today, 15(4):155-160 (1994).;;R. Tisch, et al., Proc. Natl. Acad. Sci. USA, 91:437-438 (1994).;;Science, 259:1691-1692 (1993).;;J. Ulmer, et al., Science, 259:1745-1749 (1993).;;H. Ploegh, et al., Nature, 364:16-17 (1993).;;J. Brown, et al., Nature, 364:33-39 (1993).;;D. O'Sullivan, et al., Journal of Immunology, 147:2663-2669 (1991).;;J. Hammer, et al., J. Exp. Med., 176:1007-1013 (1992).;;L. Stern, et al., Cell, 68:465-477 (1992).;;K. Webber, et al., Molecular Immunology, 32:249-258 (1995).;;Y. Reiter, et al., The Journal of Biological Chemistry, 269:18327-18331 (1994).;;K. O'Neil, et al., Science, 249:774-778.;;U.S. Appl. No. 08/283,302, filed Jul. 29, 1994, Hing C. Wong et al.;;U.S. Appl. No. 08/382,454, filed Mar. 2, 1998, Peter Rhode et al.;;U.S. Appl. No. 09/848,164, filed May 3, 2001, Martin Burkhardt et al.;;U.S. Appl. No. 09/900,379, filed Jan. 17, 1997, Peter Rhode et al.",EXPIRED
42,US,A1,US 2021/0113223 A1,158-617-848-085-778,2021-04-22,2021,US 201917252865 A,2019-06-20,EP 18178849 A;;US 2019/0038116 W,2018-06-20,PERCUTANEOUS TARGETING DEVICE,"A percutaneous targeting device comprises a body holding an extension. The body has a target guide holding a target pin which may be a K-wire. The exten-sion has two guide sleeves, holding a guide wire. All wires are held in a common plane. The guide wires serve as a guide for cannulated fixation screws. The ex-tension is movable against the body to adjust the angle between the target pin and the guide wires.",ARTHREX INC,SCHAUMANN MICHAEL;;WESCHENFELDER REBECCA;;MIETZNER JÖRG;;DUBOIS-FERRIÈRE VICTOR;;DAY ZACK;;ACEVEDO JORGE,ARTHREX INC (2020-01-21),https://lens.org/158-617-848-085-778,Patent Application,yes,0,4,9,9,0,A61B17/1775;;A61B2017/565;;A61B17/1775;;A61B17/848;;A61B17/8897;;A61B2017/565;;A61B90/11,A61B17/17;;A61B17/84;;A61B17/88,,0,0,,,,DISCONTINUED
43,WO,A1,WO 1999/021572 A1,013-124-220-020-094,1999-05-06,1999,US 9821520 W,1998-10-13,US 96019097 A,1997-10-29,SOLUBLE MHC COMPLEXES AND METHODS OF USE THEREOF,"The present invention relates to novel complexes of major histocompatibility complexe (MHC) molecules and uses of such complexes. In one aspect, the invention relates to single chain MHC class II complexes that include a class II β2 chain modification, e.g., deletion of essentially the entire class II β2 chain. In another aspect, the invention features single chain MHC class II which comprise an immunoglobin constant chain or fragment. Further provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.",SUNOL MOLECULAR CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,,https://lens.org/013-124-220-020-094,Patent Application,yes,1,26,15,15,0,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C12N15/09;;C07K19/00;;C12P21/08,,4,3,119-721-080-776-226;;096-808-659-810-496;;001-935-495-782-059,1379437;;10.1007/bf02918107;;3114395;;7679510;;pmc45923;;10.1073/pnas.90.4.1604,"GORGA J. C.: ""STRUCTURAL ANALYSIS OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX PROTEINS."", CRITICAL REVIEWS IN IMMUNOLOGY., CRC PRESS, INC., US, vol. 11., no. 05., 1 January 1992 (1992-01-01), US, pages 305 - 335., XP002916388, ISSN: 1040-8401;;MARGULIES D. H., ET AL.: ""ENGINEERING SOLUBLE MAJOR HISTOCOMPATIBILITY MOLECULES: WHY AND HOW."", IMMUNOLOGIC RESEARCH., HUMANA PRESS, INC, US, vol. 06., 1 January 1987 (1987-01-01), US, pages 101 - 116., XP002916389, ISSN: 0257-277X, DOI: 10.1007/BF02918107;;NAG B., ET AL.: ""STIMULATION OF T CELLS BY ANTIGENIC PEPTIDE COMPLEXED WITH ISOLATED CHAINS OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II MOLECULES."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 90., 1 February 1993 (1993-02-01), US, pages 1604 - 1608., XP002916405, ISSN: 0027-8424, DOI: 10.1073/pnas.90.4.1604;;See also references of EP 1027066A4",PATENTED
44,AU,A,AU 1998/098001 A,069-745-026-743-524,1999-05-17,1999,AU 1998/098001 A,1998-10-13,US 96019097 A;;US 9821520 W,1997-10-29,Soluble mhc complexes and methods of use thereof,,ALTOR BIOSCIENCE CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,ALTOR BIOSCIENCE CORPORATION (2004-10-28),https://lens.org/069-745-026-743-524,Patent Application,no,0,0,15,15,0,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C12N15/09;;A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C07K19/00;;C12P21/08,,0,0,,,,EXPIRED
45,MX,A,MX 2022012646 A,164-008-986-812-033,2022-11-07,2022,MX 2022012646 A,2022-10-07,MX 2022012646 A,2022-10-07,DEVICE AND METHOD TO MEASURE WITH ARTIFICIAL VISION THE GEOMETRY OF THE WET BULB IN DRIP IRRIGATION.,"The present invention relates to a device for measuring the geometry of the wet bulb in drip irrigation with an artificial vision. Said device comprises a computer to connect with one digital or thermal camera to focus and take images of the wet bulb on a surface with a distance measuring device, imaging camera lens to the soil surface locating the wet bulb and used to calculate the geometry. Also, it includes a cooling system or temperature regulator controlled by said computer for circulating cooling air within the device, a human-machine interface system for the interaction between the user and the device, an information communication system, and a casing housing said components. Further, a support and leveling system and a power supply for the computer provide energy to the whole system.",UNIV AUTONOMA CHAPINGO,VELÁZQUEZ LÓPEZ NOÉ;;PRADO HERNÁNDEZ JORGE VICTOR;;CRISTOBAL MUÑOZ IROURI;;CRISTOBAL ACEVEDO DAVID,,https://lens.org/164-008-986-812-033,Patent Application,no,0,0,1,1,0,,A01G25/02,,0,0,,,,PENDING
46,JP,A,JP 2009213483 A,192-605-602-198-347,2009-09-24,2009,JP 2009114585 A,2009-05-11,US 96019097 A,1997-10-29,SOLUBLE MHC COMPLEX AND METHOD OF USE THEREOF,"<P>PROBLEM TO BE SOLVED: To provide new complexes of major histocompatibility complex (MHC) molecules, and to provide uses of such complexes. <P>SOLUTION: Provided are single chain MHC class II complexes that include a class II β2 chain modification, e.g. deletion of essentially the entire class II β2 chain. In another aspect, provided is single chain MHC class II which comprises an immunoglobin constant chain or fragment. Further, provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. The MHC complexes are useful for a variety of applications including: (1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and (2) methods for suppressing or inducing an immune response in a mammal. <P>COPYRIGHT: (C)2009,JPO&INPIT",ALTOR BIOSCIENCE CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,,https://lens.org/192-605-602-198-347,Patent Application,no,0,0,15,15,36,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C12N15/09;;A61K38/00;;A61K39/395;;A61P37/02;;A61P37/06;;A61P43/00;;C07K14/74;;C07K19/00;;C12P21/02;;C12P21/08,,0,0,,,,PENDING
47,AU,B2,AU 755941 B2,152-338-324-044-422,2003-01-02,2003,AU 1998/098001 A,1998-10-13,US 96019097 A;;US 9821520 W,1997-10-29,Soluble MHC complexes and methods of use thereof,,SUNOL MOLECULAR CORP,RHODE PETER R;;ACEVEDO JORGE;;BURKHARDT MARTIN;;JIAO JIN-AN;;WONG HING C,ALTOR BIOSCIENCE CORPORATION (2004-10-28),https://lens.org/152-338-324-044-422,Granted Patent,no,1,0,15,15,0,A61K38/00;;C07K14/70539;;C07K2319/00;;C12N2799/026;;A61P37/02;;A61P37/06;;A61P43/00;;A61K38/00;;C07K14/70539;;C12N2799/026;;A61K38/00;;C07K2319/00,C12N15/09;;A61K38/00;;A61P37/06;;A61P43/00;;C07K14/74;;C07K19/00;;C12P21/08,,0,0,,,,EXPIRED
48,ES,A1,ES 2141679 A1,194-619-633-823-088,2000-03-16,2000,ES 9801067 A,1998-05-22,ES 9801067 A,1998-05-22,"Application of a visual immunoassay for identification of coeliac disease, using wheat gliadins as antigen","Process for visualising the detection of antigliadin antibodies, characterised by the use of a wheat-gliadin extract as antigen and a system which employs opaque white polystyrene sheets as solid support and protein A conjugated with colloidal gold as detection substance.",CONSEJO SUPERIOR INVESTIGACION;;CIGB,MENDEZ ENRIQUE;;ALONSO SANSEGUNDO PATRICIA;;ACEVEDO CASTRO BORIS ERNESTO;;SORELL LUIS;;GAVILONDO COWLEY JORGE,,https://lens.org/194-619-633-823-088,Patent Application,no,1,2,2,2,0,,G01N33/549,,2,2,039-430-147-358-409;;104-564-005-926-553,6352817;;10.1016/0022-1759(83)90421-0;;1432469;;10.1097/00005176-199210000-00012,"TRONCONE R. et al.: ""A solid-phase radioimmunoassay for IgG gliadin antibodies using 125I-labelled staphylococcal protein A"". Octubre 1983. JOURNAL OF IMMUNOLOGICAL METHODS, Vol. 63 (2), paginas 163-70.;;PERTICARARI S. et al.: ""ELISA method for quantitative measurement of IgA and IgG specific anti-gliadin antibodies"". Octubre 1992. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. Vol. 15 (3), paginas 302-309.",EXPIRED
49,MX,A,MX 2016003689 A,180-120-681-892-845,2017-09-21,2017,MX 2016003689 A,2016-03-22,MX 2016003689 A,2016-03-22,METHOD FOR DUPLEX SURFACE THERMAL TREATMENT BY PLASMA STEEL GRADE OF AN H13 TOOL.,"The present invention discloses a duplex plasma treatment method for a grade steel of an H13 tool, which comprises a first step of plasma heat treatment in a temperature range of up 470°C to 530°C, for four hours at a two Torr pressure. All of that in a gaseous atmosphere of nitrogen and hydrogen, at a current density of up between 1.0 mA / cm2. The said first stage promotes the formation of a surface layer consisting of Fe3N and Fen type iron nitrides. Also, it comprises a second step by plasma heat treatment in a temperature range of up 470°C to 530°C for one hour at a two Torr pressure in a gaseous atmosphere of oxygen and hydrogen, using a current density of up to 0.5 mA /cm2. This second step promotes the formation of a layer of surface oxides of the type Fe2O3 and Fe3O4. The pieces treated under the duplex treatment exhibit a decrease in the value of the friction coefficient at 37.5% concerning the untreated material and 40% of the value obtained for the nitride material, and co ncerning the surface hardness, it exhibits properties with values at 190% of above the untreated material.",CORPORACIÓN MEXICANA DE INVESTIGACIÓN EN MAT S A DE C V,JORGE LEOBARDO ACEVEDO DAVILA;;ALEJANDRO GARZA GOMEZ;;JUAN CARLOS DIAZ GUILLEN;;RITA MUÑOZ ARROYO,,https://lens.org/180-120-681-892-845,Patent Application,no,0,0,1,1,0,,C21D1/09,,0,0,,,,PENDING
50,CU,A1,CU 22826 A1,073-154-541-022-406,2003-01-29,2003,CU 20000262 A,2000-11-24,CU 20000262 A,2000-11-24,ANTICUERPOS MONOCLONALES DE RATÓN QUE RECONOCEN EL ANTÍGENO ESPECÍFICO DE PRÓSTATA (PSA) HUMANO UTILIDAD PARA LA DETECCIÓN DEL PSA TOTAL EN SUERO Y SU INMUNOPURIFICACIÓN DESDE LÍQUIDO SEMINAL,"La presente invención está relacionada con la aplicación en el diagnóstico y tratamiento del cáncer y, en particular, con 3 anticuerpos monoclonales (AcM) de ratón que conocen el antígeno específico de próstata humano (PSA), con aplicabilidad en el desarrollo de inmunoensayos en vitro que detecten el PSA total y/o libre, en la inmunopurificación del PSA, y para dirigir agentes con potencial diagnóstico y terapéutico específicamente hacia células tumorales humanas que expresen PSA.",CT INGENIERIA GENETICA BIOTECH,AYALA AVILA MARTHA;;GAVILONDO COWLEY JORGE V;;ROJAS DORANTES GERTRUDIS;;ACEVEDO CASTRO BORIS ERNESTO,,https://lens.org/073-154-541-022-406,Limited Patent,no,0,0,1,1,0,,C07K16/18;;C07K17/00;;G01N33/574,,0,0,,,,EXPIRED
51,ES,B1,ES 2141679 B1,148-342-731-412-314,2000-12-01,2000,ES 9801067 A,1998-05-22,ES 9801067 A,1998-05-22,APLICACION DE UN INMUNOENSAYO VISUAL PARA LA IDENTIFICACION DE LA ENFERMEDAD CELIACA UTILIZANDO COMO ANTIGENO GLIADINAS DE TRIGO.,"Aplicación de un inmunoensayo visual para la identificación de la enfermedad celíaca utilizando como antígeno gliadinas de trigo. Procedimiento para visualizar la detección de anticuerpos antigliadina, caracterizado por la utilización de un extracto de gliadina de trigo como antígeno y un sistema que emplea láminas de polientireno blanco opaco como soporte sólido y proteína A conjugada con oro colodial como sustancia de detección.",CONSEJO SUPERIOR INVESTIGACION;;CT INGENIERIA GENETICA BIOTECH,MENDEZ ENRIQUE;;ALONSO SANSEGUNDO PATRICIA;;ACEVEDO CASTRO BORIS ERNESTO;;SORELL LUIS;;GAVILONDO COWLEY JORGE,,https://lens.org/148-342-731-412-314,Granted Patent,no,0,1,2,2,0,,G01N33/549,,0,0,,,,EXPIRED
52,EP,A1,EP 3509390 A1,181-489-601-775-339,2019-07-10,2019,EP 18214829 A,2018-12-20,ES 201830014 A,2018-01-08,DOMESTIC APPLIANCE,"Die Erfindung geht aus von einer Haushaltsgerätevorrichtung (10), insbesondere einer Kochfeldvorrichtung, mit zumindest einer Funktionseinheit (12) und mit einer Steuereinheit (14), welche zu einer Ansteuerung der Funktionseinheit (12) vorgesehen ist. Um eine Betriebssicherheit zu erhöhen wird vorgeschlagen, dass die Haushaltsgerätevorrichtung eine von der Steuereinheit (14) separat ausgebildete Sicherheitselektronikeinheit (16) aufweist, welche in zumindest einem Betriebszustand zu einer Überprüfung zumindest eines Signals (18) der Funktionseinheit (12) und/oder der Steuereinheit (14) vorgesehen ist.
",BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;PASCUAL AZA JORGE;;PUYAL PUENTE DIEGO;;VALEAU MARTIN DAVID,,https://lens.org/181-489-601-775-339,Patent Application,yes,8,0,3,3,0,H05B1/0266;;G05B23/0205;;G06F11/30;;H05B6/666,H05B1/02,,0,0,,,,ACTIVE
53,ES,A1,ES 2719154 A1,015-228-173-068-851,2019-07-08,2019,ES 201830014 A,2018-01-08,ES 201830014 A,2018-01-08,"Household appliance device (Machine-translation by Google Translate, not legally binding)","Domestic appliance device. The present invention relates to a domestic appliance device (10), in particular, to a cooking field device, with at least one functional unit (12) and with a control unit (14), which is intended to activate the functional unit (12). In order to increase the safety of operation, it is proposed that the home appliance device has a safety electronics unit (16) made separately from the control unit (14), which is provided in at least one state of operation to examine at least one signal (18) of the functional unit (12) and/or of the control unit (14). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA SA;;BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;PASCUAL AZA JORGE;;PUYAL PUENTE DIEGO;;VALEAU MARTÍN DAVID,,https://lens.org/015-228-173-068-851,Patent Application,no,3,0,3,3,0,H05B1/0266;;G05B23/0205;;G06F11/30;;H05B6/666,G05B23/02;;G06F11/30;;H05B6/68,,0,0,,,,DISCONTINUED
54,EP,B1,EP 3509390 B1,112-595-707-895-44X,2022-11-09,2022,EP 18214829 A,2018-12-20,ES 201830014 A,2018-01-08,DOMESTIC APPLIANCE,,BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;PASCUAL AZA JORGE;;PUYAL PUENTE DIEGO;;VALEAU MARTIN DAVID,,https://lens.org/112-595-707-895-44X,Granted Patent,yes,3,0,3,3,0,H05B1/0266;;G05B23/0205;;G06F11/30;;H05B6/666,H05B1/02,,0,0,,,,ACTIVE
55,CL,A1,CL 2020002901 A1,151-192-707-844-624,2021-04-23,2021,CL 2020002901 A,2020-11-09,CL 2020002901 A,2020-11-09,Método para el tratamiento de un mineral.,"Un método para el aumento de la densidad de las grietas, y poros de un mineral tratado, mejorando por un lado la condición geomecánica de la roca de modo de facilitar su conminución y por otro lado al mejoramiento de la penetración de agentes lixiviantes para la mejora de la extracción de metales valiosos y debilitamiento de un mineral a ser tratado de modo de facilitar su fragmentación, por medio de aplicar descargas eléctricas de potencia a alta frecuencia al material mineral a tratar.",NGEN POWER SPA,CARLOS ANDRÉS SANHUEZA LOYOLA;;MANUEL ALONSO ACEVEDO ESCOBAR;;FERNANDO ANDRES FERNANDEZ DIAZ;;JORGE ANDRES MUÑOZ FREIRE,,https://lens.org/151-192-707-844-624,Patent Application,no,0,0,2,2,0,E21B43/20;;B02C19/18,E21B43/20,,0,0,,,,PENDING
56,MX,A,MX 2016006105 A,011-779-679-185-989,2017-11-09,2017,MX 2016006105 A,2016-05-10,MX 2016006105 A,2016-05-10,TREATMENT METHOD FOR REMOVING MAGNESIUM DURING THE PRODUCTION OF AN ALUMINUM A380 ALLOY.,"The present disclosure is related to a treatment method for removing magnesium during the production of an A380 aluminum alloy; specifically during its liquid state in the oven, in order to obtain a low density, mechanical strength and high corrosion resistance alloy, through a reactive agent composed of mineral zeolite and potentiated with SiO2 nanoparticles (NPS); achieving efficiencies superior to 80% of magnesium elimination in just 55 minutes of processing, impacting positively on energy consumption by lowering costs associated with the same, as well as operation and raw material costs.",CORPORACIÓN MEXICANA DE INVESTIGACIÓN EN MAT S A DE C V,JORGE LEOBARDO ACEVEDO DAVILA;;JUAN CARLOS DIAZ GUILLEN;;ALEJANDRO GARZA GOMEZ;;RITA MUÑOZ ARROYO;;HÉCTOR MANUEL HERNÁNDEZ GARCÍA,,https://lens.org/011-779-679-185-989,Patent Application,no,0,0,1,1,0,,C22B21/00,,0,0,,,,PENDING
57,ES,A2,ES 2592960 A2,115-207-044-403-783,2016-12-02,2016,ES 201530771 A,2015-06-02,ES 201530771 A,2015-06-02,"Indicator of the water terrain state and method of measurement of the water state of the terrain (Machine-translation by Google Translate, not legally binding)","Indicator of the hydric state of the land and method of measuring the water status of the land. Indicator of hydric state of terrain that has: a sensor (4) sensitive to an interaction with water molecules; wiring (2) to feed the sensor (4) and to take a measurement provided by the sensor (4); a contact junction (3) between the wiring (2) and the sensor (4). Method of measuring the ground water status by means of the indicator that implies: introducing the indicator in the terrain; facing a lower part (a) of the indicator to the ground; in such a way that an opening of the cavity (5) is inside the ground. (Machine-translation by Google Translate, not legally binding)",MACRAUT INGENIEROS S L,CORREA DUARTE MIGUEL;;FARIÑA RODRÍGUEZ JOSÉ;;MARCOS ACEVEDO JORGE;;FARIÑA ALVAREZ PEDRO;;FRANCO MARTÍNEZ MIGUEL;;AMENEIRO PRIETO OSCAR,"ELECTROSON GALICIA, S.A. (2018-02-20)",https://lens.org/115-207-044-403-783,Patent Application,no,0,0,3,3,0,G01N33/24;;G01N27/06,G01N33/24;;G01N27/06,,0,0,,,,INACTIVE
58,WO,A1,WO 2019/135121 A1,101-503-914-494-315,2019-07-11,2019,IB 2018059326 W,2018-11-27,ES 201830016 A,2018-01-08,HOB DEVICE,"The aim of the invention is to provide such a device with improved properties with respect to heating cookware. This is achieved in that a hob device, in particular an induction hob device, is proposed with a plurality of heating units (12a-c) which define at least one variable cooking surface region (14a-c); at least one first heating frequency unit (28a-c) which is solely paired with first heating units (12a1-c1) of the heating units (12a-c), said first heating units defining a first cooking surface section (20a-c) of the variable cooking surface region (14a-c); at least one second heating frequency unit (30a-c) which is solely paired with second heating units (12a2-c2) of the heating units (12a-c), said second heating units defining a second cooking surface section (22a-c) of the variable cooking surface region (14a-c) differing from the first cooking surface section (20a-c); and at least one third heating frequency unit (32a-c) which can be selectively paired with at least some of the first heating units (12a1-c1) and/or at least some of the second heating units (12a2-c2).",BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;ESPAÑOL LEZA JORGE;;LAFUENTE URETA JULIO;;PALLARES ZAERA OSCAR;;VALEAU MARTIN DAVID,,https://lens.org/101-503-914-494-315,Patent Application,yes,6,0,3,3,0,H05B3/74;;H05B6/065;;H05B6/12;;H05B2213/03,H05B6/06,,0,0,,,,PENDING
59,DE,A5,DE 112018006790 A5,011-799-009-393-656,2020-11-12,2020,DE 112018006790 T,2018-11-27,ES 201830016 A;;IB 2018059326 W,2018-01-08,Kochfeldvorrichtung,,BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;ESPAÑOL LEZA JORGE;;LAFUENTE URETA JULIO;;PALLARES ZAERA OSCAR;;VALEAU MARTIN DAVID,,https://lens.org/011-799-009-393-656,Patent Application,no,0,0,3,3,0,H05B3/74;;H05B6/065;;H05B6/12;;H05B2213/03,H05B6/06,,0,0,,,,PENDING
60,ES,B1,ES 2592960 B1,037-452-892-460-002,2017-11-20,2017,ES 201530771 A,2015-06-02,ES 201530771 A,2015-06-02,INDICADOR DEL ESTADO HIDRICO DE TERRENO Y METODO DE MEDIDA DEL ESTADO HIDRICO DEL TERRENO,,MACRAUT INGENIEROS S L,CORREA DUARTE MIGUEL;;FARIÑA RODRÍGUEZ JOSÉ;;MARCOS ACEVEDO JORGE;;FARIÑA ALVAREZ PEDRO;;FRANCO MARTÍNEZ MIGUEL;;AMENEIRO PRIETO OSCAR,"ELECTROSON GALICIA, S.A. (2018-02-20)",https://lens.org/037-452-892-460-002,Granted Patent,no,0,0,3,3,0,G01N33/24;;G01N27/06,G01N33/24;;G01N27/06,,0,0,,,,INACTIVE
61,MX,A,MX 2015017132 A,096-357-288-614-540,2017-06-12,2017,MX 2015017132 A,2015-12-11,MX 2015017132 A,2015-12-11,METHOD FOR THE THERMAL SUPERFICIAL TREATMENT BY PLASMA FOR THE AUSTENITIC STAINLESS STEEL.,"The present disclosure is related to a method for the thermal superficial treatment by plasma for the austenitic stainless steel; comprising the plasma heat treatment stage in a temperature range of 370°C to 430°C, for a time between half an hour and one hour, at a pressure of between 100 and 500 Pa, in a gaseous atmosphere based on low pressure Oxygen and Hydrogen, at a current density of 0.5 to 1.5 mA/cm2, promoting the formation of a superficial austenite layer consisting of hematite and magnetite iron oxides.",CORPORACIÓN MEXICANA DE INVESTIGACIÓN EN MAT S A DE C V,JORGE LEOBARDO ACEVEDO DAVILA;;EVERARDO EFREN GRANDA GUTIERREZ;;JUAN CARLOS DIAZ GUILLEN;;RITA MUÑOZ ARROYO;;ALEJANDRO GARZA GÓMEZ,,https://lens.org/096-357-288-614-540,Patent Application,no,0,0,1,1,0,,C21D1/06;;C21D5/08;;C21D6/00;;C23C8/10,,0,0,,,,PENDING
62,MX,A,MX 2017016019 A,038-088-308-370-154,2019-06-10,2019,MX 2017016019 A,2017-12-08,MX 2017016019 A,2017-12-08,NANO-STRUCTURED COATING METHOD WITH TITANIUM CARBIDE (TIC) AND COATING COMPOSITION.,"The present disclosure is related to a method and product derived from the application of a nanostructured cobalt base coating with titanium carbide (TiCNPS) for a base metal of a D2 steel, which is initially enabled through the application of a tempering treatment on the substrate. Subsequently the coating is applied through a plasma-transferred arc (PTA) method, in order to increase the resistance to wear-abrasion through the improvement of the refinement of the microstructure by titanium. On the other hand, the anticorrosive property of cobalt increases the anticorrosive properties of D2 steel, which synergistically influences on increasing the useful life of the coated material of the rehabilitated component.",CORPORACION MEXICANA DE INVESTIGACION EN MAT S A DE C V,JORGE LEOBARDO ACEVEDO DAVILA;;JUAN CARLOS DIAZ GUILLEN;;RITA MUÑOZ ARROYO;;HÉCTOR MANUEL HERNÁNDEZ GARCÍA;;MELVYN ALVAREZ VERA,,https://lens.org/038-088-308-370-154,Patent Application,no,0,0,1,1,0,,C23C28/00,,0,0,,,,PENDING
63,ES,R1,ES 2592960 R1,028-565-340-442-361,2017-02-10,2017,ES 201530771 A,2015-06-02,ES 201530771 A,2015-06-02,INDICADOR DEL ESTADO HIDRICO DE TERRENO Y METODO DE MEDIDA DEL ESTADO HIDRICO DEL TERRENO,,MACRAUT INGENIEROS S L,CORREA DUARTE MIGUEL;;FARIÑA RODRÍGUEZ JOSÉ;;MARCOS ACEVEDO JORGE;;FARIÑA ALVAREZ PEDRO;;FRANCO MARTÍNEZ MIGUEL;;AMENEIRO PRIETO OSCAR,"ELECTROSON GALICIA, S.A. (2018-02-20)",https://lens.org/028-565-340-442-361,Unknown,no,2,0,3,3,0,G01N33/24;;G01N27/06,G01N33/24;;G01N27/06,,2,2,050-038-466-983-537;;000-460-401-521-155,10649989;;0010649989;;10.1126/science.287.5453.622;;10.1088/0957-4484/15/9/029,"KONG, J. et al. ""Nanotube Molecular WIres as Chemical Sensors"". Science 287, 622 (2000);;HUANG, X. et al. ""Carboxylation multi-walled carbon nanotubes modified with LiClO4 for water vapour detection"" Nanotechnology 15 (2004) 1284-1288",INACTIVE
64,ES,A1,ES 2719650 A1,194-692-862-572-981,2019-07-11,2019,ES 201830016 A,2018-01-08,ES 201830016 A,2018-01-08,"COOKING FIELD DEVICE (Machine-translation by Google Translate, not legally binding)","Cooking range device. In order to provide a generic cooking range device with better heating properties of the cooking batteries, a cooking range device, in particular an induction cooking range device, is proposed with multiple units of heating (12a-c) defining at least one variable cooking surface area (14a-c), with at least one first heating frequency unit (28a-c) that is exclusively assigned to first heating units (12a1- c1) of the heating units (12a-c), which define a first cooking surface section (20a-c) of the variable cooking surface area (14a-c), and with at least a second frequency unit heating unit (30a-c) that is exclusively assigned to second heating units (12a2-c2) of the heating units (12a-c), which define a second cooking surface section (22a-c) of the variable area. the cooking surface (14a-c), distinct from the first cooking surface section (20a-c), and with at least a third heating frequency unit (32a-c), which is optionally assignable to at least a part of the first heating units (12a1-c1) and/or at least a part of the second heating units (12a2-c2). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA SA;;BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;ESPAÑOL LEZA JORGE;;LAFUENTE URETA JULIO;;PALLARES ZAERA OSCAR;;VALEAU MARTÍN DAVID,,https://lens.org/194-692-862-572-981,Patent Application,no,3,0,3,3,0,H05B3/74;;H05B6/065;;H05B6/12;;H05B2213/03,H05B3/74;;H05B6/12,,0,0,,,,DISCONTINUED
65,MX,A,MX 2015006130 A,049-055-183-328-048,2016-11-14,2016,MX 2015006130 A,2015-05-15,MX 2015006130 A,2015-05-15,METHOD FOR THE THERMAL TREATMENT BY PLASMA OF AN AUSTENITIC STAINLESS STEEL.,"A method for the thermal treatment by plasma of an austenitic stainless steel, which comprises the step of thermal treatment by plasma of an austenitic stainless steel in a temperature range of from about 470°C to about 490°C, for a period of time of 1 hour, at a pressure of 267 Pa, in a gas atmosphere of Nitrogen and Hydrogen at a low pressure at a current density of 1.5 mA/cm2 that promotes the formation of a superficial austenitic layer free of chromium nitride.",CORPORACIÓN MEXICANA DE INVESTIGACIÓN EN MAT S A DE C V,JORGE LEOBARDO ACEVEDO DAVILA;;EVERARDO EFREN GRANDA GUTIERREZ;;JUAN CARLOS DIAZ GUILLEN;;ALEJANDRO GARZA GOMEZ;;RITA MUÑOZ ARROYO,,https://lens.org/049-055-183-328-048,Patent Application,no,0,0,1,1,0,,C21D1/76;;C23C8/26,,0,0,,,,PENDING
66,WO,A3,WO 2001/090747 A3,124-505-601-407-886,2002-07-11,2002,US 0115699 W,2001-05-16,US 20692000 P,2000-05-25,MODULATION OF T-CELL RECEPTOR INTERACTIONS,Disclosed are methods for identifying compounds that modulate an immune complex that includes a T cell receptor (TCR) and a major histocompatibility complex (MHC) antigen. The invention has many useful applications including providing high throughput screening assays for detecting compositions that can modulate an immune response.,SUNOL MOLECULAR CORP,RHODE PETER;;WITTMAN VAUGHAN;;WEIDANZ JON A;;BURKHARDT MARTIN;;CARD KIMBERLYN F;;TAL RONY;;ACEVEDO JORGE;;WONG HING C,,https://lens.org/124-505-601-407-886,Search Report,yes,3,0,8,8,0,G01N33/505;;G01N2333/70539;;A61P37/04;;A61P37/06;;G01N33/505;;G01N2333/70539,A61K45/00;;A61P37/04;;A61P37/06;;G01N33/15;;G01N33/50;;G01N33/53;;G01N33/543;;G01N33/553,,4,4,023-067-098-960-481;;003-169-562-620-897;;026-249-754-693-42X;;006-008-655-205-838,10.1007/bf02918604;;1602179;;7512979;;10.1172/jci117112;;pmc294148;;10.4049/jimmunol.157.11.4885;;8943392;;10.1016/s1074-7613(00)80035-7;;10204491,"WILLIAMS, W.V. ET AL.: ""Modulation of T Cell responses with MHC-derived peptides"", IMMUNOL RES, no. 11, 1992, pages 11-23, XP001069829;;NICOLLE M.W. ET AL.: ""Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class I-peptide complexes"", J. CLIN. INVEST., vol. 93, April 1994 (1994-04-01), pages 1361 - 1369, XP001068785;;RHODE P R ET AL: ""SINGLE-CHAIN MHC CLASS II MOLECULES INDUCE T CELL ACTIVATION AND APOPTOSIS"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 157, no. 11, 1996, pages 4885 - 4891, XP000652225, ISSN: 0022-1767;;WILLCOX B E ET AL: ""TCR BINDING TO PEPTIDE-MHC STABILIZES A FLEXIBLE RECOGNITION INTERFACE"", IMMUNITY, CELL PRESS, US, vol. 10, no. 3, March 1999 (1999-03-01), pages 357 - 365, XP000979767, ISSN: 1074-7613",PENDING
67,WO,A2,WO 2001/090747 A2,155-885-584-192-992,2001-11-29,2001,US 0115699 W,2001-05-16,US 20692000 P,2000-05-25,MODULATION OF T-CELL RECEPTOR INTERACTIONS,Disclosed are methods for identifying compounds that modulate an immune complex that includes a T cell receptor (TCR) and a major histocompatibility complex (MHC) antigen. The invention has many useful applications including providing high throughput screening assays for detecting compositions that can modulate an immune response.,SUNOL MOLECULAR CORP,RHODE PETER;;WITTMAN VAUGHAN;;WEIDANZ JON A;;BURKHARDT MARTIN;;CARD KIMBERLYN F;;TAL RONY;;ACEVEDO JORGE;;WONG HING C,,https://lens.org/155-885-584-192-992,Patent Application,yes,0,34,8,8,49,G01N33/505;;G01N2333/70539;;A61P37/04;;A61P37/06;;G01N33/505;;G01N2333/70539,A61K45/00;;A61P37/04;;A61P37/06;;G01N33/15;;G01N33/50;;G01N33/53;;G01N33/543;;G01N33/553,,0,0,,,,PENDING
68,CA,A1,CA 2410642 A1,164-927-682-695-752,2001-11-29,2001,CA 2410642 A,2001-05-16,US 20692000 P;;US 0115699 W,2000-05-25,MODULATION OF T-CELL RECEPTOR INTERACTIONS,,SUNOL MOLECULAR CORP,BURKHARDT MARTIN;;CARD KIMBERLYN F;;TAL RONY;;WEIDANZ JON A;;ACEVEDO JORGE;;WONG HING C;;RHODE PETER;;WITTMAN VAUGHAN,,https://lens.org/164-927-682-695-752,Patent Application,no,0,0,8,8,49,G01N33/505;;G01N2333/70539;;A61P37/04;;A61P37/06;;G01N33/505;;G01N2333/70539,A61K45/00;;A61P37/04;;A61P37/06;;G01N33/15;;G01N33/50;;G01N33/53;;G01N33/543;;G01N33/553,,0,0,,,,DISCONTINUED
69,ES,U,ES 1035872 U,057-184-480-290-200,1997-06-01,1997,ES 9603225 U,1996-12-16,ES 9603225 U,1996-12-16,"Interior electric heater for motor vehicle windshields. (Machine-translation by Google Translate, not legally binding)","Interior electric heater windshield of motor vehicle, for windshield temperature raising motor vehicles order to prevent or eliminate forming foreign icecaps essentially characterized by comprising a group of electricity resistencias housed on a stand that sustains, whose form makes the windshield adaptable inwardly, connected together, and fed by a cable whose end has a connector for power of lighter interior of motor vehicle. (Machine-translation by Google Translate, not legally binding)",SICILIA BURGOA ALEJANDRO;;ACEVEDO QUERO FERNANDO;;ZURDO SAIZ DAVID;;RONDA CORROCHANO ANGEL;;RODRIGUEZ SIGUEROS JOSE LUIS;;TRAVER MARTIN JORGE,SICILIA BURGOA ALEJANDRO;;ACEVEDO QUERO FERNANDO;;ZURDO SAIZ DAVID;;RONDA CORROCHANO ANGEL;;RODRIGUEZ SIGUEROS JOSE LUIS;;TRAVER MARTIN JORGE,,https://lens.org/057-184-480-290-200,Patent Application,no,0,0,2,2,0,,H05B3/84,,0,0,,,,EXPIRED
70,AU,A,AU 2001/061624 A,136-991-811-995-884,2001-12-03,2001,AU 2001/061624 A,2001-05-16,US 20692000 P;;US 0115699 W,2000-05-25,Modulation of t-cell receptor interactions,,SUNOL MOLECULAR CORP,RHODE PETER;;WITTMAN VAUGHAN;;WEIDANZ JON A;;BURKHARDT MARTIN;;CARD KIMBERLYN F;;TAL RONY;;ACEVEDO JORGE;;WONG HING C,,https://lens.org/136-991-811-995-884,Patent Application,no,0,0,8,8,0,G01N33/505;;G01N2333/70539;;A61P37/04;;A61P37/06;;G01N33/505;;G01N2333/70539,A61K45/00;;A61P37/04;;A61P37/06;;G01N33/15;;G01N33/50;;G01N33/53;;G01N33/543;;G01N33/553,,0,0,,,,DISCONTINUED
71,EP,A2,EP 1287363 A2,063-547-885-275-516,2003-03-05,2003,EP 01935537 A,2001-05-16,US 0115699 W;;US 20692000 P,2000-05-25,MODULATION OF T-CELL RECEPTOR INTERACTIONS,,SUNOL MOLECULAR CORP,RHODE PETER;;WITTMAN VAUGHAN;;WEIDANZ JON A;;BURKHARDT MARTIN;;CARD KIMBERLYN F;;TAL RONY;;ACEVEDO JORGE;;WONG HING C,ALTOR BIOSCIENCE CORPORATION (2004-05-26),https://lens.org/063-547-885-275-516,Patent Application,yes,0,0,8,8,0,G01N33/505;;G01N2333/70539;;A61P37/04;;A61P37/06;;G01N33/505;;G01N2333/70539,A61K45/00;;A61P37/04;;A61P37/06;;G01N33/15;;G01N33/50;;G01N33/53;;G01N33/543;;G01N33/553,,0,0,,,,DISCONTINUED
72,ES,Y,ES 1028961 Y,038-213-647-040-811,1995-10-01,1995,ES 9402380 U,1994-09-16,ES 9402380 U,1994-09-16,APARATO ELECTRONICO PORTATIL PARA LA PRONUNCIACION ARTIFICIAL DE PALABRAS ACCIONADO MANUALMENTE.,,ZURDO SAIZ DAVID;;ACEVEDO QUERO FERNANDO DAVID;;RODRIGUEZ SIGUEROS JOSE LUIS;;RONDA CORROCHANO ANGEL;;SICILIA BURGOA ALEJANDRO;;TRAVER MARTIN JORGE,ZURDO SAIZ DAVID;;ACEVEDO QUERO FERNANDO DAVID;;RODRIGUEZ SIGUEROS JOSE LUIS;;RONDA CORROCHANO ANGEL;;SICILIA BURGOA ALEJANDRO;;TRAVER MARTIN JORGE,,https://lens.org/038-213-647-040-811,Limited Patent,no,0,0,2,2,0,,G09B21/04,,0,0,,,,EXPIRED
73,US,A1,US 2004/0253632 A1,148-768-479-531-896,2004-12-16,2004,US 85901201 A,2001-05-16,US 85901201 A;;US 20692000 P,2000-05-25,Modulation of T -cell receptor interactions,"
   Disclosed are methods for identifying compounds that modulate an immune complex that includes a T cell receptor (TCR) and a major histocompatibility complex (MHC) antigen. The invention has many useful applications including providing high throughput screening assays for detecting compositions that can modulate an immune response. 
",SUNOL MOLECULAR CORP,RHODE PETER R;;WITTMAN VAUGHAN;;WEIDANZ JON A;;BURKHARDT MARTIN;;CARD KIMBERLYN F;;TAL RONY;;ACEVEDO JORGE;;WONG HING C,ALTOR BIOSCIENCE CORPORATION (2003-08-27);;SUNOL MOLECULAR CORPORATION (2001-07-05),https://lens.org/148-768-479-531-896,Patent Application,yes,7,56,8,8,49,G01N33/505;;G01N2333/70539;;A61P37/04;;A61P37/06;;G01N33/505;;G01N2333/70539,A61K45/00;;A61P37/04;;A61P37/06;;G01N33/15;;G01N33/50;;G01N33/53;;G01N33/543;;G01N33/553,435/7.1;;435/7.2,0,0,,,,DISCONTINUED
74,US,A1,US 2015/0190472 A1,179-345-255-692-383,2015-07-09,2015,US 201214390663 A,2012-04-05,CL 2012000016 W,2012-04-05,"USE OF THE ANGIOTENSIN-(1-9) PEPTIDE OR DERIVATIVES THEREOF, USE OF VECTORS OVEREXPRESSING THE ACE2 ENZYME THAT PRODUCES ANGIOTENSIN-(1-9) FOR PREPARING MEDICAMENTS USEFUL FOR PREVENTING, REVERTING, INHIBITING AND/OR REDUCING HYPERTENSION AND/OR INDUCING VASODILATION","The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2. This invention allows the administration of angiotensin-(1-9) or the derivatives thereof in oral form, injectable form, continuous infusion pump, or for increasing its levels in the body by means of the combined treatment with angiotensin-I converting enzyme inhibitors, with angiotensin-II receptor antagonists (ARA II), with Rho kinase inhibitors, with renin inhibitors, with L-type calcium channel antagonists and/or with diuretics.",OCARANZA JERALDINO MARÍA PAZ;;JALIL MILAD JORGE EMILIO;;LAVANDERO GONZÁLEZ SERGIO ALEJANDRO;;CHIONG LAY MARIO MARTÍN;;MICHEA ACEVEDO LUIS FERNANDO;;PONTIFICA UNIVERSIDAD CATOLICA DE CHILE;;UNIV CHILE,OCARANZA JERALDINO MARÍA PAZ;;JALIL MILAD JORGE EMILIO;;LAVANDERO GONZÁLEZ SERGIO ALEJANDRO;;CHIONG LAY MARIO MARTÍN;;MICHEA ACEVEDO LUIS FERNANDO,UNIVERSIDAD DE CHILE (2014-10-30);;PONTIFICA UNIVERSIDAD CATÓLICA DE CHILE (2014-10-30),https://lens.org/179-345-255-692-383,Patent Application,yes,1,1,3,3,7,A61K38/22;;A61K38/22;;A61K38/085;;A61K38/085;;A61K38/4813;;A61K38/4813;;A61K38/553;;A61K38/553;;A61K38/556;;A61K38/556;;A61K45/06;;A61K45/06,A61K38/22,,6,4,028-907-478-776-978;;130-202-253-970-240;;130-202-253-970-240;;081-258-955-215-482,10.1155/2012/594361;;22315665;;pmc3270559;;10.1152/physiolgenomics.00312.2005;;16788004;;10.1152/physiolgenomics.00312.2005;;16788004;;10.1161/01.hyp.0000188905.20884.63;;pmc1564276;;16246972,"Ocaranza, M.P., et al ""Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling,"" Int J Hypertens. 2012; pages 1-12;;C. D´ıez-Freire, J. V´azquez, M. F. Correa De Adjounian et al., “ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR,” Physiological Genomics, vol. 27, no. 1, pp. 12–19, 2006.;;Treatment definition of treatment by The Free Dictionary 2016 pages 1-5;;Diovan (Valsartan) Drug Information: Description, User Reviews, Drug Side Effects, Interactions PrescribingInformation at RxList 2016 pages 1-3;;C. DÂ´Ä±ez-Freire, J. VÂ´azquez, M. F. Correa De Adjounian et al., âACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR,â Physiological Genomics, vol. 27, no. 1, pp. 12â19, 2006.;;Chen, Zhenlong; et al., âHydrolysis of Angiotensin Peptides by Human I-Converting Enzyme and the Resensitization of B2 Kinin Receptors,â Hypertension (2005), 46(6), 1368-1373",ACTIVE
75,ES,U,ES 1028961 U,112-021-211-133-991,1995-04-01,1995,ES 9402380 U,1994-09-16,ES 9402380 U,1994-09-16,"Portable electronic device for artificial pronunciation of words manually operated. (Machine-translation by Google Translate, not legally binding)","Electronic device portable for pronunciación artificial words powered by hand, for translate electronically language written and oral code entered push button essentially characterized by comprising a housing with clamping system hand (24), and an electronic circuit composed a step of feeding (22) enabling operation of the apparatus with rechargeable batteries, non-refillable or power grid transformer, a block (23) state control of batteries, push for introduction of codes of user alphabet letters or syllables, numbers and punctuation orthographic (6), milking pulsator pronunciation of the introduced to the time (7), a control step (1) formed by a processor (5) and a volatile memory (4) storage of codes entered, a step of displaying (2) staffed by a circuit (8) manager to translate codes their representation on a screen (9), a stage of sound production (3) comprising a circuit (10) generating audible signals from codes provided by the stage of control and entering a permanent memory in which they are stored data necessary for proper pronunciation (program; phonemes, syllables, digitalized words; maps of sound), an amplifier (11), an external speaker (12) and an outlet (21) for connection to external systems (21), and a switch on / off on own volume control (20). (Machine-translation by Google Translate, not legally binding)",ZURDO SAIZ DAVID;;ACEVEDO QUERO FERNANDO DAVID;;RODRIGUEZ SIGUEROS JOSE LUIS;;RONDA CORROCHANO ANGEL;;SICILIA BURGOA ALEJANDRO;;TRAVER MARTIN JORGE,ZURDO SAIZ DAVID;;ACEVEDO QUERO FERNANDO DAVID;;RODRIGUEZ SIGUEROS JOSE LUIS;;RONDA CORROCHANO ANGEL;;SICILIA BURGOA ALEJANDRO;;TRAVER MARTIN JORGE,,https://lens.org/112-021-211-133-991,Patent Application,no,0,0,2,2,0,,G09B21/04,,0,0,,,,EXPIRED
76,WO,A1,WO 2013/149355 A1,066-424-788-387-005,2013-10-10,2013,CL 2012000016 W,2012-04-05,CL 2012000016 W,2012-04-05,USE OF ANGIOTENSIN 1-9 IN COMBINATION IN ORDER TO PREVENT ARTERIAL HYPERTENSION,"The invention relates to the use of the angiotensin-(1-9) peptide or peptides derived therefrom that are biological or chemical analogues of same, for the preparation of drugs for preventing, reversing, inhibiting and/or reducing arterial hypertension and/or inducing vasodilatation. In addition, the invention relates to a vector that overexpresses homologous angiotensin II-converting enzyme (ECA2) which can be used to increase the concentration of the angiotensin-(1-9) peptide in the blood and/or tissues. Said vector can be an adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene that codes for ECA2. The invention can be used to administer angiotensin-(1-9) or derivatives thereof in an oral or injectable form or by means of continuous pump infusion, or to raise the levels of same in the body by means of a treatment together with: angiotensin-I-converting-enzyme inhibitors, angiotensin II receptor antagonists (ARA II), Rho kinase inhibitors, renin inhibitors, L-channel calcium antagonists, and/or diuretics.",UNIV PONTIFICIA CATOLICA CHILE;;UNIV CHILE;;OCARANZA JERALDINO MARIA PAZ;;JALIL MILAD JORGE EMILIO;;LAVANDERO GONZALEZ SERGIO ALEJANDRO;;CHIONG LAY MARIO MARTIN;;MICHEA ACEVEDO LUIS FERNANDO,OCARANZA JERALDINO MARIA PAZ;;JALIL MILAD JORGE EMILIO;;LAVANDERO GONZALEZ SERGIO ALEJANDRO;;CHIONG LAY MARIO MARTIN;;MICHEA ACEVEDO LUIS FERNANDO,,https://lens.org/066-424-788-387-005,Patent Application,yes,0,1,3,3,0,A61K38/22;;A61K38/22;;A61K38/085;;A61K38/085;;A61K38/4813;;A61K38/4813;;A61K38/553;;A61K38/553;;A61K38/556;;A61K38/556;;A61K45/06;;A61K45/06,A61K38/08,,5,5,028-907-478-776-978;;015-467-350-229-045;;139-445-494-948-590;;001-067-040-398-985;;117-870-550-211-147,10.1155/2012/594361;;22315665;;pmc3270559;;10.4067/s0718-85602010000100007;;10.1161/hypertensionaha.111.177485;;22184331;;10.1152/ajpheart.01170.2005;;16415071;;17583183;;pmc1994039,"OCARANZA, M.P. ET AL.: ""Protective role of the ACE2/Ang-(1-9) axis in cardiovascular remodeling"", INTERNATIONAL JOURNAL OF HYPERTENSION., vol. 2012, 19 January 2012 (2012-01-19), pages 1 - 12;;OCARANZA, M.P. ET AL.: ""Menores niveles tisulares from enzima convertidora of angiotensina I homologa (ECA-2) and angiotensina-(1-9) estan asociados a mayor remodelamiento from pared aortica of ratas hipertensas"", REVISTA CHILENA DE CARDIOLOGIA., vol. 29, no. 1, 2010, pages 69 - 82;;FLORES-MUNOZ, M. ET AL.: ""Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor"", HYPERTENSION., vol. 59, no. 2, 1 February 2012 (2012-02-01), pages 300 - 307;;GROBE, J.L. ET AL.: ""Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension"", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 290, no. 6, 1 June 2006 (2006-06-01), pages H2417 - H2423;;SCHINDLER, C. ET AL.: ""Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy"", VASCULAR HEALTH AND RISK MANAGEMENT., vol. 3, no. 1, 1 February 2007 (2007-02-01), pages 125 - 137",PENDING
77,US,B2,US 9511120 B2,027-267-734-403-240,2016-12-06,2016,US 201214390663 A,2012-04-05,CL 2012000016 W,2012-04-05,"Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ACE2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation","The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogs, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2. This invention allows the administration of angiotensin-(1-9) or the derivatives thereof in oral form, injectable form, continuous infusion pump, or for increasing its levels in the body by means of the combined treatment with angiotensin-I converting enzyme inhibitors, with angiotensin-II receptor antagonists (ARA II), with Rho kinase inhibitors, with renin inhibitors, with L-type calcium channel antagonists and/or with diuretics.",OCARANZA JERALDINO MARIA PAZ;;JALIL MILAD JORGE EMILIO;;LAVANDERO GONZÁLEZ SERGIO ALEJANDRO;;CHIONG LAY MARIO MARTIN;;MICHEA ACEVEDO LUIS FERNANDO;;PONTIFICA UNIV CATÓLICA DE CHILE;;UNIV CHILE,OCARANZA JERALDINO MARIA PAZ;;JALIL MILAD JORGE EMILIO;;LAVANDERO GONZÁLEZ SERGIO ALEJANDRO;;CHIONG LAY MARIO MARTIN;;MICHEA ACEVEDO LUIS FERNANDO,UNIVERSIDAD DE CHILE (2014-10-30);;PONTIFICA UNIVERSIDAD CATÓLICA DE CHILE (2014-10-30),https://lens.org/027-267-734-403-240,Granted Patent,yes,1,0,3,3,7,A61K38/22;;A61K38/22;;A61K38/085;;A61K38/085;;A61K38/4813;;A61K38/4813;;A61K38/553;;A61K38/553;;A61K38/556;;A61K38/556;;A61K45/06;;A61K45/06,A61K38/08;;A61K38/22;;A61K38/48;;A61K38/55;;A61K45/06,,5,3,028-907-478-776-978;;130-202-253-970-240;;081-258-955-215-482,10.1155/2012/594361;;22315665;;pmc3270559;;10.1152/physiolgenomics.00312.2005;;16788004;;10.1161/01.hyp.0000188905.20884.63;;pmc1564276;;16246972,"Ocaranza, M.P., et al ""Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling,"" Int J Hypertens. 2012; pp. 1-12.;;C. D'iez-Freire, J. V'azquez, M. F. Correa De Adjounian et al., ""ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR,"" Physiological Genomics, vol. 27, No. 1, pp. 12-19, 2006.;;Treatment definition of treatment by The Free Dictionary 2016 pp. 1-5.;;Diovan (Valsartan) Drug Information: Description, User Reviews, Drug Side Effects, Interactions Prescribing Information at RxList 2016 pp. 1-3.;;Chen, Zhenlong; et al., ""Hydrolysis of Angiotensin Peptides by Human I-Converting Enzyme and the Resensitization of B2 Kinin Receptors,"" Hypertension (2005), 46(6), 1368-1373.",ACTIVE
78,ES,B2,ES 2296461 B2,060-953-107-357-034,2008-11-01,2008,ES 200501825 A,2005-07-26,ES 200501825 A,2005-07-26,"PROCEDIMIENTO DE PREDICCION Y CONTROL DE LA CAPACIDAD DE UN CABLE DE PAR TRENZADO CON DRENAJE, APANTALLADO CON LAMINA DE DOBLE CAPA Y CON CUBIERTA PROTECTORA, MEDIANTE LA VARIACION DEL PASO DEL TRENZADO.","Procedimiento de predicción y control de la capacidad de un cable de par trenzado con drenaje, apantallado con lámina de doble capa y con cubierta protectora, mediante la variación del paso del trenzado. El procedimiento permite la predicción y el control de la capacidad eléctrica de un cable de par trenzado determinada por las dimensiones y la naturaleza de los elementos que lo conforman, y controlada mediante el parámetro paso del trenzado. El resultado de su aplicación es la obtención de un cable final de capacidad predefinida o la determinación de las características de diseño del cable a fabricar para satisfacer un valor de esta capacidad. El procedimiento y el producto de su aplicación son de interés en industrias de fabricación de cable destinado a transmisión de señal o a alimentación de circuitos electrónicos.",UNIV VIGO,MARTINEZ-PENALVER FREIRE CARLOS;;LORENZO LOPEZ JOSE CARLOS;;MARCOS ACEVEDO JORGE;;LAGO FERREIRO ALFONSO;;DOVAL GANDOY JESUS;;NOGUEIRAS MELENDEZ ANDRES AUGUSTO,,https://lens.org/060-953-107-357-034,Granted Patent,no,0,0,2,2,0,H01B13/02,H01B13/02,,0,0,,,,ACTIVE
79,EP,A1,EP 3509393 A1,048-604-096-062-029,2019-07-10,2019,EP 19150140 A,2019-01-03,ES 201830015 A,2018-01-08,HOTPLATE DEVICE,"Die Erfindung geht aus von einer Kochfeldvorrichtung (10a-c), insbesondere von einer Induktionskochfeldvorrichtung, mit zumindest drei Heizeinheiten (12a-c), mit zumindest einer Energieversorgungseinheit (20a-c), welche zumindest drei Energieversorgungsausgänge (22a-c) aufweist und welche in wenigstens einem Betriebszustand zumindest eine der Heizeinheiten (12a-c) mit Energie versorgt, mit zumindest einer Konfigurationseinheit (24a-c), welche zumindest drei Konfigurationseingänge (26a-c), die jeweils mit einem der Energieversorgungsausgänge (22a-c) elektrisch leitend verbunden sind, und zumindest drei Konfigurationsausgänge (28a-c) aufweist, wobei ein erster Konfigurationseingang (26a1-c1) mit einem ersten Konfigurationsausgang (28a1-c1) und ein zweiter Konfigurationseingang (26a2-c2) mit einem zweiten Konfigurationsausgang (28a2-c2) elektrisch leitend verbunden ist, und mit zumindest einer Zuordnungseinheit (30a-c), welche zumindest drei Zuordnungseingänge (32a-c), die jeweils mit einem der Konfigurationsausgänge (28a-c) elektrisch leitend verbunden sind, und zumindest drei Zuordnungsausgänge (34a-c) aufweist, die jeweils mit einer der Heizeinheiten (12a-c) elektrisch leitend verbindbar sind, und mittels welcher in dem Betriebszustand die Zuordnungsausgänge (34-c) mit den Zuordnungseingängen (32-c) elektrisch leitend verbindbar sind. Um eine gattungsgemäße Vorrichtung mit verbesserten Eigenschaften hinsichtlich einer Flexibilität bereitzustellen, wird vorgeschlagen, dass ein dritter Konfigurationseingang (26a3-c3) in dem Betriebszustand wahlweise mit zumindest einem der Konfigurationsausgänge (28a-c) elektrisch leitend verbindbar ist.
",BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;LAFUENTE URETA JULIO;;PALACIOS TOMAS DANIEL;;PASCUAL AZA JORGE;;PUYAL PUENTE DIEGO;;VALEAU MARTIN DAVID,,https://lens.org/048-604-096-062-029,Patent Application,yes,5,0,2,2,0,H05B6/065;;H05B2213/03;;H05B6/065;;H05B6/1272;;H05B2213/03,H05B6/06,,0,0,,,,PENDING
80,ES,B2,ES 2312232 B2,102-534-727-094-189,2009-09-22,2009,ES 200501962 A,2005-08-04,ES 200501962 A,2005-08-04,"PROCEDIMIENTO DE PREDICCION Y CONTROL DE LA INDUCTANCIA DE UN CABLE DE PAR TRENZADO CON DRENAJE, APANTALLADO CON LAMINA DE DOBLE CAPA Y CON CUBIERTA PROTECTORA, MEDIANTE LA VARIACION DEL PASO DEL TRENZADO.",,UNIV VIGO,MARTINEZ-PENALVER FREIRE CARLOS;;LORENZO LOPEZ JOSE CARLOS;;MARCOS ACEVEDO JORGE;;LAGO FERREIRO ALFONSO;;DOVAL GANDOY JESUS;;NOGUEIRAS MELENDEZ ANDRES AUGUSTO,,https://lens.org/102-534-727-094-189,Granted Patent,no,0,0,2,2,0,H01B11/002;;H01B11/02,H01B11/02,,0,0,,,,ACTIVE
81,ES,A1,ES 2312232 A1,077-862-538-688-760,2009-02-16,2009,ES 200501962 A,2005-08-04,ES 200501962 A,2005-08-04,"Prediction procedure and control of the inductance of a cable of braided torque with drainage, screwed with double layered plate and with protective cover, through the variation of the step of the braid. (Machine-translation by Google Translate, not legally binding)","Method of prediction and control of the inductance of a twisted pair cable with drainage, shielded with double-layer sheet and with protective cover, by varying the pitch of the braid. The procedure allows the prediction and control of the electrical inductance of a given twisted pair cable, by the dimensions and nature of the elements that comprise it, and controlled by the step parameter of the braid. The result of its application is the obtaining of a predefined final inductance cable or the determination of the design characteristics of the cable to be manufactured to satisfy a value of this electrical characteristic. The procedure and the product of its application are of interest in the cable manufacturing industry intended for signal transmission or powering of electronic circuits. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,MARTINEZ-PENALVER FREIRE CARLO;;LORENZO LOPEZ JOSE CARLOS;;MARCOS ACEVEDO JORGE;;LAGO FERREIRO ALFONSO;;DOVAL GANDOY JESUS;;NOGUEIRAS MELENDEZ ANDRES AUGUSTO,,https://lens.org/077-862-538-688-760,Patent Application,no,2,0,2,2,0,H01B11/002;;H01B11/02,H01B11/02,,0,0,,,,ACTIVE
82,ES,A1,ES 2719129 A1,192-243-159-239-216,2019-07-08,2019,ES 201830015 A,2018-01-08,ES 201830015 A,2018-01-08,"COOKING FIELD DEVICE (Machine-translation by Google Translate, not legally binding)","Cooking field device. The present invention relates to a cooking field device (10a-c), in particular, to an induction cooking field device, with at least three heating units (12a-c), with at least one heating unit. power supply (20a-c) having at least three power supply outputs (22a-c) and which supplies power to one or more of the heating units (12a-c) in at least one operating state, with at least one configuration unit (24a-c), which has at least three configuration inputs (26a-c), each of which is electrically conductively connected to one of the power supply outputs (22a) -c), and at least three configuration outputs (28a-c), wherein the first configuration input (26a1-c1) is electrically conductively connected to the first configuration output (28a1-c1) and the second configuration input (28a-c). configuration (26a2-c2) is connected in a electrically with the second configuration output (28a2-c2), and with at least one assignment unit (30a-c), which has at least three assignment inputs (32a-c), each of which is connected in an electrically conductive manner with one of the configuration outputs (28a-c), and at least three assignment outputs (34a-c), each of which is electrically conductively connectable with one of the heating units (12a) -c), and by means of which the assignment outputs (34a-c) are electrically conductively connectable with the assignment inputs (32a-c) in the operating state. In order to provide a generic cooking field device with better properties in terms of its flexibility, it is proposed that the third configuration input (26a3-c3) be optionally connectable with at least one of the configuration outputs (28a-c)) electrically conductive in the operating state. (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA SA;;BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;BLASCO RUEDA NICOLAS;;LAFUENTE URETA JULIO;;PALACIOS TOMÁS DANIEL;;PASCUAL AZA JORGE;;PUYAL PUENTE DIEGO;;VALEAU MARTÍN DAVID,,https://lens.org/192-243-159-239-216,Patent Application,no,4,0,2,2,0,H05B6/065;;H05B6/065;;H05B6/1272;;H05B2213/03;;H05B2213/03,H05B6/06,,0,0,,,,DISCONTINUED
83,ES,A1,ES 2296461 A1,023-710-867-804-88X,2008-04-16,2008,ES 200501825 A,2005-07-26,ES 200501825 A,2005-07-26,"Method for prediction and control of electrical capacity of twisted cable shielded with foil and double-layer protective cover, involves determining size and nature of elements, and is controlled by variation of passage parameters","The method involves determining size and nature of the elements, and is controlled by variation of the passage parameters. Independent claims are also included for the following: (1) a method for implementation in manufacturing industries of cable for use in transmission of signal or power electronic circuits (2) a product for implementation in manufacturing industries of cable for use in transmission of signal or power electronic circuits.",UNIV VIGO,MARTINEZ-PENALVER FREIRE CARLO;;LORENZO LOPEZ JOSE CARLOS;;MARCOS ACEVEDO JORGE;;LAGO FERREIRO ALFONSO;;DOVAL GANDOY JESUS;;NOGUEIRAS MELENDEZ ANDRES AUGU,,https://lens.org/023-710-867-804-88X,Patent Application,no,2,0,2,2,0,H01B13/02,H01B13/02,,1,0,,,"BASE DE DATOS WPI en EPOQUE, semana 198702, THOMPSON, AN 1987-011480 & JP 61269812 A (FURUKAMA ELECTRIC CO) 29.11.1986, resumen.",ACTIVE
84,CO,A1,CO 2017002052 A1,187-556-264-045-380,2018-10-22,2018,CO 2017002052 A,2017-02-28,CO 2017002052 A,2017-02-28,Conservador de alimentos,"Resumen La presente invención corresponde un dispositivo para la conservación de alimentos en frio que comprende: una cámara (1), con una puerta (9) que, en su posición de cerrado, sella herméticamente la cámara (1), un evaporador (2) ubicado al interior de la cámara (1), un compresor (5) conectado en un primer extremo al evaporador (2), un condensador (3) conectado al compresor (5), un elemento de expansión (4) conectado a un segundo extremo del evaporador (2) y al condensador (3), en donde, el aire que está alrededor del evaporador se enfría, descendiendo hacia la superficie inferior de la cámara (1). El aire caliente que está presente dentro de la cámara (1), asciende hacia la superficie superior de la cámara (1) en el lado opuesto al aire frío, recirculando de tal manera que, el aire caliente entra en contacto con el evaporador (2). El aire frio (11) y el aire caliente (12) circulan ininterrumpidamente sobre el volumen interno de la cámara (1).",IND HACEB S A,CORTES TORRES JAIME HERNAN;;GARCIA POSADA JORGE MARIO;;ACEVEDO ALZATE JOSÉ MARÍA;;VALENCIA JOHN JAIRO;;CORREA CESAR AUGUSTO;;MARTÍNEZ CARMONA JUAN GUILLERMO;;RAMIREZ NORVEY ANTONIO;;BEDOYA JORGE ADRIÁN;;LÓPEZ NINO ANDRÉS,,https://lens.org/187-556-264-045-380,Patent Application,no,0,0,1,1,0,,F25D3/10;;F25D13/02,,0,0,,,,PENDING
85,WO,A1,WO 2022/248174 A1,047-616-071-841-458,2022-12-01,2022,EP 2022061928 W,2022-05-04,EP 21382476 A,2021-05-26,DOMESTIC APPLIANCE DEVICE AND METHOD FOR OPERATING A DOMESTIC APPLIANCE DEVICE,"The invention relates to a domestic appliance device (10), in particular an induction cooking appliance device, comprising at least one switch unit (12, 30) and at least one driver circuit (14) which is designed to set a control voltage for the switch unit (12, 30) and which has a bootstrap unit (16) comprising an adaptation unit (18) that is designed to change at least one parameter of the bootstrap unit (16). In order to increase the operational reliability, the bootstrap unit (16) has a voltage limiting unit (20) for limiting a bootstrap voltage (VBS) dropping across the adaptation unit (18).",BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;CALVO MESTRE CARLOS;;CROS QUEROL DAVID;;DIEZ ESTEBAN CRISTINA;;FERNANDEZ MARTINEZ MANUEL;;LAZARO AMATRIAIN GUILLERMO;;PASCUAL AZA JORGE;;PUYAL PUENTE DIEGO,,https://lens.org/047-616-071-841-458,Patent Application,yes,3,0,1,1,0,H05B6/062,H05B6/06,,0,0,,,,PENDING
86,CL,A1,CL 2020003433 A1,038-593-176-973-638,2021-09-10,2021,CL 2020003433 A,2020-12-30,CL 2020003433 A,2020-12-30,Sistema y método para la enseñanza y auto-aprendizaje de procedimientos de auscultación.,"Un sistema y un método para la enseñanza y auto-aprendizaje de procedimientos de auscultación, el cual constituye una herramienta de apoyo en cada una de las etapas de enseñanza de los procesos de auscultación. El sistema comprende: un dispositivo de detección de sonidos configurado para detectar sonidos corporales desde uno o más puntos de auscultación; un sistema de comunicación inalámbrica que comunica el dispositivo de detección de sonidos con un dispositivo portátil; y medios de procesamiento que permiten procesar los sonidos detectados y desplegar información relativa a los sonidos procesados en una interfaz de usuario en el dispositivo portátil; en donde el dispositivo portátil comprende medios para la identificación de los uno o más puntos de auscultación mediante la utilización de realidad aumentada, que permiten la visualización de los puntos de auscultación y permiten guiar el posicionamiento del dispositivo de detección de sonidos hacia dichos puntos.",UNIV DE VALPARAISO,OMAR RAFAEL ACEVEDO PÉREZ;;ÁLVARO NICOLÁS HUIRIMILLA THIZNAU;;LUIS TOGO ARREDONDO GAMBOA;;MARÍA CONSTANZA RUBIO DÍAZ;;DANIEL OSVALDO CIUDAD ANTOGNINI;;JORGE ANTONIO QUIROZ HERNÁNDEZ,,https://lens.org/038-593-176-973-638,Patent Application,no,0,0,1,1,0,,A61B5/00;;A61B7/00;;A61B7/04;;A61B8/00;;G09B23/30,,0,0,,,,PENDING
87,ES,T3,ES 2325492 T3,143-612-317-293-757,2009-09-07,2009,ES 03720119 T,2003-04-28,CU 20020086 A,2002-04-29,FRAGMENTOS DE ANTICUERPOS ESPECIFICOS PARA EL ANTIGENO CARCINOEMBRIONARIO (ACE) HUMANO.,"Fragmentos de anticuerpo tipo Fv de cadena sencilla (scFv) mono y divalente (diacuerpo), obtenidos por técnicas de ADN recombinante a partir del anticuerpo monoclonal (AcM) anti-antígeno carcinoembrionario (CEA) CB/ior-CEA.1. Este AcM tiene muy alta afinidad por el CEA y se emplea en el diagnóstico y seguimiento de tumores colorectales del hombre. Como el AcM original, los fragmentos scFv monovalente y diacuerpo exhiben altas afinidades por el CEA humano y reconocen un epítope dependiente de la conservación de carbohidratos. El fragmento scFv monovalente y diacuerpo tienen constantes de afinidad por el CEA de (5.0 ñ 0.4) x 109 L mol-1 y (2.8 ñ 0.3) x 1010 L mol-1, respectivamente. Estos dos fragmentos no presentan reactividad cruzada con células y tejidos humanos normales, excepto la mucosa colónica normal donde el CEA está ocasionalmente presente. Los fragmentos pueden producirse mediante la expresión en microorganismos recombinantes, a partir del clonaje de secuencias de ácidos nucleicoscodificantes para regiones variables obtenidas del hibridoma que produce el AcM CB/ior-CEA.1. Al igual que el AcM original, el scFv monovalente y el diacuerpo tienen la capacidad de identificar in vivo en ratones a células productoras de CEA humano que crecen formando tumores. El scFv monovalente y el diacuerpo tienen un tamaño molecular 5 y 2.5 veces inferior, respectivamente, que el AcM de ratón y no poseen dominios Fc, lo que les confiere el potencial de penetrar mejor los tejidos in vivo y de ser menos inmunogénicos en el hombre.",CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MILAGROS;;ACEVEDO CASTRO BORIS E;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA,,https://lens.org/143-612-317-293-757,Granted Patent,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,C07K16/30;;A61K39/00;;A61K39/39;;A61K47/48;;A61K51/10;;C07K14/22,,0,0,,,,EXPIRED
88,CN,A,CN 1646153 A,112-921-723-584-79X,2005-07-27,2005,CN 03808567 A,2003-04-11,CU 20020076 A;;CU 0300004 W,2002-04-15,Active antiangiogenic therapy,,CT INGENIERIA GENETICA BIOTECH,MONICA BEQUET ROMERO;;ERNESTO ACEVEDO CASTRO BORIS;;VICTOR GAVILONDO COWLEY JORGE;;ENRIQUE FERNANDEZ MOLINA LUIS;;OMAR LOPEZ OCEJO;;LA SILVA RODRIGUEZ RICARDO DE;;MUS,,https://lens.org/112-921-723-584-79X,Patent Application,no,0,6,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
89,AT,T1,AT E511851 T1,170-210-226-500-746,2011-06-15,2011,AT 03711811 T,2003-04-11,CU 20020076 A;;CU 0300004 W,2002-04-15,VERWENDUNG EINES VGEFMUTANTS ZUR ANTIANGIOGENE THERAPIE,,CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS;;GAVILONDO COWLEY JORGE;;FERNANDEZ MOLINA LUIS;;LAPEZ OCEJO OMAR;;SILVA RODROEGUEZ RICARDO;;MUSACHIO LASA ALEXIS;;GALBAN RODROEGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA,,https://lens.org/170-210-226-500-746,Granted Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
90,ES,T3,ES 2365329 T3,147-127-240-640-744,2011-09-29,2011,ES 03711811 T,2003-04-11,CU 20020076 A,2002-04-15,USO DE VEGF MUTADO PARA LA TERAPIA ANTIANGIOGENICA.,"Aplicacion de secuencias oligonucleotídicas y polipeptídicas de moléculas pertenecientes a la familia del factor de permeabilidad vascular (VPF), sus receptores y correceptores; así como modificaciones de los mismos, en la inmunoterapia activa de entidades patológicas cuyo curso se asocia al aumento de la vasculatura.Estos procedimientos pueden ser empleados en la terapia única o combinada para el tratamiento del cáncer y sus metástasis, los procesos inflamatorios agudos y crónicos, enfermedades infecciosas, enfermedades autoinmunes, la retinopatía diabética y del recién nacido, el rechazo al transplante de órganos, la degeneración macular, los glaucomas neovasculares, hemangiomas y los angiofibromas, entre otros.",CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONI;;ACEVEDO CASTRO BORIS;;GAVILONDO COWLEY JORGE;;FERNANDEZ MOLINA LUIS;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA,,https://lens.org/147-127-240-640-744,Granted Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/19;;A61K38/18;;A61K39/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
91,DE,A5,DE 112021004020 A5,125-065-178-374-246,2023-06-01,2023,DE 112021004020 T,2021-07-08,EP 20382694 A;;EP 2021068998 W,2020-07-30,Haushaltsgerätevorrichtung,,BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;ALONSO ORTIZ DAVID;;CALVO MESTRE CARLOS;;DONAIRE CLAVERÍA CARLOS;;ELENA VALERO LAURA;;GIMENO MELENDO ALBERTO;;HERNANDEZ BLASCO PABLO JESUS;;MUÑOZ FUMANAL ANTONIO;;PUYAL PUENTE DIEGO;;TESA BETES JORGE,,https://lens.org/125-065-178-374-246,Patent Application,no,0,0,2,2,0,H02M1/32;;H02M1/36;;H02M1/44,H02J3/01;;H03H7/01,,0,0,,,,PENDING
92,WO,A1,WO 2022/022977 A1,192-292-195-030-488,2022-02-03,2022,EP 2021068998 W,2021-07-08,EP 20382694 A,2020-07-30,DOMESTIC APPLIANCE DEVICE,"The invention relates to a domestic appliance device (10), in particular a cooking device, comprising at least one suppression capacitor (12), in particular for reducing electromagnetic disturbances, and a discharge unit (14) which has at least one first switch element (16) and at least one second switch element (18) and which is designed to discharge the suppression capacitor (12) in a discharge operating state (70). The aim of the invention is to provide a device with improved properties with respect to efficiency. This is achieved in that the first switch element (16) and the second switch element (18) are arranged relative to each other in an antiparallel circuit.",BSH HAUSGERAETE GMBH,ACEVEDO SIMON ARTURO;;ALONSO ORTIZ DAVID;;CALVO MESTRE CARLOS;;DONAIRE CLAVERÍA CARLOS;;ELENA VALERO LAURA;;GIMENO MELENDO ALBERTO;;HERNANDEZ BLASCO PABLO JESUS;;MUÑOZ FUMANAL ANTONIO;;PUYAL PUENTE DIEGO;;TESA BETES JORGE,,https://lens.org/192-292-195-030-488,Patent Application,yes,4,0,2,2,0,H02M1/32;;H02M1/36;;H02M1/44,H02M1/32;;H02M1/36;;H02M1/44,,0,0,,,,PENDING
93,ZA,B,ZA 200408460 B,179-981-300-033-57X,2005-08-30,2005,ZA 200408460 A,2004-10-19,CU 20020076 A,2002-04-15,Active antiangiogenic therapy.,,CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;GAVILONDO COWLEY JORGE VICTOR;;LOPEZ EJO OMAR;;MUSACHIO LASA ALEXIS;;BLOMQUIST DANIA MARCIA VAZQUEZ;;CASTRO BORIS ERNESTO ACEVEDO;;MOLINA LUIS ENRIQUE FERNANDEZ;;RODRIGUEZ RICARDO DE LA CARIDA;;RODRIGUEZ ERNESTO GALBAN,,https://lens.org/179-981-300-033-57X,Granted Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,ACTIVE
94,CA,A1,CA 2480079 A1,048-879-473-297-249,2003-10-23,2003,CA 2480079 A,2003-04-11,CU 20020076 A;;CU 0300004 W,2002-04-15,ACTIVE ANTIANGIOGENIC THERAPY,"The invention relates to the application of oligonucleotide and polypeptide sequences of molecules belonging to the vascular permeability factor (VPF) family, their receptors and co-receptors and to their modifications in activ e immunotherapy against pathological entities whose course is associated with an increase in vasculature. Said procedures can be used, inter alia, in monotherapy or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and infant retinopathy, rejection of transplanted organs, macular degeneration, neovascular glaucoma, hemangioma and angiofibroma.",CT INGENIERIA GENETICA BIOTECH,SILVA RODRIGUEZ RICARDO DE LA;;MUSACHIO LASA ALEXIS;;LOPEZ OCEJO OMAR;;VAZQUEZ BLOMQUIST DANIA MARCIA;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;GALBAN RODRIGUEZ ERNESTO;;BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO,,https://lens.org/048-879-473-297-249,Patent Application,no,0,0,28,28,26,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
95,WO,A1,WO 2003/086450 A1,170-004-233-365-266,2003-10-23,2003,CU 0300004 W,2003-04-11,CU 20020076 A,2002-04-15,ACTIVE ANTIANGIOGENIC THERAPY,"The invention relates to the application of oligonucleotide and polypeptide sequences of molecules belonging to the vascular permeability factor (VPF) family, their receptors and co-receptors and to their modifications in active immunotherapy against pathological entities whose course is associated with an increase in vasculature. Said procedures can be used, inter alia, in monotherapy or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and infant retinopathy, rejection of transplanted organs, macular degeneration, neovascular glaucoma, hemangioma and angiofibroma.",CT INGENIERIA GENETICA BIOTECH;;BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO DE LA;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO DE LA;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/170-004-233-365-266,Patent Application,yes,1,0,28,28,18,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,3,3,038-384-962-493-921;;023-308-707-283-119;;086-466-187-383-405,pmc58766;;10.1073/pnas.191112198;;11553767;;11555605;;10537299,"WEI, Y-Q ET AL.: ""Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen."", PNAS, vol. 98, no. 20, September 2001 (2001-09-01), XP002248645;;DAVIDOFF, A.M. ET AL.: ""Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice."", CLINICAL CANCER RESEARCH, vol. 7, September 2001 (2001-09-01), XP002248646;;PREWETT, M. ET AL.: ""Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors."", CANCER RESEARCH, vol. 59, October 1999 (1999-10-01), XP002248647",PENDING
96,AU,A1,AU 2003/218603 A1,092-456-115-967-119,2003-10-27,2003,AU 2003/218603 A,2003-04-11,CU 20020076 A;;CU 0300004 W,2002-04-15,ACTIVE ANTIANGIOGENIC THERAPY,,CT INGENIERIA GENETICA BIOTECH,ROMERO MONICA BEQUET;;CASTRO BORIS ERNESTO ACEVEDO;;COWLEY JORGE VICTOR GAVILONDO;;MOLINA LUIS ENRIQUE FERNANDEZ;;OCEJO OMAR LOPEZ;;RODRIGUEZ RICARDO DE LA CARIDA;;LASA ALEXIS MUSACHIO;;RODRIGUEZ ERNESTO GALBAN;;BLOMQUIST DANIA MARCIA VAZQUEZ,,https://lens.org/092-456-115-967-119,Patent Application,no,0,1,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
97,CU,A1,CU 23178 A1,070-766-584-260-699,2006-09-22,2006,CU 20020076 A,2002-04-15,CU 20020076 A,2002-04-15,INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA,"Aplicacion de secuencias oligonucleotídicas y polipÉotidas de molÉculas pertenecientes a la familia del factor de permeabilidad vascular (VPF), sus receptores y correceptores; así como modificaciones de los mismos, en la inmunoterapia activa de entidades patologicas cuyo curso se asocia al aumento de la vasculatura. Estos procedimientos pueden ser empleados en la terpaia Unica o combinada para el tratamiento del cAncer y sus metAstasis, los procesos inflamatorios agudos y cronicos, enfermedades infecciosas, enfermedades autoinmunes, la retinopatía diabÉtica y del reciÉn nacido, el rechazo a trasplante de organos, la degeneracion macular, los glaucomas neovasculares, hemangiomas y los angiofibromas, entre otros.",CT INGENIERIA GENETICA BIOTECH,GALBAN RODRIGUEZ ERNESTO;;MUSACHIO LASA ALEXIS;;LOPEZ OCEJO OMAR;;BEQUET ROMERO MONICA;;VAZQUEZ BLOMQUIST DANIA MARCIA;;ACEVEDO CASTRO BORIS ERNESTO;;FERNANDEZ MOLINA LUIS ENRIQUE;;GAVILONDO COWLEY JORGE VICTOR;;SILVA RODRIGUEZ RICARDO DE LA,,https://lens.org/070-766-584-260-699,Limited Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
98,US,B2,US 8883724 B2,150-064-728-421-230,2014-11-11,2014,US 61245509 A,2009-11-04,US 61245509 A;;CU 20020076 A;;US 78752207 A;;US 51138405 A;;CU 0300004 W,2002-04-15,Active antiangiogenic therapy,"Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.",BEQUET ROMERO MÓNICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNÁNDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;DE LA CARIDAD SILVA RODRIGUEZ RICARDO;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VÁSQUEZ BLOMQUIST DANIA MARCIA;;CT DE INGENIERIA GENÉTICA Y BIOTECNOLOGIA,BEQUET ROMERO MÓNICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNÁNDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;DE LA CARIDAD SILVA RODRIGUEZ RICARDO;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VÁSQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/150-064-728-421-230,Granted Patent,yes,6,0,28,28,226,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K39/395;;A61K48/00;;A61P43/00;;C07K14/475;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C07K16/00;;C12N15/12,514/8.1;;424/143.1;;424/145.1;;424/184.1;;424/185.1;;424/198.1;;424/278.1;;435/6.17;;514/7.6;;530/388.24,14,14,067-246-602-635-478;;075-298-078-114-493;;127-009-325-566-421;;084-180-626-446-118;;014-663-388-758-059;;026-112-682-644-380;;026-778-282-901-430;;027-099-352-142-620;;023-308-707-283-119;;086-466-187-383-405;;038-384-962-493-921;;032-065-353-097-45X;;045-964-705-369-967;;019-289-765-682-825,10.1073/pnas.94.14.7192;;pmc23789;;9207067;;9627059;;10.1089/hyb.1998.17.185;;11016638;;9753694;;10.1016/s0969-2126(98)00116-6;;10.1016/s0168-3659(01)00333-9;;11489493;;10969766;;16373345;;10.1074/jbc.m507783200;;10.1093/jnci/94.19.1484;;12359857;;11555605;;10537299;;pmc58766;;10.1073/pnas.191112198;;11553767;;10.1074/jbc.274.49.34884;;10574962;;10.1074/jbc.275.19.14321;;10799512;;9556597;;10.1074/jbc.273.18.11115,"Muller et al., ""Vascular Endothelial Growth Factor: Crystal Structure and Functional Mapping of the Kinase Domain Receptor Binding Site"", Proc. Natl. Acad. Sci USA, vol. 94, No. 14, 7192-7197 (1997).;;Asano et al., ""An Anti-Human VEGF Monoclonal Antibody, MV833, that Exhibits Potent Anti-Tumor Activity In Vivo"", Hybridoma, vol. 17, No. 2, 185-190 (1998).;;Brekken et al., ""Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice"", Cancer Research, vol. 60, No. 18, 5117-5124 (2000).;;Muller et al., ""VEGF and the Fab Fragment of a Humanized Neutralizing Antibody: Crystal Structure of the Complex at 2.4 Å Resolution and Mutational Analysis of the Interface"", Structure, Current Biology Ltd., vol. 6, No. 9, 1153-1167 (1998).;;Brekken et al., ""VEGF-VEGF Receptor Complexes as Markers of Tumor Vascular Endothelium"", Journal of Controlled Release, vol. 74, No. 1-3, 173-181 (2001).;;Vitaliti et al., ""Inhibition of Tumor Angiogenesis by a Single-Chain Antibody Directed Against Vascular Endothelial Growth Factor"", Cancer Research, vol. 60, No. 16, 4311-4314 (2000).;;Fuh et al., ""Structure-Function Studies of Two Synthetic Anti-Vascular Endothelial Growth Factor Fabs and Comparison with the Avastin(TM) Fab"", Journal of Biological Chemistry, vol. 281, No. 10, 6625-6631 (2006).;;Jayson et al., ""Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies"", Journal of the National Cancer Institute, vol. 94, No. 19, 1484-1493 (2002).;;Davidoff, Andrew M. et al., ""Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice"", Clinical Cancer Research 2001, 7:2870-2879.;;Prewitt, Marie et al., ""Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors"", Cancer Research 1999, 59:5209-5218.;;Wei, Yu-quan et al., ""Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen"", PNAS 2001, 98(20):11545-11550.;;Stacker et al., ""A Mutant Form of Vascular Endothelial Growth Factor (VEGF) that Lacks VEGF Receptor-2 Activation Retains the Ability to Induce Vascular Permeability"", J Biol Chemistry, vol. 274, No. 49, Dec. 1999, pp. 34884-34892.;;Dan Lu, et al., ""Identification of the Residues in the Extracellular Region of KDR Important for Interaction With Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies"", J Biol Chemistry, vol. 275, No. 19, May 2000, pp. 14321-14330.;;Gerhard Siemeister et al ""The a-Helical Domain Near the Amino Terminus is Essential for Dimerization of Vascular Endothelial Growth Factor"", J Biol Chemistry, vol. 273, No. 18, May 1998, pp. 11115-11120.",ACTIVE
99,US,B2,US 7556809 B2,142-984-354-917-89X,2009-07-07,2009,US 51138405 A,2005-04-27,CU 20020076 A;;CU 0300004 W,2002-04-15,Active antiangiogenic therapy,"Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.",CT INGENIERIA GENETICA BIOTECH,ROMERO MONICA BEQUET;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;OCEJO OMAR LOPEZ;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;LASA ALEXIS MUSACHIO;;RODRIGUEZ ERNESTO GALBAN;;VAZQUEZ BLOMQUIST DANIA MARCIA,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2004-12-28),https://lens.org/142-984-354-917-89X,Granted Patent,yes,4,25,28,28,226,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K39/095;;A61K38/04;;A61K38/18;;A61K39/00;;A61K39/39;;A61K39/395;;A61K48/00;;A61P43/00;;C07K4/12;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,424/185.1;;424/192.1;;424/193.1;;530/328;;530/399,10,8,025-730-498-839-307;;165-322-209-862-791;;032-065-353-097-45X;;045-964-705-369-967;;019-289-765-682-825;;023-308-707-283-119;;086-466-187-383-405;;038-384-962-493-921,9794403;;2005389;;10.4049/jimmunol.146.6.2017;;10.1074/jbc.274.49.34884;;10574962;;10.1074/jbc.275.19.14321;;10799512;;9556597;;10.1074/jbc.273.18.11115;;11555605;;10537299;;pmc58766;;10.1073/pnas.191112198;;11553767,"Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.;;Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.;;Leggatt et al, J Immunology 161: 4728-4735, 1998.;;Kobrin et al, J Immunology 146: 2017-2020, 1991.;;Stacker et al, J Biol Chemistry 274(49): 34884-92, Dec. 1999.;;Lu et al, J Biol Chemistry 275(19): 14321-14330, May 2000.;;Siemeister et al, J Biol Chemistry 273(18): 11115-11120, 1998.;;Davidoff, Andrew M., et al., ""Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice"", Clinical Cancer Research 2001, 7:2870-2879.;;Prewett, Marie, et al., ""Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors"", Cancer Research 1999, 59:5209-5218.;;Wei, Yu-quan, et al., ""Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen"", PNAS 2001, 98(20):11545-11550.",EXPIRED
100,BR,A,BR 0304649 A,085-998-239-863-63X,2004-07-20,2004,BR 0304649 A,2003-04-28,CU 20020086 A;;CU 0300005 W,2002-04-29,"Fragmento de anticorpo, composição farmacêutica, reagente para diagnóstico in vitro ou ex vivo, células e organismos multicelulares que expressam fragmentos de anticorpos e vetores codificadores de fragmentos de anticorpos","""FRAGMENTO DE ANTICORPO, COMPOSIçãO FARMACêUTICA, REAGENTE PARA DIAGNóSTICO IN VITRO OU EX VIVO, CéLULAS E ORGANISMOS MULTICELULARES QUE EXPRESSAM FRAGMENTOS DE ANTICORPOS E VETORES CODIFICADORES DE FRAGMENTOS DE ANTICORPOS"". Fragmentos de anticorpo de tipo Fv de cadeia simples (scFV) mono e divalente (diacorpo), obtidos por técnicas de ADN recombinante a partir de anticorpo monoclonal (AcM) anti-antígeno carcinoembrionário (CEA) CB/ior-CEA.1. Este AcM tem afinidade muito alta pelo CEA e se emprega em um diagnóstico e seguimento de tumores colorretais de homem. Como o AcM original, os fragmentos scfv monovalentes e diacorpo exibem afinidades altas pelo CEA humano e reconhecem um epitopo dependente da conservação de carboidratos. O fragmento scFv monovalente e diacorpo têm constantes de afinidade por CEA de (5,0 <sym> 0,4) x 10^ 9^ L mol^ -1^ e (2,8 <sym> 0,3) x 10^ 10^ L mol^ -1^, respectivamente. Estes dois fragmentos não apresentam reatividade cruzada com células e tecidos humanos normais, exceto a mucosa do cólon normal onde o CEA está ocasionalmente presente. Os fragmentos podem se produzir mediante a expressão em microorganismos recombinantes, a partir da clonagem de seq³ências de ácidos nucleicos codificadores de regiões variáveis obtidas do hibridoma que produz o AcM CB/ior-CEA.1. Igualmente ao AcM original, o scFv monovalente e o diacorpo têm a capacidade de identificar in vivo em ratos as células produtoras de CEA humano e crescem formando tumores. O scFv monovalente e o diacorpo têm um tamanho molecular 5 e 2,5 vezes menor, respectivamente, do que o AcM de rato e não possuem domínios Fc, o que lhes confere o potencial de penetrarem melhor nos tecidos in vivo e de serem menos imunogênicos no homem.",CT INGENIERIA GENETICA BIOTECH,COWLEY JORGE VICTOR GAVILONDO;;AVILA MARTA AYALA;;ALMEIDA FREYA DE LOS MILAGROS;;CASTRO BORIS ERNESTO ACEVEDO;;GARCIA HANSSEL BELL;;NAVARRO TATIANA LOURDES ROQUE;;LOPEZ LUIS JAVIER GONZALES;;ALVAREZ JOSE ALBERTO CREMATA;;SEGUI RAQUEL MONTESINO,,https://lens.org/085-998-239-863-63X,Patent Application,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,DISCONTINUED
101,DK,T3,DK 1502599 T3,054-162-809-006-847,2011-08-01,2011,DK 03711811 T,2003-04-11,CU 20020076 A;;CU 0300004 W,2002-04-15,Anvendelse af muteret VEGF til antiangiogen terapi,,CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;GAVILONDO COWLEY JORGE VICTOR;;MUSACHIO LASA ALEXIS;;ACEVEDO CASTRO BORIS ERNESTO;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/054-162-809-006-847,Granted Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/19;;A61K38/18;;A61K39/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
102,EP,B1,EP 1502599 B1,131-984-865-402-848,2011-06-08,2011,EP 03711811 A,2003-04-11,CU 0300004 W;;CU 20020076 A,2002-04-15,Use of mutated VEGF for antiangiogenic therapy,,CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/131-984-865-402-848,Granted Patent,yes,1,1,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/19;;A61K38/18;;A61K39/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,3,0,,,"WEI, Y-Q ET AL.: ""Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen."" PNAS, vol. 98, no. 20, September 2001 (2001-09), XP002248645;;DAVIDOFF, A.M. ET AL.: ""Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice."" CLINICAL CANCER RESEARCH, vol. 7, September 2001 (2001-09), XP002248646;;PREWETT, M. ET AL.: ""Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors."" CANCER RESEARCH, vol. 59, October 1999 (1999-10), XP002248647",EXPIRED
103,AU,B2,AU 2003/218603 B2,008-555-084-550-026,2009-05-28,2009,AU 2003/218603 A,2003-04-11,CU 20020076 A;;CU 0300004 W,2002-04-15,Active antiangiogenic therapy,,CT INGENIERIA GENETICA BIOTECNOLOGIA,RODRIGUEZ RICARDO DE LA CARIDAD SILVA;;BLOMQUIST DANIA MARCIA VAZQUEZ;;COWLEY JORGE VICTOR GAVILONDO;;OCEJO OMAR LOPEZ;;CASTRO BORIS ERNESTO ACEVEDO;;MOLINA LUIS ENRIQUE FERNANDEZ;;LASA ALEXIS MUSACHIO;;RODRIGUEZ ERNESTO GALBAN;;ROMERO MONICA BEQUET,,https://lens.org/008-555-084-550-026,Granted Patent,no,4,2,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,3,3,030-179-640-818-750;;100-808-243-681-312;;038-384-962-493-921,10.1074/jbc.271.13.7788;;8631822;;10.1074/jbc.271.10.5638;;8621427;;pmc58766;;10.1073/pnas.191112198;;11553767,"KEYT et al. J. Biol. Chem. 1996. 271: 7788-7795;;KEYT et al. J. Biol. Chem. 1996. 271: 5638-5646;;Wei, Y-Q. et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc. Natl. Acad. Sci. USA, 2001, vol. 98, no. 20, pages 11545-11550.",EXPIRED
104,EP,A1,EP 1502599 A1,179-328-861-330-871,2005-02-02,2005,EP 03711811 A,2003-04-11,CU 0300004 W;;CU 20020076 A,2002-04-15,Use of mutated VEGF for antiangiogenic therapy,"The invention relates to the application of oligonucleotide and polypeptide sequences of molecules belonging to the vascular permeability factor (VPF) family, their receptors and co-receptors and to their modifications in active immunotherapy against pathological entities whose course is associated with an increase in vasculature. Said procedures can be used, inter alia, in monotherapy or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and infant retinopathy, rejection of transplanted organs, macular degeneration, neovascular glaucoma, hemangioma and angiofibroma.",CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/179-328-861-330-871,Patent Application,yes,0,12,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/19;;A61K38/18;;A61K39/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
105,AR,A1,AR 039285 A1,196-694-139-812-87X,2005-02-16,2005,AR P030101264 A,2003-04-10,CU 20020076 A,2002-04-15,INMUNOTERAPIA ACTIVA ANTIANGIOGENICA COMPOSICION VACUNAL,"Aplicación de secuencias oligonucleotídicas y polipeptídicas de moléculas pertenecientes a una familia del factor de permeabilidad vascular (VPF), sus receptores y correceptores; así como modificaciones de los mismos, en la inmunoterapia activa de entidades patológicas cuyo curso se asocia al aumento de la vasculatura. Estos procedimientos pueden ser empleados en la terapia única o combinada para el tratamiento del cáncer y sus metástasis, los procesos inflamatorios agudos y crónicos, enfermedades infecciosas, enfermedades autoinmunes, la retinopatía diabética y del recién nacido, el rechazo del transplante de órganos, la degeneración macular, los glaucomas neovasculares, hemangiomas en los angiofibromas, entre otros.",CT INGENIERIA GENETICA BIOTECH,LOPEZ OCEJO OMAR;;SILVA RODRIQUEZ RICARDO DE LA CARIDAD;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA;;BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE,,https://lens.org/196-694-139-812-87X,Patent Application,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,PENDING
106,US,A1,US 2010/0047265 A1,112-298-900-309-659,2010-02-25,2010,US 61245509 A,2009-11-04,US 61245509 A;;CU 20020076 A;;US 78752207 A;;US 51138405 A;;CU 0300004 W,2002-04-15,ACTIVE ANTIANGIOGENIC THERAPY,"Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.",CT INGENIERIA GENETICA BIOTECH,ROMERO MONICA BEQUET;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;DE LA CARIDAD SILVA RODRIGUEZ RICARDO;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VASQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/112-298-900-309-659,Patent Application,yes,3,4,28,28,226,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K39/00;;A61K31/7088;;A61K38/18;;A61K48/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,424/185.1;;X514 44  R,0,0,,,,EXPIRED
107,ZA,B,ZA 200408720 B,139-514-429-947-408,2006-03-29,2006,ZA 200408720 A,2004-10-27,CU 20020086 A,2002-04-29,Antibody fragments specific for human carcinoembryonic antigen (CEA),,CT DE INGENERIA Y BIOTECNOLOGI,GAVILODO COWLEY JORGE V;;ALMEIDA FREYA DE LOS MILAGROS;;GARCIA HANSSEL BELL;;GONZALEZ LOPEZ LUIS J;;SEGUI RAQUEL MONTESINO;;AVILA MARTA AYALA;;ACEVEDO CASTRO BORIS E;;ROQUE NAVARRO LOURDES T;;CREMETA ALVAREZ JOSE A,,https://lens.org/139-514-429-947-408,Granted Patent,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K/;;A61K39/00;;A61K39/39;;A61K47/48;;C07K/;;C07K14/22;;C07K16/30,,0,0,,,,ACTIVE
108,BR,A2,BR PI0400755 A2,019-471-072-476-245,2010-04-06,2010,BR PI0400755 A,2004-03-23,BR PI0400755 A,2004-03-23,"uso de polipeptìdeos e/ou oligonucleotìdeos, e, composição vacinal","USO DE POLIPEPTìDEOS E/OU OLIGONUCLEOTìDEOS, E, COMPOSIçãO VACINAL. Aplicação de seqúências oligonucleotidicas e polipeptídicas de moléculas pertencentes à familia do fator de permeabilidade vascular (VPF), seus receptores e co-receptores; bem como modificações dos mesmos, na imunoterapia ativa de entidades patológicas cujo curso está associado com o aumento da vasculatura. Estes procedimentos podem ser empregados na terapia única ou combinada para o tratamento do câncer e suas metástases, nos processos inflamatórios agudos e crónicos, doenças infecciosas, doenças autoimunes, na retinopatia diabética e do recém-nascido, na rejeição ao transplante de órgãos, na degeneração macular, nos glaucomas neovasculares, hemangiomas e nos angiofibromas, entre outros.",CT INGENIERIA GENETICA BIOTECH,ROMERO MONICA BEQUET;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;OCEJO OMAR LOPEZ;;DE LA CARIDAD SILVA RODRIGUEZ RICARDO;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/019-471-072-476-245,Patent Application,no,0,0,1,1,0,,A61K39/00;;A61K31/713;;A61K38/18;;A61P19/02;;A61P35/00;;C07K14/515,,0,0,,,,DISCONTINUED
109,AU,A1,AU 2003/223831 A1,165-101-808-357-675,2003-11-17,2003,AU 2003/223831 A,2003-04-28,CU 20020086 A;;CU 0300005 W,2002-04-29,SPECIFIC ANTIBODY FRAGMENTS FOR THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA),,CT INGENIERIA GENETICA BIOTECNOLOGIA,LOPEZ LUIS JAVIER GONZALEZ;;ALVAREZ JOSE ALBERTO CREMATA;;SEGUI RAQUEL MONTESINO;;COWLEY JORGE VICTOR GAVILONDO;;AVILA MARTA AYALA;;ALMEIDA FREYA DE LOS MILAGROS;;CASTRO BORIS ERNESTO ACEVEDO;;GARCIA HANSSEL BELL;;NAVARRO LOURDES TATIANA ROQUE,,https://lens.org/165-101-808-357-675,Patent Application,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,DISCONTINUED
110,CA,C,CA 2480079 C,067-477-658-300-19X,2013-07-30,2013,CA 2480079 A,2003-04-11,CU 20020076 A;;CU 0300004 W,2002-04-15,ANTIANGIOGENIC ACTIVE IMMUNOTHERAPY,"Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.",CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/067-477-658-300-19X,Granted Patent,no,0,0,28,28,26,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K38/17;;A61K39/00;;A61K48/00;;A61P43/00;;C07K14/475;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
111,SI,T1,SI 1502599 T1,036-234-943-992-016,2011-10-28,2011,SI 200332037 T,2003-04-11,CU 20020076 A;;CU 0300004 W;;EP 03711811 A,2002-04-15,Use of mutated VEGF for antiangiogenic therapy,,CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNANDEZ MOLINA LUIS ENRIQUE;;LOPEZ OCEJO OMAR;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;MUSACHIO LASA ALEXIS;;GALBAN RODRIGUEZ ERNESTO;;VAZQUEZ BLOMQUIST DANIA MARCIA,,https://lens.org/036-234-943-992-016,Granted Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/19;;A61K38/18;;A61K39/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
112,US,A1,US 2008/0254050 A1,119-511-120-342-153,2008-10-16,2008,US 78752207 A,2007-04-17,US 78752207 A;;CU 20020076 A;;US 51138405 A;;CU 0300004 W,2002-04-15,Antiangiogenic active immunotherapy,"Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.",CT INGENIERIA GENETICA BIOTECH,ROMERO MONICA BEQUET;;CASTRO BORIS ERNESTO ACEVEDO;;COWLEY JORGE VICTOR GAVILONDO;;MOLINA LUIS ENRIQUE FERNANDEZ;;OCEJO OMAR LOPEZ;;RODRIGUEZ RICARDO DE LA CARIDA SILVA;;LASA ALEXIS MUSACHIO;;RODRIGUEZ ERNESTO GALBAN;;BLOMQUIST DANIA MARCIA VAZQUEZ,,https://lens.org/119-511-120-342-153,Patent Application,yes,1,7,28,28,18,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K39/00;;A61K38/18;;A61K48/00;;A61P37/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,424/185.1,0,0,,,,DISCONTINUED
113,PT,E,PT 1502599 E,033-559-193-608-13X,2011-08-03,2011,PT 03711811 T,2003-04-11,CU 20020076 A,2002-04-15,USE OF MUTATED VEGF FOR ANTIANGIOGENIC THERAPY,,CT INGENIERIA GENETICA BIOTECH,ROMERO MONICA BEQUET;;CASTRO BORIS ERNESTO ACEVEDO;;COWLEY JORGE VICTOR GAVILONDO;;MOLINA LUIS ENRIQUE CALLE FERNANDEZ;;OCEJO OMAR LOPEZ;;RODRIGUEZ RICARDO DE LA CARIDAD SILVA;;LASA ALEXIS MUSACHIO;;ERNESTO GALBAN RODRIGUEZ;;BLOMQUIST DANIA MARCIA VAZQUEZ,,https://lens.org/033-559-193-608-13X,Granted Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/19;;A61K38/18;;A61K39/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12,,0,0,,,,EXPIRED
114,RU,C2,RU 2329824 C2,167-715-378-268-830,2008-07-27,2008,RU 2004133338 A,2003-04-11,CU 20020076 A,2002-04-15,ACTIVE ANGIOGENESIS-PREVENTING IMMUNETHERAPY,"FIELD: medicine. ^ SUBSTANCE: invention refers to medicine and concerns angiogenesis-preventing immunotherapy. Invention substance includes immunogenic compositions for treatment of disorders associated with angiogenesis intensification, containing oligonucleotides, coding polypeptides VEGFR2, introduced as a part of plasmid or viral vectors, as well as polypeptides VEGFR2, oligonucleotides, coding autologous VEGF with damaged function of receptor activation, polypeptides VEGF and their combinations. Immunogenic compositions can be used for treatment of malignant neoplasms and metastasises, at benign neoplasm and chronic inflammatory and autoimmune diseases. Advantage of invention lies in humoral and cellular immunity induction by means of specified compositions. ^ EFFECT: development of effective method angiogenesis preventive immunotherapy. ^ 19 cl, 11 ex, 7 tbl",CIGB,ROMERO MONICA BEQUET;;CASTRO BORIS ERNESTO ACEVEDO;;COWLEY JORGE VICTOR GAVILONDO;;MOLINA LUIS ENRIQUE CALLE FERNANDEZ;;OCEJO OMAR LOPEZ;;RODRIGUEZ RICARDO DE LA CARIDAD SILVA;;LASA ALEXIS MUSACHIO;;ERNESTO GALBAN RODRIGUEZ;;BLOMQUIST DANIA MARCIA VAZQUEZ,,https://lens.org/167-715-378-268-830,Granted Patent,no,0,0,28,28,0,A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;C07K14/715;;A61P1/16;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P3/10;;A61P31/00;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K39/001109;;A61K39/001135;;A61K38/18;;A61K48/00;;A61K38/17;;A61K39/0005;;A61K39/0008;;A61K39/001;;A61K48/005;;A61K2039/5256;;A61K2039/5258;;A61K2039/53;;A61K2039/55516;;A61K2039/55594;;C07K14/515;;C07K14/52;;C07K14/71;;A61K38/1858;;A61K38/1866;;A61K39/001135;;A61K39/001109;;C07K14/715,A61K38/18;;A61K39/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/475;;C07K14/515;;C07K14/52;;C07K14/71;;C07K14/715;;C12N15/12;;C12N15/19,,0,0,,,,EXPIRED
115,AR,A1,AR 039454 A1,083-302-664-692-359,2005-02-23,2005,AR P030101442 A,2003-04-25,CU 20020086 A,2002-04-29,FRAGMENTOS DE ANTICUERPOS ESPECIFICOS PARA EL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA),"Fragmentos de anticuerpo tipo Fv de cadena sencilla (scFv) mono y divalente (diacuerpo), obtenidos por técnicas de ADN recombinante a partir del anticuerpo monoclonal (AcM) anti-antígeno carcinoembrionario (CEA) CB/ior-CEA.1. Este AcM tiene muy alta afinidad por el CEA y se emplea en el diagnóstico y seguimiento de tumores colorectales del hombre. Como el AcM original, los fragmentos scFv monovalentes y diacuerpo exhiben altas afinidades por el CEA humano y reconocen un epítope dependiente de la conservación de los carbohidratos. El fragmento scFV monovalente y diacuerpo tiene constantes de afinidad por el CEA de (5.0 +- 0.4) x 109 L mol-1 y (2.8 +- 0.3) x 10 10 L mol-1, respectivamente. Estos dos fragmentos no presentan reactividad cruzada con células y tejidos humanos normales, excepto la mucosa colónica normal donde el CEA está ocasionalmente presente. Los fragmentos pueden producirse mediante la expresión en microorganismos recombinantes, a partir del clonaje de secuencias de ácidos nucleicos codificantes para regiones variables obtenidas del hibridoma que produce el AcM CB/ior-CEA.1. Al igual que el AcM original, el scFv monovalente y el diacuerpo tienen la capacidad de identificar in vivo en ratones a células productoras de CEA humano que crecen formando tumores. El scFv monovalente y el diacuerpo tienen un tamano molecular 5 y 2.5 veces inferior, respectivamente, que el AcM de ratón y no poseen dominios Fc, lo que les confiere el potencial de penetrar mejor los tejidos in vivo y de ser menos inmunogénicos en el hombre. Reivindicación 1: Un fragmento de anticuerpo tipo scFv monomérico obtenido a partir del ARN extraído del hibridoma productor del AcM CB/ior-CEA.1 específico para al antígeno carcinoembrionario (CEA) humano soluble, adsorbido a superficies sólidas, o presente en células, con una constante de afinidad por el CEA de (5.0 +- 0.4) x 109 L mol-1 y un reconocimiento por dicho antígeno dependiente de la conservación de la glicosidación del mismo.",CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MILAGROS;;ACEVEDO CASTRO BORIS ERNESTO;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,,https://lens.org/083-302-664-692-359,Patent Application,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,EXPIRED
116,CN,C,CN 1326877 C,093-258-906-800-242,2007-07-18,2007,CN 03809658 A,2003-04-28,CU 20020086 A,2002-04-29,Specific antibody fragments for the human carcinoembryonic antigen (CEA),,CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MILAGROS;;ACEVEDO CASTRO BORIS E;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,,https://lens.org/093-258-906-800-242,Granted Patent,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,C07K16/00;;A61K39/00;;A61K39/39;;A61K47/48;;A61K51/10;;A61P35/00;;C07K14/22;;C07K16/30;;C12N15/63,,1,0,,,"bacterial single-chain antibody fragments,specific forcarcinoembryonic antigen Ayala.M等,biotechniques,Vol.13 No.5 1992",EXPIRED
117,CA,A1,CA 2482411 A1,143-632-571-342-874,2003-11-13,2003,CA 2482411 A,2003-04-28,CU 20020086 A;;CU 0300005 W,2002-04-29,ANTIBODY FRAGMENTS SPECIFIC FOR HUMAN CANCINOEMBRYONIC ANTIGEN (CEA),"The invention relates to mono- and bivalent (diabody) single-chain Fv-type (scFv) antibody fragments which are obtained using recombinant DNA technique s from the carcinoembryonic anti-antigen (CEA) monoclonal antibody (McA) CB/io r- CEA.1. The aforementioned McA has a high affinity for the CEA and is used in the diagnosis and monitoring of colorectal tumours in humans. As with the original McA, diabody and monovalent scFv fragments exhibit high affinities for the human CEA and recognise an epitope that is dependent on carbohydrate conservation. The diabody and monovalent scFv fragments have affinity constants for the CEA of (5.0 .plusmn. 0.4) x 109 L mol-1 and (2.8 .plusmn. 0.3) x 1010 L mol-1 respectively. The two aforementioned fragments do not display cross-reactivity with normal human tissues and cells, except for the normal colonic mucosa where the CEA is occasionally present. Said fragments can be produced through expression in recombinant micro-organisms from the cloning of nucleic acid sequences that code for variable regions obtained fr om the hybridoma that is produced by the CB/ior-CEA.1 McA. As with the original McA, the diabody and the monovalent scFv have a capacity for thein vivo identification in rats of human CEA-producing cells which grow forming tumours. The monovalent scFvand diabody do not posses Fc domains and the molecular sizes of said monovalent scFv and diabody are 5 and 2.5 times, respectively, less than the rat McA. As a result, the aforementioned monovalent scFv and diabody can better penetrate tissues in vivo and are les s immunogenic in humans.",CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;CREMATA ALVAREZ JOSE ALBERTO;;GONZALEZ LOPEZ LUIS JAVIER;;ROQUE NAVARRO LOURDES TATIANA;;MONTESINO SEGUI RAQUEL;;BELL GARCIA HANSSEL;;ACEVEDO CASTRO BORIS ERNESTO;;FREYRE ALMEIDA FREYA DE LOS MI,,https://lens.org/143-632-571-342-874,Patent Application,no,0,0,23,23,21,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,DISCONTINUED
118,WO,A2,WO 2003/093315 A2,095-442-219-640-542,2003-11-13,2003,CU 0300005 W,2003-04-28,CU 20020086 A,2002-04-29,SPECIFIC ANTIBODY FRAGMENTS FOR THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA),"The invention relates to mono- and bivalent (diabody) single-chain Fv-type (scFv) antibody fragments which are obtained using recombinant DNA techniques from the carcinoembryonic anti-antigen (CEA) monoclonal antibody (McA) CB/ior-CEA.1. The aforementioned McA has a high affinity for the CEA and is used in the diagnosis and monitoring of colorectal tumours in humans. As with the original McA, diabody and monovalent scFv fragments exhibit high affinities for the human CEA and recognise an epitope that is dependent on carbohydrate conservation. The diabody and monovalent scFv fragments have affinity constants for the CEA of (5.0 ± 0.4) x 109 L mol-1 and (2.8 ± 0.3) x 1010 L mol-1 respectively. The two aforementioned fragments do not display cross-reactivity with normal human tissues and cells, except for the normal colonic mucosa where the CEA is occasionally present. Said fragments can be produced through expression in recombinant micro-organisms from the cloning of nucleic acid sequences that code for variable regions obtained from the hybridoma that is produced by the CB/ior-CEA.1 McA. As with the original McA, the diabody and the monovalent scFv have a capacity for the in vivo identification in rats of human CEA-producing cells which grow forming tumours. The monovalent scFv and diabody do not posses Fc domains and the molecular sizes of said monovalent scFv and diabody are 5 and 2.5 times, respectively, less than the rat McA. As a result, the aforementioned monovalent scFv and diabody can better penetrate tissues in vivo and are less immunogenic in humans.",CT INGENIERIA GENETICA BIOTECH;;GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MI;;ACEVEDO CASTRO BORIS ERNESTO;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MI;;ACEVEDO CASTRO BORIS ERNESTO;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,,https://lens.org/095-442-219-640-542,Patent Application,yes,0,0,23,23,21,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,PENDING
119,EP,B1,EP 1505076 B1,123-640-031-629-895,2009-04-08,2009,EP 03720119 A,2003-04-28,CU 0300005 W;;CU 20020086 A,2002-04-29,SPECIFIC ANTIBODY FRAGMENTS FOR THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA),,CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MILAGROS;;ACEVEDO CASTRO BORIS E;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CI (2011-03-31),https://lens.org/123-640-031-629-895,Granted Patent,yes,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,C07K16/30;;A61K39/00;;A61K39/39;;A61K47/48;;A61K51/10;;C07K14/22,,2,0,,,"SE-HO KIM ET AL.: ""Characterization of Monoclonal Antibodies Against Carcinoembryonic Antigen (CEA) and Expression in E. coli"" HYBRIDOMA, vol. 20, num. 4, Agosto 2001 (2001-08), XP002251700;;HOLLIGER P. ET AL.: """"Diabodies"": Small bivalent and bispecific antibody fragments"" PROC. NATL. ACAD. SCI., vol. 90, Julio 1993 (1993-07), XP002251701",EXPIRED
120,CU,A1,CU 23228 A1,105-076-635-001-073,2007-09-26,2007,CU 20020086 A,2002-04-29,CU 20020086 A,2002-04-29,FRAGMENTOS DE ANTICUERPOS ESPECIFICOS PARA EL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA) SECUENCIAS DE SUS REGIONES VARIABLES Y VECTORES PARA LA EXPRESION MICROBIANA DE LOS MISMOS,,CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MILAGROS;;ACEVEDO CASTRO BORIS E;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,,https://lens.org/105-076-635-001-073,Limited Patent,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,EXPIRED
121,AT,T1,AT E427967 T1,036-118-241-425-510,2009-04-15,2009,AT 03720119 T,2003-04-28,CU 20020086 A,2002-04-29,SPEZIFISCHE ANTIKÍRPERFRAGMENTE FUR DAS HUMANE CARCINOEMBRYONIC ANTIGEN (CEA),,CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MILAGROS;;ACEVEDO CASTRO BORIS E;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,,https://lens.org/036-118-241-425-510,Granted Patent,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,EXPIRED
122,WO,A3,WO 2003/093315 A3,015-505-653-248-395,2004-01-08,2004,CU 0300005 W,2003-04-28,CU 20020086 A,2002-04-29,SPECIFIC ANTIBODY FRAGMENTS FOR THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA),"The invention relates to mono- and bivalent (diabody) single-chain Fv-type (scFv) antibody fragments which are obtained using recombinant DNA techniques from the carcinoembryonic anti-antigen (CEA) monoclonal antibody (McA) CB/ior-CEA.1. The aforementioned McA has a high affinity for the CEA and is used in the diagnosis and monitoring of colorectal tumours in humans. As with the original McA, diabody and monovalent scFv fragments exhibit high affinities for the human CEA and recognise an epitope that is dependent on carbohydrate conservation. The diabody and monovalent scFv fragments have affinity constants for the CEA of (5.0 ± 0.4) x 109 L mol-1 and (2.8 ± 0.3) x 1010 L mol-1 respectively. The two aforementioned fragments do not display cross-reactivity with normal human tissues and cells, except for the normal colonic mucosa where the CEA is occasionally present. Said fragments can be produced through expression in recombinant micro-organisms from the cloning of nucleic acid sequences that code for variable regions obtained from the hybridoma that is produced by the CB/ior-CEA.1 McA. As with the original McA, the diabody and the monovalent scFv have a capacity for the in vivo identification in rats of human CEA-producing cells which grow forming tumours. The monovalent scFv and diabody do not posses Fc domains and the molecular sizes of said monovalent scFv and diabody are 5 and 2.5 times, respectively, less than the rat McA. As a result, the aforementioned monovalent scFv and diabody can better penetrate tissues in vivo and are less immunogenic in humans.",CT INGENIERIA GENETICA BIOTECH;;GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MI;;ACEVEDO CASTRO BORIS ERNESTO;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MI;;ACEVEDO CASTRO BORIS ERNESTO;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,,https://lens.org/015-505-653-248-395,Search Report,yes,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,2,2,056-513-334-447-183;;066-749-017-721-197,11604113;;10.1089/027245701753179857;;8341653;;10.1073/pnas.90.14.6444;;pmc46948,"SE-HO KIM ET AL.: ""Characterization of Monoclonal Antibodies Against Carcinoembryonic Antigen (CEA) and Expression in E. coli"", HYBRIDOMA, vol. 20, no. 4, August 2001 (2001-08-01), XP002251700;;HOLLIGER P. ET AL.: """"Diabodies"": Small bivalent and bispecific antibody fragments"", PROC. NATL. ACAD. SCI., vol. 90, July 1993 (1993-07-01), XP002251701",PENDING
123,DE,D1,DE 60327072 D1,049-797-917-334-221,2009-05-20,2009,DE 60327072 T,2003-04-28,CU 20020086 A;;CU 0300005 W,2002-04-29,SPEZIFISCHE ANTIKÖRPERFRAGMENTE FÜR DAS HUMANE CARCINOEMBRYONIC ANTIGEN (CEA),,CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MILAGROS;;ACEVEDO CASTRO BORIS E;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,,https://lens.org/049-797-917-334-221,Granted Patent,no,0,0,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,C07K16/30;;A61K39/00;;A61K39/39;;A61K47/48;;A61K51/10;;C07K14/22,,0,0,,,,EXPIRED
124,EP,A2,EP 1505076 A2,063-555-356-195-553,2005-02-09,2005,EP 03720119 A,2003-04-28,CU 0300005 W;;CU 20020086 A,2002-04-29,SPECIFIC ANTIBODY FRAGMENTS FOR THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA),"The invention refers to mono- and divalent (diabody) single chain Fv (scFv) antibody fragments, obtained by recombinant DNA techniques from the anti-carcinoembryonic antigen (CEA) monoclonal antibody (Mab) CB/ior-CEA.1. This antibody has high affinity for CEA and is employed in the diagnosis and follow-up of human colorectal tumors. As the original Mab, the monovalent fragment and the diabody exhibit high affinity for human CEA and recognize an epitope dependent of carbohydrate conservation. The monovalent scFv fragment and the diabody have affinity constants for CEA of (5.0 ± 0.4) x 10 9  L mol -1  and (2.8 ± 0.3) x 10 10  L mol -1 , respectively. These two fragments do not show cross reactivity with human normal cells and tissues, exception made of the normal colonic mucosa, where CEA is occasionally present. The fragments can be produced through the expression in recombinant microorganisms, starting from the cloning of the encoding variable region nucleic acid sequences obtained from the hybridoma that produces Mab CB/ior-CEA.1. As the original Mab, the monovalent scFv and the diabody have the ability to identify in vivo cells that produce human CEA and grow as tumors in mice. The monovalent scFv and the diabody have a molecular size 5 and 2.5 times lower, respectively, than the mouse Mab, and do not have Fc domains, fact this that confers them the potential to better penetrate tissues  in vivo  and to be less immunogenic in man.",CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;AYALA AVILA MARTA;;FREYRE ALMEIDA FREYA DE LOS MI;;ACEVEDO CASTRO BORIS E;;BELL GARCIA HANSSEL;;ROQUE NAVARRO LOURDES TATIANA;;GONZALEZ LOPEZ LUIS JAVIER;;CREMATA ALVAREZ JOSE ALBERTO;;MONTESINO SEGUI RAQUEL,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CI (2011-03-31),https://lens.org/063-555-356-195-553,Patent Application,yes,0,5,23,23,0,C07K14/22;;C07K16/3007;;C07K2317/622;;C07K2317/626;;A61P35/00;;C07K16/30;;A61K51/10;;C07K14/22;;C07K2317/622;;A61K47/6851;;C07K16/3007;;C07K2317/626;;A61K39/00;;A61K2039/505,A61K39/00;;A61K39/39;;A61K47/48;;C07K14/22;;C07K16/30,,0,0,,,,EXPIRED
125,PE,Z,PE 20221118 Z,122-070-484-227-436,2022-07-12,2022,PE 2022000611 U,2022-04-11,PE 2022000611 U,2022-04-11,EQUIPO AUXILIAR PARA EL LAVADO OTICO,"Un equipo auxiliar para el lavado otico del tipo que comprende una base circular que soporta a una columna vertical; caracterizada porque: el extremo superior de la columna vertical sostiene a una rinonera semicircular; la columna sostiene a una pluralidad de brazos horizontales; uno de los brazos horizontales sostiene a un tanque de liquidos con tapa; la rinonera semicircular presenta dos sumideros en sus extremos, cada sumidero cuenta con un filtro de solidos; y unos tubos conectan a los sumideros de la rinonera semicircular con la tapa del tanque de liquidos.",UNIV PRIVADA SAN JUAN BAUTISTA S A C,MORILLO FLORES JOHN JANEL;;FUSTER GUILLEN DORIS ELIDA;;OCANA FERNANDEZ YOLVI JAVIER;;ACEVEDO FLORES JESSICA ELIZABETH;;ZAVALETA OLIVER JENNY;;SHARDIN FLORES LINDA;;BRYSON MALCA WALTER FLORENCIO;;MENACHO VARGAS ISABEL;;TAQUIO YANGALI JOHN ALEXANDER;;HILARIO SANCHEZ JORGE ALFREDO,,https://lens.org/122-070-484-227-436,Patent Application,no,0,0,1,1,0,,A61B1/227,,0,0,,,,PENDING
126,PE,Z,PE 20220993 Z,176-369-882-086-806,2022-06-15,2022,PE 2022000610 U,2022-04-11,PE 2022000610 U,2022-04-11,ORTESIS SEMIRIGIDO DE PRESOTERAPIA PARA EXTREMIDADES,"Una ortesis semirrigida de presoterapia para extremidades con el tamano y forma de una extremidad humana que tiene una capa exterior semirrigida a base de material polimerico y una capa interior flexible de silicona; caracterizado porque: la ortesis esta dividida en dos mitades longitudinales, donde dichas mitades estan unidas por bisagras por un lado y cuentan con elementos de ajuste en el otro lado; cada mitad longitudinal de la ortesis esta dividida en tres secciones separadas por cintas flexibles; la capa interior tiene empotrada una pluralidad de sensores de presion tipo galgas extensiometricas; y hay una carcasa en la capa exterior que aloja en su interior a un controlador electronico con un modulo de comunicacion inalambrico y unas baterias recargables, donde dicho controlador electronico esta conectado a las galgas extensiometricas.",UNIV PRIVADA SAN JUAN BAUTISTA S A C,MORILLO FLORES JOHN JANEL;;FUSTER GUILLEN DORIS ELIDA;;OCANA FERNANDEZ YOLVI JAVIER;;ACEVEDO FLORES JESSICA ELIZABETH;;ZAVALETA OLIVER JENNY MARIELLA;;SHARDIN FLORES LINDA;;BRYSON MALCA WALTER FLORENCIO;;MENACHO VARGAS ISABEL;;TAQUIO YANGALI JOHN ALEXANDER;;HILARIO SANCHEZ JORGE ALFREDO,,https://lens.org/176-369-882-086-806,Patent Application,no,0,0,1,1,0,,A61F5/00,,0,0,,,,PENDING
127,WO,A1,WO 2019/155106 A1,139-437-374-915-356,2019-08-15,2019,ES 2019070064 W,2019-02-06,ES 201830121 A,2018-02-09,TEST MACHINE AND METHOD FOR DETERMINING A BALL REBOUND HEIGHT,"A test machine (1) for determining a ball rebound height comprises an arm (2) hinged to a motorized actuator located in a housing (3), the arm (2) having a pivot point defining a circular path, the arm (2) including a fastening means provided for fixedly fastening a ball, an electronic board configured to detect an angle α defined by the arm (2) and a surface for bouncing the ball, upon which the ball is bounced, the housing (3) being movable by moving means designed to move on a surface. This machine is intended for automatically determining the height of rebound of a ball, for example a football ball on an artificial turf surface, eliminating the human factor during the performance of the test.",UNIV CASTILLA LA MANCHA,GALLARDO GUERRERO LEONOR;;RODRÍGUEZ ROSA DAVID;;SÁNCHEZ SÁNCHEZ JAVIER;;MONTALVO MARTÍN DE ALMAGRO JUAN ANTONIO MARÍA;;GARCÍA UNANUE JORGE FERNANDO;;GONZÁLEZ RODRÍGUEZ ANTONIO;;FELIPE HERNÁNDEZ JOSÉ LUIS;;CASTILLO GARCÍA FERNANDO JOSÉ;;COLINO ACEVEDO ENRIQUE;;LEÓN JIMÉNEZ MANUEL;;JUÁREZ PÉREZ SERGIO,,https://lens.org/139-437-374-915-356,Patent Application,yes,11,0,2,2,0,G01N3/30;;G01N3/52;;G01N3/303;;G01N3/40;;G01N3/52;;G01N2203/0039;;G01N2203/0083,G01N3/30;;G01N3/303;;G01N3/40;;G01N3/52,,0,0,,,,PENDING
128,ES,A1,ES 2699123 A1,069-683-445-585-582,2019-02-07,2019,ES 201830121 A,2018-02-09,ES 201830121 A,2018-02-09,"Test machine to determine the bounce height of a ball and method (Machine-translation by Google Translate, not legally binding)","Test machine (1) for determining the rebound height of a ball, comprising an arm (2) that is articulated to a motorized actuator located in a casing (3), such that the arm (2) has a pivot point which describes a circular path, the arm (2) including a holding means provided for fixedly holding a balloon, an electronic plate configured to detect an angle α defined by the arm (2) and the surface on which the balloon bounces after a rebound action of the balloon on said surface, the casing (3) being movable by displacement means provided to move on a surface. This machine is intended to determine the height of rebound of a ball, for example, a soccer ball on an artificial turf surface in an automated manner, whereby the human factor is eliminated during the performance of the test. (Machine-translation by Google Translate, not legally binding)",UNIV CASTILLA LA MANCHA,GALLARDO GUERRERO LEONOR;;RODRÍGUEZ ROSA DAVID;;SÁNCHEZ SÁNCHEZ JAVIER;;MONTALVO MARTÍN DE ALMAGRO JUAN ANTONIO MARÍA;;GARCÍA UNANUE JORGE FERNANDO;;GONZÁLEZ RODRÍGUEZ ANTONIO;;FELIPE HERNÁNDEZ JOSÉ LUIS;;CASTILLO GARCÍA FERNANDO JOSÉ;;COLINO ACEVEDO ENRIQUE;;LEÓN JIMÉNEZ MANUEL;;JUÁREZ PÉREZ SERGIO,,https://lens.org/069-683-445-585-582,Patent Application,no,3,0,2,2,0,G01N3/30;;G01N3/52;;G01N3/303;;G01N3/40;;G01N3/52;;G01N2203/0039;;G01N2203/0083,G01N3/52,,1,0,,,Jornada de conocimiento y gestión de campos de fútbol de césped artificial y natural. (CATÓN) ¿Jornada de conocimiento y gestión de campos de fútbol de césped artificial y natural¿. Páginas 16-18. Mondoturf. Santiago de Compostela 27/01/018,ACTIVE
129,ES,Y,ES 1251544 Y,022-139-292-315-068,2020-11-12,2020,ES 202031767 U,2018-02-09,ES 202031767 U,2018-02-09,Máquina de ensayo para determinar la altura de rebote de un balón,,UNIV CASTILLA LA MANCHA,GALLARDO GUERRERO LEONOR;;RODRÍGUEZ ROSA DAVID;;SÁNCHEZ SÁNCHEZ JAVIER;;MONTALVO MARTÍN DE ALMAGRO JUAN ANTONIO MARÍA;;GARCÍA UNANUE JORGE FERNANDO;;GONZÁLEZ RODRÍGUEZ ANTONIO;;FELIPE HERNÁNDEZ JOSÉ LUIS;;CASTILLO GARCÍA FERNANDO JOSÉ;;COLINO ACEVEDO ENRIQUE;;LEÓN JIMÉNEZ MANUEL;;JUÁREZ PÉREZ SERGIO,,https://lens.org/022-139-292-315-068,Limited Patent,no,0,0,2,2,0,,G01N3/52,,0,0,,,,ACTIVE
130,ES,U,ES 1251544 U,081-087-107-003-192,2020-08-21,2020,ES 202031767 U,2018-02-09,ES 202031767 U,2018-02-09,"Testing machine to determine the rebound height of a ball (Machine-translation by Google Translate, not legally binding)","Testing machine (1) to determine the rebound height of a ball, characterized by the fact that it comprises an arm (2) that is articulated to a motorized actuator located in a housing (3) by means of a rotational articulation located at one end of said arm (2), such that the arm (2) has a pivot point that describes a circular path, the arm (2) including a fastening means designed to fix a ball, a plate Electronic configured to detect an angle α defined by the arm (2) and the surface on which to bounce the ball after a bouncing action of the ball on said surface, the housing (3) being movable by means of movement provided to move on a surface. (Machine-translation by Google Translate, not legally binding)",UNIV CASTILLA LA MANCHA,GALLARDO GUERRERO LEONOR;;RODRÍGUEZ ROSA DAVID;;SÁNCHEZ SÁNCHEZ JAVIER;;MONTALVO MARTÍN DE ALMAGRO JUAN ANTONIO MARÍA;;GARCÍA UNANUE JORGE FERNANDO;;GONZÁLEZ RODRÍGUEZ ANTONIO;;FELIPE HERNÁNDEZ JOSÉ LUIS;;CASTILLO GARCÍA FERNANDO JOSÉ;;COLINO ACEVEDO ENRIQUE;;LEÓN JIMÉNEZ MANUEL;;JUÁREZ PÉREZ SERGIO,,https://lens.org/081-087-107-003-192,Patent Application,no,0,0,2,2,0,,G01N3/52,,0,0,,,,ACTIVE
131,CY,T1,CY 1111791 T1,044-931-901-319-88X,2015-10-07,2015,CY 111100832 T,2011-08-30,EP 03711811 A;;CU 20070602 A,2002-04-15,ΧΡΗΣΗ ΤΟΥ ΜΕΤΑΛΛΑΓΜΕΝΟΥ VEGF ΓΙΑ ΑΝΤΙΑΓΓΕΙΟΓΕΝΕΤΙΚΗ ΘΕΡΑΠΕΙΑ,"Η εφεύρεση αναφέρεται στην εφαρμογή ολιγονουκλεοτιδικών και πολυπεπτιδικών αλληλουχιών μορίων που ανήκουν στην οικογένεια του παράγοντα αγγειακής διαπερατότητας (VPF), των υποδοχέων τους και συν-υποδοχέων και στις τροποποιήσεις τους στην ενεργή ανοσοθεραπεία κατά παθολογικών καταστάσεων των οποίων η πορεία συνδέεται με μία αύξηση στην αγγείωση. Οι εν λόγω διαδικασίες μπορούν να χρησιμοποιηθούν, μεταξύ άλλων, στην μονοθεραπεία ή συνδυασμένη θεραπεία για την θεραπευτική αγωγή καρκίνου και των μεταστάσεων του, οξέων και χρόνιων φλεγμονωδών διεργασιών, μολυσματικών νόσων, αυτοάνοσων νόσων, διαβητικής αμφιβληστροειδίτιδας και αμφιβληστροειδίτιδας νεογέννητων, απόρριψης μεταμοσχευμένων οργάνων, εκφύλισης ωχράς κηλίδας, νεοαγγειακού γλαυκώματος, αιμαγγειώματος και αγγειοϊνώματος.",CT INGENIERIA GENETICA BIOTECH,BEQUET ROMERO MONICA;;ACEVEDO CASTRO BORIS ERNESTO;;GAVILONDO COWLEY JORGE VICTOR;;FERNÁNDEZ MOLINA LUIS ENRIQUE;;LÓPEZ OCEJO OMAR;;SILVA RODRÍGUEZ RICARDO;;MUSACHIO LASA ALEXIS;;GALBAN RODRÍGUEZ ERNESTO;;VÁZQUEZ BLOMQUIST DANIA MARCIA;;CUBA;;CUBA;;CUBA;;CUBA;;CUBA;;CUBA;;CUBA;;CUBA;;CUBA,,https://lens.org/044-931-901-319-88X,Granted Patent,no,0,0,1,1,0,,A61K38/19;;A61P35/00,,0,0,,,,ACTIVE
132,ES,T3,ES 2398586 T3,192-029-704-932-941,2013-03-20,2013,ES 07711104 T,2007-02-28,CU 20064920 A;;CU 2007000010 W,2006-02-28,Uso del inhibidor de CK2 para el tratamiento y la quimiosensibilización de tumores refractarios a fármacos anticancerosos,"La presente invención se relaciona con una combinación farmacéutica que incluye un inhibidor de la fosforilación de la Caseína Kinasa 2 (denominado P15) y los citostáticos usados en la quimioterapia del cáncer los cuales son administrados simultáneos, separados o secuencialmente. Los citostáticos preferidos son los platinos, taxanos, alcaloides de la Vinca, 5-fluorouracilo, doxorubicina,ciclofosfamida, etoposide, mitomicina C, imatinib, iressa y el velcade (vortezomib). La sinergia entre el péptido P15 y los compuestos químicos anticancerígenos, hace que la concentración eficazde cada citostático en la combinación sea entre uno y dos órdenes de magnitud menor que la correspondiente a los citostaticos sólos. Consecuentemente, la combinación descrita en la invención tiene una toxicidad mucho menor que la reportada para los citostaticos anticancerígenos lo cual representa una ventaja crucial para su uso en el tratamiento del cáncer. Adicionalmente, la combinación administrada de manera secuencial produce la quimiosensibilización de tumores refractarios a los citostáticos mencionados mediante el pretratamiento con el péptido P15.",CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,PEREA RODRIGUEZ SILVIO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA;;BETANCOURT NUNEZ LAZARO;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS;;GONZALEZ LOPEZ LUIS;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL;;GOMEZ DANIEL,,https://lens.org/192-029-704-932-941,Granted Patent,no,0,0,4,4,0,,A61K38/08;;A61K31/555;;A61K33/24;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
133,MX,A,MX 2008011141 A,089-039-913-386-647,2009-01-26,2009,MX 2008011141 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS.,"The present invention relates to a pharmaceutical combination that includes a casein kinase 2 phosphorylation inhibitor (called p15) and cytostatics used in cancer chemotherapy, which are administered simultaneously, separately or sequentially. The preferred cytostatics are platinums, taxans, vinca alkaloids, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). Synergy between peptide p15 and the anticancer chemical compounds means that the effective concentration of each cytostatic in the combination is between 1 and 2 orders of magnitude less than that corresponding to cytostatics alone. Consequently, the combination described in the invention has a much lower toxicity than that reported for anticancer cytostatics, which represents a crucial advantage in their use in cancer treatment. Additionally, administered sequentially, the combination gives rise to the chemosensitization of refractory tumours to the cytostatics mentioned by means of pre-treatment with peptide p15.",CT INGENIERIA GENETICA BIOTECH,BETANCOURT NUNEZ LAZARO HIRAM;;CASTELLANOS SERRA LILA ROSA;;PERERA NEGRIN YASSER;;GONZALEZ LOPEZ LUIS JAVIER;;PEREA RODRIGUEZ SILVIO ERNESTO;;ACEVEDO CASTRO BORIS ERNESTO;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO,,https://lens.org/089-039-913-386-647,Patent Application,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,0,0,,,,ACTIVE
134,CN,B,CN 101432012 B,129-269-313-733-484,2013-01-02,2013,CN 200780015234 A,2007-02-28,CU 2007000010 W;;CU 20060049 A,2006-02-28,Pharmaceutical combination for the treatment and or chemosensibilization of refractory tumors to anticancer drugs,,CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,ULLOA ARIELIS RODRIGUEZ;;SERRA LILA ROSA CASTELLANOS;;PUENTE ANIEL SANCHEZ;;PEREZ VLADIMIR BESADA;;VALDES JEOVANIS GIL;;GOMEZYASSEL RAMOS;;CASTRO BORIS ERNESTO ACEVEDO;;ALONSO DANIEL FERNANDO;;NEGRIN YASSER PERERA;;LOPEZ LUIS JAVIER GONZALEZ;;NUNEZ LAZARO HIRAM BETANCOURT;;DUQUE JORGE FERNANDEZ COSSIO DORTA;;GOMEZ DANIEL EDUARDO;;RODRIGUEZ SILVIO ERNESTO PEREA,,https://lens.org/129-269-313-733-484,Granted Patent,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,0,0,,,,ACTIVE
135,US,B2,US 9226946 B2,033-966-110-885-704,2016-01-05,2016,US 201414490856 A,2014-09-19,US 201414490856 A;;CU 20060049 A;;US 28062909 A;;CU 2007000010 W;;US 28062908 A,2006-02-28,Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs,"This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.",CT INGENIERIA GENETICA BIOTECH;;BIOREC SA,PEREA RODRÍGUEZ SILVIO ERNESTO;;PERERA NEGRÍN YASSER;;RODRÍGUEZ ULLOA ARIELIS;;GIL VALDÉS JEOVANIS;;RAMOS GÓMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NÚÑEZ LÁZARO HIRAM;;SÁNCHEZ PUENTE ANIEL;;FERNÁNDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZÁLEZ LÓPEZ LUIS JAVIER;;BESADA PÉREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/033-966-110-885-704,Granted Patent,yes,4,0,40,40,1,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/04;;A61K38/08;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/555;;A61K31/675;;A61K31/69;;A61K31/704;;A61K33/243;;A61K45/06;;C07K7/00,,2,1,026-957-007-518-289,15466209;;10.1158/0008-5472.can-04-2086,"Perea, S. et al., Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2), Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 64, Oct. 1, 2004, pp. 7127-7129, XP002399575.;;Piazza F. et al, ""Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2"", Blood, vol. 104, No. 11, Nov. 16, 2004, p. 186A, XP009086788.",ACTIVE
136,AU,A1,AU 2007/219572 A1,056-435-804-078-386,2007-09-07,2007,AU 2007/219572 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs,,BIOREC B V;;CT INGENIERIA GENETICA BIOTECH,DUQUE JORGE FERNANDEZ DE COSSIO DORTA;;PUENTE ANIEL SANCHEZ;;SERRA LILA ROSA CASTELLANOS;;ULLOA ARIELIS RODRIGUEZ;;NUNEZ LAZARO HIRAM BETANCOURT;;LOPEZ LUIS JAVIER GONZALEZ;;ALONSO DANIEL FERNANDO;;NEGRIN YASSER PERERA;;PEREZ VLADIMIR BESADA;;GOMEZ YASSEL RAMOS;;GOMEZ DANIEL EDUARDO;;CASTRO BORIS ERNESTO ACEVEDO;;VALDES JEOVANIS GIL;;RODRIGUEZ SILVIO ERNESTO PEREA,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA; BIO (2013-09-05),https://lens.org/056-435-804-078-386,Patent Application,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,0,0,,,,ACTIVE
137,JP,A,JP 2013231065 A,132-495-232-260-105,2013-11-14,2013,JP 2013146681 A,2013-07-12,CU 20060049 A,2006-02-28,USE OF CK 2 INHIBITOR FOR TREATMENT AND CHEMICAL SENSITIZATION OF TUMOR UNRESPONSIVE TO ANTICANCER AGENT,"PROBLEM TO BE SOLVED: To evade chemotherapy resistance of a tumor to a cell proliferation inhibitor.SOLUTION: This invention relates to a method for combined use for administering simultaneously, individually or sequentially a combination of agents containing a casein kinase 2 phosphorylated inhibitor (called as p 15) and a cell proliferation inhibitor used in cancer chemotherapy. A preferable cell proliferation inhibitor is platinum, taxane, Vinca major L. genus alkaloid, 5-fluorouracil, Doxorubicin, Cyclophosphamide, Etoposide, mitomycin C, imatinib, Iressa and velcade (bortezomib). A synergistic effect between the peptide p 15 and an anticancer compound means that the effective concentration of each cell proliferation inhibitor in the method for combined use is lower by 1-2 figures than an effective concentration corresponding to a cell proliferation inhibitor as a single agent. Resultantly, the combination described in this invention has far lower toxicity than toxicity reported relative to an anticancer cell proliferation inhibitor, and the fact is an important advantage for the use thereof in cancer treatment. Further, sequential administration brings about chemical sensitization by premedication of the peptide p 15 of a tumor unresponsive to the anticancer cell proliferation inhibitor.",CT INGENIERIA GENETICA BIOTECH;;BIOREC SA,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/132-495-232-260-105,Patent Application,no,4,0,40,40,1,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/00;;A61K38/08;;A61K31/282;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K33/243;;A61K36/00;;A61K36/24;;A61K45/00;;A61P35/00;;A61P35/02;;A61P43/00,,2,0,,,"JPN6014034419; Ｍ． Ｆａｒａｈ ｅｔ ａｌ．: Ａｍ． Ｊ． Ｐｈｙｓｉｏｌ． Ｇａｓｔｒｏｉｎｔｅｓｔ． Ｌｉｖｅｒ Ｐｈｙｓｉｏｌ． ｖｏｌ．２８５, 2003, ｐ．Ｇ９１９-Ｇ９２８;;JPN6012022852; Ｓ． Ｅ． Ｐｅｒｅａ ｅｔ ａｌ．: Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ ｖｏｌ．６４， Ｎｏ．１９, 2004, ｐ．７１２７-７１２９",DISCONTINUED
138,CY,T1,CY 1114686 T1,061-126-237-246-92X,2016-10-05,2016,CY 131100142 T,2013-02-15,EP 07711104 A;;CU 20060049 A,2006-02-28,ΧΡΗΣΗ TOY CK2 ΑΝΑΣΤΟΛΕΑ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΚΑΙ ΧΗΜΕΙΟΕΥΑΙΣΘΗΤΟΠΟΙΗΣΗ ΤΩΝ ΑΝΘΕΚΤΙΚΩΝ ΣΕ ΑΝΤΙΚΑΡΚΙΝΙΚΑ ΦΑΡΜΑΚΑ ΟΓΚΩΝ,"Αυτή η εφεύρεση σχετίζεται με έναν φαρμακευτικό συνδυασμό που περιέχει έναν πεπτιδικό αναστολέα (ονομαζόμενο Ρ15) της κινάσης της Καζεϊνης 2 (CK2) μαζί με τα τυπικά χημειοθεραπευτικά φάρμακα που χρησιμοποιούνται στην αντικαρκινική θεραπεία και τα οποία χορηγούνται μαζί, χωριστά ή διαδοχικά. Τα χημειοθεραπευτικά φάρμακα περιλαμβάνουν σισπλατίνη, ταξόλη, αλκαλοειδή της Vinca, 5-φθοριοουρακίλη, δοξορουβικίνη, κυκλοφωσφαμίδη, ετοποσίδη, μιτομυκίνη C, ιματινίμπη, Iressa, και velcade (βορτεζομίμπη). Η συνεργεία ανάμεσα στο Ρ15 πεπτίδιο και στα αντικαρκινικά φάρμακα επιτυγχάνει μία αποτελεσματική συγκέντρωση κάθε κυτταροστατικού φαρμάκου στον συνδυασμό η οποία είναι από 10- έως 100-φορές μικρότερη από αυτήν για κάθε κυτταροστατικό φάρμακο μόνο του. Ο φαρμακευτικός συνδυασμός που περιγράφεται σε αυτή την εφεύρεση δείχνει χαμηλότερη τοξικότητα σε σύγκριση με αυτήν που αναφέρεται για τα αντικαρκινικά θεραπευτικά και επομένως, αντιπροσωπεύει ένα καίριο πλεονέκτημα για την χρήση του στην καρκινική θεραπεία. Ακόμη, η διαδοχική χορήγηση αυτού του φαρμακευτικού συνδυασμού μέσω της προηγούμενης αγωγής με το Ρ15 πεπτίδιο οδηγεί στην χημειοευαισθητοποίηση των ανθεκτικών όγκων προς τα αντικαρκινικά θεραπευτικά.",CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CIGB),PEREA RODRÍGUEZ SILVIO ERNESTO;;PERERA NEGRÍN YASSER;;RODRÍGUEZ ULLOA ARIELIS;;GIL VALDÉS JEOVANIS;;RAMOS GÓMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NÚÑEZ LÁZARO HIRAM;;SÁNCHEZ PUENTE ANIEL;;FERNÁNDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZÁLEZ LÓPEZ LUIS JAVIER;;BESADA PÉREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO;;CUBA,,https://lens.org/061-126-237-246-92X,Granted Patent,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/555;;A61K33/243;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
139,CA,C,CA 2642943 C,074-985-502-088-748,2013-07-23,2013,CA 2642943 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,"This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.",CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/074-985-502-088-748,Granted Patent,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,0,0,,,,ACTIVE
140,HK,A1,HK 1132451 A1,149-348-667-733-888,2010-02-26,2010,HK 09110055 A,2009-10-29,CU 2007000010 W;;CU 20060049 A,2006-02-28,USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,,CT INGENIERIA GENETICA BIOTECH;;BIOREC SA,RODRIGUEZ SILVIO ERNESTO PEREA;;NEGRIN YASSER PERERA;;ULLOA ARIELIS RODRIGUEZ;;VALDES JEOVANIS GIL;;GOMEZ YASSEL RAMOS;;SERRA LILA ROSA CASTELLANOS;;NUNEZ LAZARO HIRAM BETANCOURT;;PUENTE ANIEL SANCHEZ;;DUQUE JORGE FERNANDEZ DE COSSIO DORTA;;CASTRO BORIS ERNESTO ACEVEDO;;LOPEZ LUIS JAVIER GONZALEZ;;PEREZ VLADIMIR BESADA;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/149-348-667-733-888,Patent Application,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K33/243,,0,0,,,,DISCONTINUED
141,BR,B1,BR PI0708307 B1,131-501-037-403-352,2019-07-23,2019,BR PI0708307 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,"combinação farmacêutica para administração simultânea, separada ou sequencial, e, uso de um peptídeo como inibidor do sítio de fosforilação sobre os substratos de ck2 e um citostático farmaceuticamente aceitável","combinação farmacêutica para administração simultânea, separada ou seqüencial e usos de combinações farmacêuticas e de um inibidor do sítio de fosforilação sobre os substratos de ck2 e um citostático farmaceuticamente aceitável. a presente invenção se refere a uma combinação farmacêutica que inclui um inibidor da fosforilação da caseína quinase 2 (denominado p15) e os citostáticos usados na quimioterapia do câncer os quais são administrados simultâneos, separados ou sequencialmente. os citostáticos preferidos são as platinas, taxanos, alcalóides da vinca, 5-fluorouracilo, doxorubicina, ciclofosfamida, etoposide, mitomicina c, imatinib, iressa e o velcade (vortezomib). a sinergia entre o peptídeo p15 e os compostos químicos anticancerígenos faz com que a concentração eficaz de cada citostático na combinação esteja entre uma e duas ordens de magnitude menor do que a correspondente aos citostáticos sozinhos. conseqúentemente, a combinação descrita na invenção tem uma toxicidade muito menor que a reportada para os citostáticos anticancerígenos o qual representa uma vantagem crucial para seu uso no tratamento do câncer. adicionalmente, a combinação administrada de maneira seqüencial produz a quimiossensibilização de tumores refratários aos citostáticos mencionados mediante o pré-tratamento com o peptideo p15.",BIOREC B V;;CT INGENIERIA GENETICA BIOTECNOLOGIA,LILA ROSA CASTELLANOS SERRA;;LUIS JAVIER GONZÁLEZ LÓPEZ;;ANIEL SÁNCHEZ PUENTE;;ARIELIS RODRÍGUEZ ULLOA;;BORIS ERNESTO ACEVEDO CASTRO;;DANIEL FERNANDO ALONSO;;DANIEL EDUARDO GOMEZ;;JEOVANIS GIL VALDÉS;;JORGE FERNÁNDEZ DE COSSIO DORTA DUQUE;;LÁZARO HIRAM BETANCOURT NÚÑEZ;;SILVIO ERNESTO PEREA RODRÍGUEZ;;VLADIMIR BESADA PÉREZ;;YASSEL RAMOS GÓMEZ;;YASSER PERERA NEGRÍN,,https://lens.org/131-501-037-403-352,Granted Patent,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K31/00;;A61K38/08;;A61K33/243;;A61P35/00,,0,0,,,,ACTIVE
142,EP,B1,EP 1997506 B1,091-379-446-272-845,2012-12-05,2012,EP 07711104 A,2007-02-28,CU 2007000010 W;;CU 20060049 A,2006-02-28,USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,,CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,BIOREC S.A. (2013-01-09);;CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2013-01-09),https://lens.org/091-379-446-272-845,Granted Patent,yes,2,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/555;;A61K33/243;;A61K45/06;;A61P35/00,,3,0,,,"PEREA S E ET AL: ""Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2)"" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, 1 October 2004 (2004-10-01), pages 7127-7129, XP002399575 ISSN: 0008-5472 cited in the application;;PIAZZA F. ET AL.: ""Multiple myeloma cells survival and proliferation rely on high levels and activity of the serine-threonine kinase CK2."" BLOOD, vol. 104, no. 11, 16 November 2004 (2004-11-16), page 186A, XP009086788;;SARNO S. ET AL.: ""Development and exploitation of CK2 inhibitors."" MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 274, 2005, pages 69-76, XP019288786",ACTIVE
143,NO,B1,NO 341904 B1,195-491-641-984-160,2018-02-19,2018,NO 20084119 A,2008-09-29,CU 20060049 A;;CU 2007000010 W,2006-02-28,"Farmasøytisk kombinasjon for simultan, separat eller sekvensiell administrasjon","Foreliggende oppfinnelse angår en farmasøytisk kombinasjon som inneholder en Caseinkinase 2 (CK2) peptidinhibitor (navngitt P15) sammen med standard kjemoterapeutiske legemidler anvendt ved kreftbehandling og som administreres sammen, separat eller sekvensielt. De kjemoterapeutiske legemidlene inkluderer cisplatin, taxol, alkaloider fra Vinca, 5-fluoruracil, doxorubicin, cyklofosfamid, etoposid, mitomicin C, imatinib, iressa og velcade (vortezomib). Synergien mellom P15-peptidet og antikreftlegemidlene gir en effektiv konsentrasjon av hvert cytostatisk legemiddel i kombinasjonen som er fra 10 til 100 ganger lavere enn den for hvert cytostatisk legemiddel alene. Den farmasøytiske kombinasjonen beskrevet ifølge oppfinnelsen fremviser lav toksisitet sammenlignet med den som rapporteres fra antikreftterapeutiske midler og derfor representerer den en viktig fordel ved dens anvendelse ved kreftbehandling. Videre fører den sekvensielle administrasjonen av denne farmasøytiske kombinasjonen gjennom forhåndsbehandling med P15-peptidet til en kjemosensibilisering av refraktære tumorer ovenfor antikreftterapetutiske midler.",CT INGENIERIA GENETICA BIOTECNOLOGIA;;BIOREC BV,NEGRIN YASSER PERERA;;NÚNEZ LÁZARO HIRAM BETANCOURT;;RODRÍGUEZ SILVIO ERNESTO PEREA;;ULLOA ARIELIS RODRÍGUEZ;;VALDES JEOVANIS GIL;;GÓMEZ YASSEL RAMOS;;SERRA LILA ROSA CASTELLANOS;;PUENTE ANIEL SÁNCHEZ;;DUQUE JORGE FERNÁNDEZ DE COSSIO DORTA;;CASTRO BORIS ERNESTO ACEVEDO;;LÓPEZ LUIS JAVIER GONZÁLEZ;;PEREZ VLADIMIR BESADA;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/195-491-641-984-160,Granted Patent,no,2,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/555;;A61K33/243;;A61K45/06,,0,0,,,,INACTIVE
144,SI,T1,SI 1997506 T1,002-552-197-657-733,2013-03-29,2013,SI 200731152 T,2007-02-28,CU 20064920 A;;CU 2007000010 W;;EP 07711104 A,2006-02-28,USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,,CT INGENIERIA GENETICA BIOTECH;;BIOREC SA,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/002-552-197-657-733,Granted Patent,no,0,0,4,4,0,,A61K38/00;;A61K31/00;;A61K33/00;;A61K45/00;;A61P35/00,,0,0,,,,ACTIVE
145,US,A1,US 2009/0130228 A1,150-788-701-494-556,2009-05-21,2009,US 28062907 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,"This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.",PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,BIOREC S.A (2013-04-03);;CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2009-01-07),https://lens.org/150-788-701-494-556,Patent Application,yes,2,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/282;;A61K31/337;;A61K31/407;;A61K31/4745;;A61K31/4965;;A61K31/505;;A61K31/506;;A61K31/675;;A61K31/704;;A61K31/7088;;A61K33/243;;A61P35/00,424/649;;514/15;;514/492;;514/449;;514/283;;514/274;;514/34;;514/110;;514/411;;514/255.06;;514/252.18;;514/44,2,2,026-957-007-518-289;;026-957-007-518-289,15466209;;10.1158/0008-5472.can-04-2086;;15466209;;10.1158/0008-5472.can-04-2086,"PEREA, S. Cancer Research, vol. 64, 1 October 2004, pages 7127-7129.;;Perea, 2004, Cancer Research, 64, 7127-7129",ACTIVE
146,US,B2,US 9278118 B2,029-901-152-132-928,2016-03-08,2016,US 201414518242 A,2014-10-20,US 201414518242 A;;CU 20060049 A;;US 28062909 A;;CU 2007000010 W,2006-02-28,Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs,"This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.",CT INGENIERIA GENETICA BIOTECH;;BIOREC SA,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRÍGUEZ ULLOA ARIELIS;;GIL VALDÉS JEOVANIS;;RAMOS GÓMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NÚÑEZ LÁZARO HIRAM;;SÁNCHEZ PUENTE ANIEL;;FERNÁNDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZÁLEZ LÓPEZ LUIS JAVIER;;BESADA PÉREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/029-901-152-132-928,Granted Patent,yes,4,0,40,40,1,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/04;;A61K38/08;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61K33/243;;C07K7/04,,2,1,026-957-007-518-289,15466209;;10.1158/0008-5472.can-04-2086,"Perea, S. et al., Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2), Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 64, pp. 7127-7129 (2004).;;Piazza F. et al., ""Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2"", Blood, vol. 104, No. 11, p. 186A (2004).",ACTIVE
147,MY,A,MY 150135 A,069-159-375-517-814,2013-11-29,2013,MY PI20083318 A,2007-02-28,CU 20060049 A,2006-02-28,PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,"THIS INVENTION IS RELATED TO A PHARMACEUTICAL COMBINATION THAT CONTAINS A CASEIN KINASE 2 (CK2) PEPTIDE INHIBITOR (TERMED P15) ALONG WITH THE STANDARD CHEMOTHERAPEUTIC DRUGS USED IN CANCER TREATMENT AND WHICH ARE ADMINISTERED TOGETHER, SEPARATED OR SEQUENTIALLY. THE CHEMOTHEARAPEUTIC DRUGS INCLUDE CISPLATIN, TAXOL, ALKALOIDS FROM VINCA, 5-FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, MITOMICIN C, IMATINIB, IRESSA AND VELCADE (VORTEZOMIB). THE SYNERGISM BETWEEN THE P15 PEPTIDE AND THE ANTICANCER DRUGS ACHIEVES AN EFFICIENT CONCENTRATION OF EACH CYTOSTATIC DRUG IN THE COMBINATION WHICH IS FROM 10- TO 100-FOLD LOWER THAN THAT FOR EACH CYTOSTATIC DRUG ALONE. THE PHARMACEUTICAL COMBINATION DESCRIBED IN THIS INVENTION EXHIBITS LOWER TOXICITY COMPARED TO THAT REPORTED BY THE ANTICANCER THERAPEUTICS AND THEREFORE, IT REPRESENTS A CRUCIAL ADVANTAGE FOR ITS USE IN CANCER THERAPY. FURTHERMORE, THE SEQUENTIAL ADMINISTRATION OF THIS PHARMACEUTICAL COMBINATION THROUGH THE PRETREATMENT WITH THE P15 PEPTIDE LEADS TO THE CHEMO SENSIBILIZATION OF REFRACTORY TUMORS TO THE ANTICANCER THERAPEUTICS.",CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,ERNESTO PEREA RODRIGUEZ SILVIO;;ERNESTO ACEVEDO CASTRO BORIS;;JAVIER GONZALEZ LOPEZ LUIS;;VLADIMIR BESADA PEREZ;;FERNANDO ALONSO DANIEL;;EDUARDO GOMEZ DANIEL;;YASSER PERERA NEGRIN;;ARIELIS RODRIGUEZ ULLOA;;JEOVANIS GIL VALDES;;YASSEL RAMOS GOMEZ;;ROSA CASTELLANOS SERRA LILA;;HIRAM BETANCOURT NUNEZ LAZARO;;ANIEL SANCHEZ PUENTE;;JORGE FERNANDEZ DE COSSIO DORTA DUQUE,,https://lens.org/069-159-375-517-814,Granted Patent,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K33/243,,0,0,,,,ACTIVE
148,BR,A2,BR PI0708307 A2,156-886-707-129-784,2011-05-24,2011,BR PI0708307 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,"combinação farmacêutica para administração simultánea, separada ou sequencial e usos de combinações farmacêuticas e de um inibidor do sìtio de fosforilação sobre os substratos de ck2 e um citostático farmaceuticamente aceitável","COMBINAçãO FARMACêUTICA PARA ADMINISTRAçãO SIMULTáNEA, SEPARADA OU SEQUENCIAL E USOS DE COMBINAçõES FARMACêUTICAS E DE UM INIBIDOR DO SìTIO DE FOSFORILAçãO SOBRE OS SUBSTRATOS DE CK2 E UM CITOSTáTICO FARMACEUTICAMENTE ACEITáVEL A presente invenção se refere a uma combinação farmacêutica que inclui um inibidor da fosforilação da Caseína Quinase 2 (denominado P 15) e os citostáticos usados na quimioterapia do câncer os quais são administrados simultâneos, separados ou sequencialmente. Os citostáticos preferidos são as platinas, taxanos, alcalóides da Vinca, 5-fluorouracilo, doxorubicina, ciclofosfamida, etoposide, mitomicina C, imatinib, iressa e o velcade (vortezomib). á sinergia entre o peptídeo P 15 e os compostos químicos anticancerígenos faz com que a concentração eficaz de cada citostático na combinação esteja entre uma e duas ordens de magnitude menor do que a correspondente aos citostáticos sozinhos. Conseqúentemente, a combinação descrita na invenção tem uma toxicidade muito menor que a reportada para os citostáticos anticancerigenos o qual representa uma vantagem crucial para seu uso no tratamento do câncer. ádicionalmente, a combinação administrada de maneira seqúencial produz a quimiossensibilização de tumores refratários aos citostáticos mencionados mediante o pré-tratamento com o peptideo P 15.",CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,RODRIGUEZ SILVIO ERNESTO PEREA;;NEGRIN YASSER PERERA;;ULLOA ARIELIS RODRIGUEZ;;VALDES JEOVANIS GIL;;GOMEZ YASSEL RAMOS;;SERRA LILA ROSA CASTELLANOS;;NUNEZ LAZARO HIRAM BETANCOURT;;PUENTE ANIEL SANCHEZ;;DUQUE JORGE FERNANDEZ DE COSSIO DORTA;;CASTRO BORIS ERNESTO ACEVEDO;;LOPEZ LUIS JAVIER GONZALEZ;;PEREZ VLADIMIR BESADA;;GOMEZ DANIEL EDUARDO;;FERNANDO ALONSO DANIEL,,https://lens.org/156-886-707-129-784,Patent Application,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,0,0,,,,ACTIVE
149,PT,E,PT 1997506 E,199-874-529-785-640,2013-02-11,2013,PT 07711104 T,2007-02-28,CU 20064920 A,2006-02-28,USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,,CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,GOMEZ DANIEL EDUARDO;;CASTRO BORIS ERNESTO ACEVEDO;;LOPEZ LUIS JAVIER GONZALEZ;;SERRA LILA ROSA CASTELLANOS;;SILVIO ERNESTO PEREA RODRIGUEZ;;NEGRIN YASSER PERERA;;ULLOA ARIELIS RODRIGUEZ;;VALDES JEOVANIS GIL;;GOMEZ YASSEL RAMOS;;NUNEZ LAZARO HIRAM BETANCOURT;;PUENTE ANIEL SANCHEZ;;DUQUE JORGE FERNANDEZ DE COSSIO DORTA;;PEREZ VLADIMIR BESADA;;ALONSO DANIEL FERNANDO,,https://lens.org/199-874-529-785-640,Granted Patent,no,0,0,4,4,0,,A61K38/08;;A61K31/555;;A61K33/24;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
150,NO,L,NO 20084119 L,114-010-724-287-549,2008-11-25,2008,NO 20084119 A,2008-09-29,CU 20060049 A;;CU 2007000010 W,2006-02-28,Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter,"Foreliggende oppfinnelse angår en farmasøytisk kombinasjon som inneholder en Caseinkinase 2 (CK2) peptidinhibitor (navngitt P15) sammen med standard kjemoterapeutiske legemidler anvendt ved kreftbehandling og som administreres sammen, separat eller sekvensielt. De kjemoterapeutiske legemidlene inkluderer cisplatin, taxol, alkaloider fra Vinca, 5-fluoruracil, doxorubicin, cyklofosfamid, etoposid, mitomicin C, imatinib, iressa og velcade (vortezomib). Synergien mellom P15-peptidet og antikreftlegemidlene gir en effektiv konsentrasjon av hvert cytostatisk legemiddel i kombinasjonen som er fra 10 til 100 ganger lavere enn den for hvert cytostatisk legemiddel alene. Den farmasøytiske kombinasjonen beskrevet ifølge oppfinnelsen fremviser lav toksisitet sammenlignet med den som rapporteres fra antikreftterapeutiske midler og derfor representerer den en viktig fordel ved dens anvendelse ved kreftbehandling. Videre fører den sekvensielle administrasjonen av denne farmasøytiske kombinasjonen gjennom forhåndsbehandling med P15-peptidet til en kjemosensibilisering av refraktære tumorer ovenfor antikreftterapetutiske midler.",BIOREC BV,NEGRIN YASSER PERERA;;NUNEZ LAZARO HIRAM BETANCOURT;;RODRIGUEZ SILVIO ERNESTO PEREA;;ULLOA ARIELIS RODRIGUEZ;;VALDES JEOVANIS GIL;;GOMEZ YASSEL RAMOS;;SERRA LILA ROSA CASTELLANOS;;PUENTE ANIEL SANCHEZ;;DUQUE JORGE FERNANDEZ DE COSSIO DORTA;;CASTRO BORIS ERNESTO ACEVEDO;;LOPEZ LUIS JAVIER GONZALEZ;;PEREZ VLADIMIR BESADA;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/114-010-724-287-549,Abstract,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,0,0,,,,INACTIVE
151,US,A1,US 2015/0111832 A1,181-025-492-862-402,2015-04-23,2015,US 201414518242 A,2014-10-20,US 201414518242 A;;CU 20060049 A;;US 28062909 A;;CU 2007000010 W,2006-02-28,PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,"This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.",CT INGENIERIA GENETICA BIOTECH,PEREA RODRÍGUEZ SILVIO ERNESTO;;PERERA NEGRÍN YASSER;;RODRÍGUEZ ULLOA ARIELIS;;GIL VALDÉS JEOVANIS;;RAMOS GÓMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NÚÑEZ LÁRAZO HIRAM;;SÁNCHEZ PUENTE ANIEL;;FERNÁNDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZÁLEZ LÓPEZ LUIS JAVIER;;BESADA PÉREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/181-025-492-862-402,Patent Application,yes,0,1,40,40,1,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61K33/243,514/19.3,0,0,,,,ACTIVE
152,US,B2,US 8871725 B2,107-543-952-976-571,2014-10-28,2014,US 28062907 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs,"This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.",RODRIGUEZ SILVIO ERNESTO PEREA;;NEGRIN YASSER PERERA;;ULLOA ARIELIS RODRIGUEZ;;VALDÉS JEOVANIS GIL;;GÓMEZ YASSEL RAMOS;;SERRA LILA ROSA CASTELLANOS;;NÚÑEZ LÁZARO HIRAM BETANCOURT;;PUENTE ANIEL SÁNCHEZ;;DUQUE JORGE FERNÁNDEZ DE COSSIO DORTA;;CASTRO BORIS ERNESTO ACEVEDO;;LÓPEZ LUIS JAVIER GONZÁLEZ;;PÉREZ VLADIMIR BESADA;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO;;CT DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA;;BIOREC SA,RODRIGUEZ SILVIO ERNESTO PEREA;;NEGRIN YASSER PERERA;;ULLOA ARIELIS RODRIGUEZ;;VALDÉS JEOVANIS GIL;;GÓMEZ YASSEL RAMOS;;SERRA LILA ROSA CASTELLANOS;;NÚÑEZ LÁZARO HIRAM BETANCOURT;;PUENTE ANIEL SÁNCHEZ;;DUQUE JORGE FERNÁNDEZ DE COSSIO DORTA;;CASTRO BORIS ERNESTO ACEVEDO;;LÓPEZ LUIS JAVIER GONZÁLEZ;;PÉREZ VLADIMIR BESADA;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,BIOREC S.A (2013-04-03);;CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2009-01-07),https://lens.org/107-543-952-976-571,Granted Patent,yes,4,3,40,40,1,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/555;;A61K33/243;;A61K39/00;;A61K45/06;;A61P35/00;;C07K7/06,514/21.6;;514/19.3;;503/201;;424/181.1,4,3,026-957-007-518-289;;026-957-007-518-289;;026-957-007-518-289,15466209;;10.1158/0008-5472.can-04-2086;;15466209;;10.1158/0008-5472.can-04-2086;;15466209;;10.1158/0008-5472.can-04-2086,"Perea, S. Cancer Research, vol. 64, Oct. 1, 2004, pp. 7127-7129.;;Perea, 2004, Cancer Research, 64, 7127-7129.;;Perea, S. et al., Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2), Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 64, Oct. 1, 2004, pp. 7127-7129, XP002399575.;;Piazza F. et al, ""Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2"", Blood, vol. 104, No. 11, Nov. 16, 2004, p. 186A, XP009086788.",ACTIVE
153,CU,B6,CU 23511 B6,153-315-339-457-566,2010-04-13,2010,CU 20060049 A,2006-02-28,CU 20060049 A,2006-02-28,COMBINACIÓN FARMACÉUTICA PARA EL TRATAMIENTO Y/O QUIMIOSENSIBILIZACIÓN DE TUMORES REFRACTARIOS A DROGAS ANTICANCERÍGENAS,"La presente invención se relaciona con una combinación farmacéutica que incluye un inhibidor de la fosforilación de la Caseína Kinasa 2 (denominado P15) y los citostáticos usados en la quimioterapia del cáncer los cuales son administrados simultáneos, separados o secuencialmente. Los citostáticos preferidos son los platinos, taxanos, alcaloides de la Vinca, 5-fluorouracilo, doxorubicina, ciclofosfamida, etoposide, mitomicina C, imatinib, iressa y el velcade (vortezomib). La sinergía entre el péptido P15 y los compuestos químicos anticancerígenos, hace que la concentración eficaz de cada citostáticos en la combinación sea entre uno y dos órdenes de magnitud menor que la correspondiente a los citostáticos sólos. Consecuentemente, la combinación descrita en la invención tiene una toxicidad mucho menor que la reportada para los citostáticos anticancerígenos lo cual representa una ventaja crucial para su uso en el tratamiento del cáncer. Adicionalmente, la combinación administrada de manera secuencial produce la quimiosensibilización de tumores refractarios a los citostáticos mencionados mediante el pretratamiento con el péptido P15.",BIOREC B V;;CT INGENIERIA GENETICA BIOTECH,GOMEZ DANIEL EDUARDO;;ALONSO DANIEL FERNANDO;;SANCHEZ PUENTE ANIEL;;RODRIGUEZ ULLOA ARIELIS;;RAMOS GOMEZ YASSEL;;PERERA NEGRIN YASSER;;GIL VALDES JEOVANIS;;BESADA PEREZ VLADIMIR ARMANDO;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;BETANCOURT NUNEZ LAZARO HIRAM;;GONZALEZ LOPEZ LUIS JAVIER;;PEREA RODRIGUEZ SILVIO ERNESTO;;ACEVEDO CASTRO BORIS ERNESTO;;CASTELLANOS SERRA LILA ROSA,,https://lens.org/153-315-339-457-566,Limited Patent,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K33/243;;A61K38/00;;A61P31/00;;A61P35/00,,0,0,,,,ACTIVE
154,PL,T3,PL 1997506 T3,107-642-486-976-42X,2013-04-30,2013,PL 07711104 T,2007-02-28,EP 07711104 A;;CU 2007000010 W;;CU 20060049 A,2006-02-28,USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,,CT INGENIERIA GENETICA BIOTECNOLOGIA;;BIOREC SA,PEREA RODRÍGUEZ SILVIO ERNESTO;;PERERA NEGRÍN YASSER;;RODRÍGUEZ ULLOA ARIELIS;;GIL VALDÉS JEOVANIS;;RAMOS GÓMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NÚÑEZ LÁZARO HIRAM;;SÁNCHEZ PUENTE ANIEL;;FERNÁNDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZÁLEZ LÓPEZ LUIS JAVIER;;BESADA PÉREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/107-642-486-976-42X,Patent Application,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/555;;A61K33/243;;A61K45/06;;A61P35/00,,0,0,,,,PENDING
155,US,A1,US 2015/0030700 A1,137-900-013-242-60X,2015-01-29,2015,US 201414490856 A,2014-09-19,US 201414490856 A;;CU 20060049 A;;US 28062909 A;;CU 2007000010 W;;US 28062908 A,2006-02-28,PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,"This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.",CT INGENIERIA GENETICA BIOTECH,PEREA RODRÍGUEZ SILVIO ERNESTO;;PERERA NEGRÍN YASSER;;RODRÍGUEZ ULLOA ARIELIS;;GIL VALDÉS JEOVANIS;;RAMOS GÓMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NÚÑEZ LÁZARO HIRAM;;SÁNCHEZ PUENTE ANIEL;;FERNÁNDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZÁLEZ LÓPEZ LUIS JAVIER;;BESADA PÉREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/137-900-013-242-60X,Patent Application,yes,2,0,40,40,1,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K33/243,424/649;;514/19.2;;X514 44  R,0,0,,,,ACTIVE
156,PE,A1,PE 20081191 A1,114-055-198-027-825,2008-09-24,2008,PE 2007000215 A,2007-02-28,CU 20060049 A,2006-02-28,COMBINACION FARMACEUTICA PARA EL TRATAMIENTO Y/O QUIMIOSENSIBILIZACION DE TUMORES REFRACTARIOS A DROGAS ANTICANCERIGENAS,"SE REFIERE A UNA COMBINACION FARMACEUTICA PARA ADMINISTRACION SIMULTANEA, SEPARADA O SECUENCIAL QUE COMPRENDE: A) UN INHIBIDOR DE LA FOSFORILACION DE LA ENZIMA CASEINA QUINASA 2 (CK2) TAL COMO EL PEPTIDO P15 (CWMSPRHLGTC); Y B) UN CITOSTATICO TAL COMO CISPLATINO, CARBOPLATINO, PACLITAXEL, DOCETAXEL, VINCRISTINA, VINPLASTINA, 5-FLUORACILO, DOXORUBICINA, CICLOFOSFAMIDA, MITOMICIN C, IMATINIB, ENTRE OTROS. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE TUMORES SOLIDOS O DE ORIGEN HEMATOPOYETICO RESISTENTES A CITOSTATICOS",CT INGENIERIA GENETICA BIOTECH;;BIOREC B V,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/114-055-198-027-825,Patent Application,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,0,0,,,,ACTIVE
157,EP,B8,EP 1997506 B8,125-282-932-923-392,2013-02-20,2013,EP 07711104 A,2007-02-28,CU 2007000010 W;;CU 20060049 A,2006-02-28,USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS,,CT INGENIERIA GENETICA BIOTECH;;BIOREC SA,PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,BIOREC S.A. (2013-01-09);;CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2013-01-09),https://lens.org/125-282-932-923-392,Amended Patent,yes,2,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/555;;A61K33/243;;A61K45/06;;A61P35/00,,3,0,,,"PEREA S E ET AL: ""Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2)"" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, 1 October 2004 (2004-10-01), pages 7127-7129, XP002399575 ISSN: 0008-5472 cited in the application;;PIAZZA F. ET AL.: ""Multiple myeloma cells survival and proliferation rely on high levels and activity of the serine-threonine kinase CK2."" BLOOD, vol. 104, no. 11, 16 November 2004 (2004-11-16), page 186A, XP009086788;;SARNO S. ET AL.: ""Development and exploitation of CK2 inhibitors."" MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 274, 2005, pages 69-76, XP019288786",ACTIVE
158,ZA,B,ZA 200807323 B,160-418-161-088-825,2009-05-27,2009,ZA 200807323 A,2008-08-23,CU 20060049 A,2006-02-28,Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs,,CT INGENIERIA GENETICA BIOTECH,ERNESTO PERA RODRIGUEZ SILVIO;;YASSER PERERA NEGRIN;;ARIELIS RODRIGUEZ ULLOA;;JEOVANIS GIL VALDES;;YASSEL RAMOS GOMEZ;;CASTELLANOS SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;VLADIMIR BESADA PEREZ;;FERNANDO ALONSO DANIEL;;GOMEZ DANIEL EDUARDO,,https://lens.org/160-418-161-088-825,Granted Patent,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K33/243,,0,0,,,,ACTIVE
159,AU,B2,AU 2007/219572 B2,173-266-104-873-204,2012-07-05,2012,AU 2007/219572 A,2007-02-28,CU 20060049 A;;CU 2007000010 W,2006-02-28,Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs,"The present invention relates to a pharmaceutical combination that includes a casein kinase 2 phosphorylation inhibitor (called p15) and cytostatics used in cancer chemotherapy, which are administered simultaneously, separately or sequentially. The preferred cytostatics are platinums, taxans, vinca alkaloids, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). Synergy between peptide p15 and the anticancer chemical compounds means that the effective concentration of each cytostatic in the combination is between 1 and 2 orders of magnitude less than that corresponding to cytostatics alone. Consequently, the combination described in the invention has a much lower toxicity than that reported for anticancer cytostatics, which represents a crucial advantage in their use in cancer treatment. Additionally, administered sequentially, the combination gives rise to the chemosensitization of refractory tumours to the cytostatics mentioned by means of pre-treatment with peptide p15.",BIOREC SA;;CT INGENIERIA GENETICA BIOTECNOLOGIA,RAMOS GOMEZ YASSEL;;PEREA RODRIGUEZ SILVIO ERNESTO;;CASTELLANOS SERRA LILA ROSA;;GONZALEZ LOPEZ LUIS JAVIER;;PERERA NEGRIN YASSER;;ACEVEDO CASTRO BORIS ERNESTO;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;RODRIGUEZ ULLOA ARIELIS;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO;;SANCHEZ PUENTE ANIEL;;GIL VALDES JEOVANIS;;BETANCOURT NUNEZ LAZARO HIRAM;;BESADA PEREZ VLADIMIR,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA; BIO (2013-09-05),https://lens.org/173-266-104-873-204,Granted Patent,no,1,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K31/00;;A61K33/243;;A61P35/00,,1,0,,,PIAZZA F et al. Blood. 104(11): 186A (Abstract),ACTIVE
160,DK,T3,DK 1997506 T3,174-313-187-289-34X,2013-02-11,2013,DK 07711104 T,2007-02-28,CU 20064920 A;;CU 2007000010 W,2006-02-28,Anvendelse af CK2-inhibitor til behandling og chemosensibilisering af modstandsdygtige tumorer for anticancer-lægemidler,,BIOREC SA;;CT INGENIERIA GENETICA BIOTECH,PEREA RODRIGUEZ SILVIO ERNESTO;;GIL VALDES JEOVANIS;;RAMOS GOMEZ YASSEL;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;ACEVEDO CASTRO BORIS ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;CASTELLANOS SERRA LILA ROSA;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/174-313-187-289-34X,Granted Patent,no,0,0,4,4,0,,A61K38/08;;A61K31/555;;A61K33/24;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
161,DO,A,DO P2007000040 A,199-128-445-430-151,2007-09-30,2007,DO 2007000040 A,2007-02-23,CU 20060049 A,2006-02-28,COMBINACIÓN FARMACÉUTICA PARA EL TRATAMIENTO Y/O QUIMIOSENSIBILIZACIÓN DE TUMORES REFRACTARIOS A DROGAS ANTICANCERÍGENAS.,"La presente invención se relaciona con una combinación farmacéutica que incluye un inhibidor de la fosforilación de la Caseína Kinasa 2 (denominado P15) y los citostáticos usados en la quimioterapia del cáncer los cuales son administrados simultáneos, separados o secuencialmente. Los citostáticos preferidos son los platinos, taxanos, alcaloides de la Vinca, 5-fluorouracilo, doxorubicina, ciclofosfamida, etoposide, mitomicina C, imatinib, iressa y el velcade (vortezomib). La sinergia entre el péptido P15 y los compuestos químicos anticancerígenos, hace que la concentración eficaz de cada citostático en la combinación sea entre uno y dos órdenes de magnitud menor que la correspondiente a los citostaticos sólos. Consecuentemente, la combinación descrita en la invención tiene una toxicidad mucho menor que la reportada para los citostaticos anticancerígenos lo cual representa una ventaja crucial para su uso en el tratamiento del cáncer. Adicionalmente, la combinación administrada de manera secuencial produce la quimiosensibilización de tumores refractarios a los citostáticos mencionados mediante el pretratamiento con el péptido P15.",CT INGENIERIA GENETICA BIOTECH,BIOREC B V;;PEREA RODRIGUEZ SILVIO ERNESTO;;PERERA NEGRIN YASSER;;RODRIGUEZ ULLOA ARIELIS;;VALDES JEOVANIS GIL;;RAMOS GOMEZ YASSEL;;CASTELLANO SERRA LILA ROSA;;BETANCOURT NUNEZ LAZARO HIRAM;;SANCHEZ PUENTE ANIEL;;FERNANDEZ DE COSSIO DORTA DUQUE JORGE;;ACEVEDO CASTRO BORIS ERNESTO;;GONZALEZ LOPEZ LUIS JAVIER;;BESADA PEREZ VLADIMIR;;ALONSO DANIEL FERNANDO;;GOMEZ DANIEL EDUARDO,,https://lens.org/199-128-445-430-151,Patent Application,no,0,0,40,40,0,A61K31/555;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076;;A61P31/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61K33/243;;A61K38/08;;A61K33/243;;A61K31/337;;A61K31/513;;A61K31/704;;A61K31/675;;A61K31/69;;A61K31/506;;A61P35/00;;A61K2300/00;;A61K31/555;;A61K38/08;;A61K45/06;;A61K33/243;;A61K31/555;;A61K33/243;;A61K38/08;;A61K45/06;;A61K31/337;;A61K31/407;;A61K31/475;;A61K31/506;;A61K31/513;;A61K31/5377;;A61K31/675;;A61K31/69;;A61K31/704;;A61K31/136;;A61K31/282;;A61K31/7048;;A61K31/7068;;A61K31/7076,A61K38/08;;A61K33/243,,0,0,,,,PENDING
162,PE,Z,PE 20151569 Z,015-831-759-609-586,2015-12-06,2015,PE 2014001715 U,2014-10-20,PE 2014001715 U,2014-10-20,ARBOL NAVIDENOS FUNCIONAL PARA ESPACIOS REDUCIDOS,"El arbol navideno funcional para espacios reducidos es una propuesta innovadora que soluciona el problema de ubicacion de arboles en areas reducidas, lo que da mayor seguridad en la amplitud de area para evacuar en casos de sismos, es funcional por que se adapta a espacios reducidos, es liviano, facil de armar y desmontar, no ocupa espacios para su almacen porque es plegable, no posee aristas cortantes ideal para armarlo en familia, se adapta a la eleccion del color y la decoracion del cliente",INST DE EDUCACION SUPERIOR TECNOLOGICO PUBLICO JULIO CESAR TELLO;;CONDORI HUAHUAMULLO FILOMENA;;ALARCON VELAZCO JORGE ALEXANDERS;;ASTUCURI VICTORIO HANS RUDDY;;CHAVEZ LLANCARI DAVID JUNIOR;;CHAYGUAQUE EDWIN WILDER;;FARFAN FLORES LIGO;;NARVAES SALCEDO ALFREDO;;NECIOSUP BARAZORDA JOSE CARLOS;;NOVOA VELA JULIO MARTIN;;PACOMPIA CARDENAS MOADI JOSUE;;RAMON HUAMAN JOSUE FRANCO;;RODRIGUEZ ACEVEDO JUNIOR EDMUNDO RAUL;;SIESQUEN INONAN JUAN CESAR;;VARGAS NOVOAS YERLITH MILAGROS;;ZAMATA QUISPE MARIBEL,CONDORI HUAHUAMULLO FILOMENA;;ALARCON VELAZCO JORGE ALEXANDERS;;ASTUCURI VICTORIO HANS RUDDY;;CHAVEZ LLANCARI DAVID JUNIOR;;CHAYGUAQUE EDWIN WILDER;;FARFAN FLORES LIGO;;NARVAES SALCEDO ALFREDO;;NECIOSUP BARAZORDA JOSE CARLOS;;NOVOA VELA JULIO MARTIN;;PACOMPIA CARDENAS MOADI JOSUE;;RAMON HUAMAN JOSUE FRANCO;;RODRIGUEZ ACEVEDO JUNIOR EDMUNDO RAUL;;SIESQUEN INONAN JUAN CESAR;;VARGAS NOVOAS YERLITH MILAGROS;;ZAMATA QUISPE MARIBEL,,https://lens.org/015-831-759-609-586,Patent Application,no,0,0,1,1,0,,,,0,0,,,,ACTIVE
